FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Marques, L
   Fregonezi, GAD
   Santos, IP
   Marcelino, AA
   da Fonseca, JDM
   Dourado, MET
   Aliverti, A
   Sarmento, A
   Resqueti, VR
AF Marques, Layana
   de Freitas Fregonezi, Guilherme Augusto
   Santos, Ilsa Priscila
   Marcelino, Ana Aline
   Medeiros da Fonseca, Jessica Danielle
   Teixeira Dourado-Junior, Mario Emilio
   Aliverti, Andrea
   Sarmento, Antonio
   Resqueti, Vanessa Regiane
TI Effects of Positioning on Cough Peak Flow and Muscular Electromyographic
   Activation in Duchenne Muscular Dystrophy
SO RESPIRATORY CARE
LA English
DT Article
DE Duchenne muscular dystrophy; cough; plethysmography; respiratory
   muscles; electromyography
ID CHEST-WALL KINEMATICS; REFERENCE VALUES; PULMONARY MORBIDITY; VOLUNTARY
   COUGH; RIB CAGE; LUNG; DETERMINANTS; PREVENTION; PRESSURES; VOLUMES
AB BACKGROUND: Advanced stages of Duchenne muscular dystrophy (DMD) result in muscle weakness and the inability to generate an effective cough. Several factors influence the effectiveness of cough in patients with DMD. The aim of this study was to asks whether differences in positioning affect cough peak flow (CPF) and muscular electromyographic activation in subjects with DMD compared with paired healthy subjects. METHODS: Optoelectronic plethysmography and surface electromyography were used to assess chest wall volumes, chest wall inspiratory capacity, CPF, breathing pattern, and electromyographic activity of sternocleidomastoid, scalene, rectus abdominis, and external oblique muscles during inspiratory and expiratory cough phases in the supine position, supine position with headrest raised at 45 degrees, and sitting with back support at 80 degrees in 12 subjects with DMD and 12 healthy subjects. RESULTS: Subjects with DMD had lower CPF (P < .01) in comparison to control subjects in all positions; the DMD group also exhibited lower CPF (P = .045) in the supine position versus 80 degrees. Marem er, the relative volume contributions of the rib cage and abdominal compartments to tidal 's Anne modified significantly with posture. The electromyographic activity during inspiratory and expiratory cough phases was lower in subjects with DMD compared to healthy subjects for all evaluated muscles (P < .05), but no significant differences were observed with posture change. CONCLUSIONS: In subjects with DMD, posture influenced CPF and the relative contribution of the rib cage and abdominal compartments to tidal volume. However, muscular electromyographic activation was not influenced by posture in subjects with DMD and healthy subjects.
C1 [Marques, Layana; de Freitas Fregonezi, Guilherme Augusto; Santos, Ilsa Priscila; Marcelino, Ana Aline; Medeiros da Fonseca, Jessica Danielle; Sarmento, Antonio; Resqueti, Vanessa Regiane] Empresa Brasileira Serv Hosp, Hosp Univ Onofe Lopes, PneumoCardioVasc Lab, Natal, RN, Brazil.
   [Marques, Layana; de Freitas Fregonezi, Guilherme Augusto; Santos, Ilsa Priscila; Marcelino, Ana Aline; Medeiros da Fonseca, Jessica Danielle; Sarmento, Antonio; Resqueti, Vanessa Regiane] Univ Fed Rio Grande do Norte, Dept Fisioterapia, Lab Inovacao Tecnol Reabilitacao, Natal, RN, Brazil.
   [Teixeira Dourado-Junior, Mario Emilio] Univ Fed Rio Grande do Norte, Empresa Brasileira Serv Hosp EBSERH, Ambulatorio Neurol, Natal, RN, Brazil.
   [Aliverti, Andrea] Politecn Milan, Lab Tecnol Biomed, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
RP Resqueti, VR (corresponding author), Univ Fed Rio Grande do Norte, Dept Fisioterapia, Campus Univ Lagoa Nova,Caixa Postal 1524, BR-59072970 Natal, RN, Brazil.
EM vanessaresqueti@hotmail.com
RI Sarmento, Antonio/K-9999-2018
OI Sarmento, Antonio/0000-0001-6391-5652
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil
   (CAPES)CAPES [001]; Project PROCAD CAPES 2013 [88881.068409/2014-01]
FX This study were financed in part by the Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior Brasil (CAPES) Finance Code 001 and Project
   PROCAD CAPES 2013 number 88881.068409/2014-01. Vanessa Regiane Resqueti
   is a fellow of the Conselho Nacional de Desenvolvimento Cienti ' fico e
   Tecnolo ' gico (CNPq) -process number 315580/2018-6. Guilherme Augusto
   de Freitas Fregonezi is fellow of the Conselho Nacional de
   Desenvolvimento Cienti ' fico e Tecnologico (CNPq) -process number
   312876/2018-1.
CR AGOSTONI E, 1960, J APPL PHYSIOL, V15, P1087
   Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518
   Aliverti A, 2004, THORAX, V59, P210, DOI 10.1136/thorax.2003.011494
   Aliverti A, 2001, ANN BIOMED ENG, V29, P60, DOI 10.1114/1.1332084
   Bach JR, 1997, CHEST, V112, P1024, DOI 10.1378/chest.112.4.1024
   Bach JR, 1998, AM J PHYS MED REHAB, V77, P8, DOI 10.1097/00002060-199801000-00003
   BARNAS GM, 1993, ANESTHESIOLOGY, V78, P251, DOI 10.1097/00000542-199302000-00007
   Burden A, 2010, J ELECTROMYOGR KINES, V20, P1023, DOI 10.1016/j.jelekin.2010.07.004
   Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474-4422(09)70271-6
   Cala SJ, 1996, J APPL PHYSIOL, V81, P2680
   Cesareo A, 2018, RESP CARE, V63, P955, DOI 10.4187/respcare.05895
   D'Angelo MG, 2011, J NEUROL SCI, V306, P54, DOI 10.1016/j.jns.2011.03.045
   Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U
   ESTENNE M, 1993, THORAX, V48, P698, DOI 10.1136/thx.48.7.698
   ESTENNE M, 1983, AM REV RESPIR DIS, V128, P1002
   Evangelista LS, 2004, J HEART LUNG TRANSPL, V23, P360, DOI 10.1016/S1053-2498(03)00196-7
   Evangelista MD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177318
   Fayssoil Abdallah, 2018, J Neuromuscul Dis, V5, P1, DOI 10.3233/JND-170276
   Fontana GA, 2006, RESP PHYSIOL NEUROBI, V152, P266, DOI 10.1016/j.resp.2006.02.016
   Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338
   Griggs RC, 2005, NEUROLOGY, V64, P1498, DOI 10.1212/01.WNL.0000163758.84916.87
   Hegland KW, 2012, J APPL PHYSIOL, V113, P39, DOI 10.1152/japplphysiol.01299.2011
   Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4
   Iwabe C, 2008, BRAZ J PHYS THER, V12, P417, DOI 10.1590/S1413-35552008000500012
   KONNO K, 1968, J APPL PHYSIOL, V24, P544
   Kravitz RM, 2009, PEDIATRICS, V123, pS231, DOI 10.1542/peds.2008-2952G
   Lanini B, 2007, ACTA PHYSIOL, V190, P351, DOI 10.1111/j.1748-1716.2007.01701.x
   Lanini B, 2008, RESP PHYSIOL NEUROBI, V161, P62, DOI 10.1016/j.resp.2007.12.003
   Lanza FC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135662
   Lo Mauro A, 2016, BREATHE, V12, P319, DOI 10.1183/20734735.012716
   LoMauro A, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01418-2017
   LoMauro A, 2015, THER CLIN RISK MANAG, V11, P1475, DOI 10.2147/TCRM.S55889
   LoMauro A, 2014, PEDIATR PULM, V49, P357, DOI 10.1002/ppul.22836
   Massaroni C, 2017, RESPIRATION, V93, P339, DOI 10.1159/000462916
   Misuri G, 2000, CHEST, V117, P447, DOI 10.1378/chest.117.2.447
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   Perrin C, 2004, MUSCLE NERVE, V29, P5, DOI 10.1002/mus.10487
   Phillips MF, 2001, AM J RESP CRIT CARE, V164, P2191, DOI 10.1164/ajrccm.164.12.2103052
   Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312
   Romei M, 2010, RESP PHYSIOL NEUROBI, V172, P184, DOI 10.1016/j.resp.2010.05.018
   de Araujo PRS, 2012, J BRAS PNEUMOL, V38, P700, DOI 10.1590/S1806-37132012000600004
   Sarmento A, 2019, RESP PHYSIOL NEUROBI, V259, P16, DOI 10.1016/j.resp.2018.06.012
   Sarmento A, 2017, ARCH PHYS MED REHAB, V98, P2237, DOI 10.1016/j.apmr.2017.04.015
   Simonyan K, 2007, NEUROIMAGE, V37, P401, DOI 10.1016/j.neuroimage.2007.05.021
   Smith JA, 2012, J PHYSIOL-LONDON, V590, P563, DOI 10.1113/jphysiol.2011.213157
   Sociedade Brasileira de Pneumologia e Tisiologia, 2002, J PNEUMOL S3, V28, pS155
   Stefanutti D, 1999, AM J RESP CRIT CARE, V159, P107
   Tomczak M., 2014, TRENDS SPORT SCI, V1, P19, DOI DOI 10.7326/0003-4819-159-3-201308060-00005
   TOMORI Z, 1969, J PHYSIOL-LONDON, V200, P25, DOI 10.1113/jphysiol.1969.sp008680
   Trebbia G, 2005, RESP PHYSIOL NEUROBI, V146, P291, DOI 10.1016/j.resp.2005.01.001
   Tzeng AC, 2000, CHEST, V118, P1390, DOI 10.1378/chest.118.5.1390
   VANLUNTEREN E, 1989, J APPL PHYSIOL, V66, P135
   WARD ME, 1992, J APPL PHYSIOL, V72, P1338
   WEISSMAN C, 1984, J APPL PHYSIOL, V57, P475
   Wirth B, 2011, J ELECTROMYOGR KINES, V21, P450, DOI 10.1016/j.jelekin.2010.12.007
   YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101
NR 56
TC 0
Z9 0
U1 2
U2 2
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD NOV 1
PY 2020
VL 65
IS 11
BP 1668
EP 1677
DI 10.4187/respcare.07426
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA OH1OI
UT WOS:000582340500007
PM 32546537
OA Bronze
DA 2020-12-09
ER

PT J
AU Goncalves, JPN
   de Andrade, HMT
   Cintra, VP
   Bonadia, LC
   Leoni, TB
   de Albuquerque, M
   Martins, MP
   de Borba, FC
   Couteiro, RED
   de Oliveira, DS
   Claudino, R
   Goncalves, MVM
   Dourado, ME
   de Souza, LC
   Teixeira, AL
   Prado, LDR
   Tumas, V
   Oliveira, ASB
   Nucci, A
   Lopes-Cendes, I
   Marques, W
   Franca, MC
AF Nunes Goncalves, Joao Pedro
   Tavares de Andrade, Helen Maia
   Cintra, Vivian Pedigone
   Bonadia, Luciana Cardoso
   Leoni, Tauana Bernardes
   de Albuquerque, Milena
   Martins, Melina Pazian
   de Borba, Fabricio Castro
   Duarte Couteiro, Rafael Esteves
   de Oliveira, Daniel Sabino
   Claudino, Rinaldo
   Magno Goncalves, Marcos Vinicius
   Dourado, Mario Emilio
   de Souza, Leonardo Cruz
   Teixeira, Antonio Lucio
   Rousseff Prado, Laura de Godoy
   Tumas, Vitor
   Bulle Oliveira, Acary Souza
   Nucci, Anamarli
   Lopes-Cendes, Iscia
   Marques, Wilson, Jr.
   Franca, Marcondes C., Jr.
TI CAG repeats >= 34 in Ataxin-1 gene are associated with amyotrophic
   lateral sclerosis in a Brazilian cohort
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Amyotrophic lateral sclerosis; association study; populational genetics;
   ataxin-1
ID FRONTOTEMPORAL DEMENTIA; ALS; MODEL; SCA1
AB Little is known about the genetic basis of amyotrophic lateral sclerosis (ALS) outside Europe and US. In this study, we investigated whether intermediate CAG expansions at ATXN1 were associated to ALS in the Brazilian population. To accomplish that, representative samples from 411 unrelated patients and 436 neurologically normal controls from 6 centers spread over the territory were genotyped to quantify ATXN1 expansions. We found that ATXN1 intermediate-length expansion (>= 34 CAG repeats) are associated with the disease (odds ratio= 2.19, 95% CI= 1.081-4.441, p = .026). Most ATXN1-positive patients had classical phenotype, but some of them presented predominant lower motor neuron involvement. None of them had associated ataxia. Frontotemporal dementia was concomitantly found in 12.5% of patients carrying the intermediate ATXN1 expansion. Further studies are needed to validate these findings and to understand the pathophysiological mechanisms that connect ataxin-1 and ALS.
C1 [Tavares de Andrade, Helen Maia; Leoni, Tauana Bernardes; de Albuquerque, Milena; Martins, Melina Pazian; de Borba, Fabricio Castro; Nucci, Anamarli; Franca, Marcondes C., Jr.] Univ Campinas UNICAMP, Sch Med, Dept Neurol, Rua Tessalia Vieira de Camargo 126, BR-13083887 Campinas, SP, Brazil.
   [Nunes Goncalves, Joao Pedro; Bonadia, Luciana Cardoso; Lopes-Cendes, Iscia] Univ Campinas UNICAMP, Sch Med, Dept Med Genet, Rua Tessalia Vieira de Camargo 126, BR-13083887 Campinas, SP, Brazil.
   [Cintra, Vivian Pedigone; Duarte Couteiro, Rafael Esteves; de Oliveira, Daniel Sabino; Tumas, Vitor; Marques, Wilson, Jr.] Univ Sao Paulo HCFMRP USP, Ribeirao Preto Sch Med, Dept Neurosci & Behav Sci, Campus Univ S-N Monte Alegre, BR-14048900 Ribeirao Preto, SP, Brazil.
   [Claudino, Rinaldo] Univ Fed Santa Catarina, Dept Neurol, Campus Univ Reitor Joao David Ferreira Lima, BR-88040900 Florianopolis, SC, Brazil.
   [Dourado, Mario Emilio] Univ Fed Rio Grande do Norte, Dept Integrat Med, Ave Nilo Pecanha 620,Campus Univ Lagoa Nova, BR-59012300 Natal, RN, Brazil.
   [de Souza, Leonardo Cruz; Teixeira, Antonio Lucio; Rousseff Prado, Laura de Godoy] Univ Fed Minas Gerais, Dept Internal Med, Fac Med, Ave Alfredo Balena 190, Belo Horizonte, MG, Brazil.
   [Magno Goncalves, Marcos Vinicius] Univille Univ, Dept Neurol, Campus Univ Zona Ind 10, BR-89219710 Joinville, SC, Brazil.
   [Bulle Oliveira, Acary Souza] Univ Fed Sao Paulo, Dept Neurol, Neuromuscular Disorders Unit, Rua Estado Israel 899, BR-04022002 Sao Paulo, SP, Brazil.
RP Goncalves, JPN (corresponding author), Univ Campinas UNICAMP, Sch Med, Dept Med Genet, Rua Tessalia Vieira de Camargo 126, BR-13083887 Campinas, SP, Brazil.
EM jp.nunesgoncalves@gmail.com
OI Goncalves, Joao/0000-0002-1806-0525
FU Conselho Nacional de Pesquisa CNPqNational Council for Scientific and
   Technological Development (CNPq) [134391/2018-7, 404356/2016-8]
FX This work was supported by Conselho Nacional de Pesquisa CNPq (grants
   #134391/2018-7 and 404356/2016-8).
CR Brown RH, 2017, NEW ENGL J MED, V377, P162, DOI [10.1056/NEJMra1603471, 10.1056/NEJMc1710379]
   BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2
   Chadi G, 2017, AMYOTROPH LAT SCL FR, V18, P249, DOI 10.1080/21678421.2016.1254245
   Cheroni C, 2009, HUM MOL GENET, V18, P82, DOI 10.1093/hmg/ddn319
   Cintra VP, 2018, NEUROBIOL AGING, V66, DOI 10.1016/j.neurobiolaging.2018.01.007
   Conforti FL, 2012, NEUROLOGY, V79, P2315, DOI 10.1212/WNL.0b013e318278b618
   Cortes C.J., 2016, HHS PUBLIC ACCESS, V66, P53, DOI [10.1016/j.mcn.2015.03.010.Autophagy., DOI 10.1016/J.MCN.2015.03.010.AUTOPHAGY]
   Dalski A., 2002, SPINOCEREBELLAR ATAX, P204, DOI [10.1038/sj/ejhg/5200788., DOI 10.1038/SJ/EJHG/5200788]
   Deng H, 2014, NAT REV NEUROL, V10, P337, DOI 10.1038/nrneurol.2014.78
   Elden A.C., 2011, HHS PUBLIC ACCESS, V466, P1069, DOI [10.1038/nature09320.Ataxin-2, DOI 10.1038/NATURE09320.ATAXIN-2]
   Johnson JO, 2010, NEURON, V68, P857, DOI 10.1016/j.neuron.2010.11.036
   Lattante S, 2018, NEUROBIOL AGING, V64, DOI 10.1016/j.neurobiolaging.2017.11.011
   Lattante S, 2015, TRENDS GENET, V31, P263, DOI 10.1016/j.tig.2015.03.005
   Lee T., 2011, EVALUATING PREVALENC, P2062
   Ludolph A, 2015, AMYOTROPH LAT SCL FR, V16, P291, DOI 10.3109/21678421.2015.1049183
   Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108
   Orr HT, 2012, PROG NEUROBIOL, V99, P179, DOI 10.1016/j.pneurobio.2012.04.003
   Pena S.D.J., 2009, DNA TESTS PROBE GENO, V42
   Perrone B, 2020, CELL MOL NEUROBIOL, V40, P1, DOI 10.1007/s10571-019-00717-0
   Renton AE, 2014, NAT NEUROSCI, V17, P17, DOI 10.1038/nn.3584
   Sabatelli M, 2016, BRAIN PATHOL, V26, P266, DOI 10.1111/bpa.12354
   Sambrook J, 2001, MOL CLONING LAB MANU
   Tashiro Y, 2012, J BIOL CHEM, V287, P42984, DOI 10.1074/jbc.M112.417600
   de Andrade HMT, 2018, NEUROBIOL AGING, V69, DOI 10.1016/j.neurobiolaging.2018.04.020
   Taylor JP, 2016, NATURE, V539, P197, DOI 10.1038/nature20413
   van Blitterswijk M, 2012, CURR OPIN NEUROL, V25, P689, DOI 10.1097/WCO.0b013e32835a3efb
   van Es MA, 2017, LANCET, V390, P2084, DOI 10.1016/S0140-6736(17)31287-4
   VOLZ A, 1992, CYTOGENET CELL GENET, V60, P37, DOI 10.1159/000133291
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JUL 15
PY 2020
VL 414
AR UNSP 116842
DI 10.1016/j.jns.2020.116842
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LY3WA
UT WOS:000540458100028
PM 32339968
DA 2020-12-09
ER

PT J
AU Leonhard, SE
   Mandarakas, MR
   Gondim, FAA
   Bateman, K
   Ferreira, MLB
   Cornblath, DR
   van Doorn, PA
   Dourado, ME
   Hughes, RAC
   Islam, B
   Kusunoki, S
   Pardo, CA
   Reisin, R
   Sejvar, JJ
   Shahrizaila, N
   Soares, C
   Umapathi, T
   Wang, YZ
   Yiu, EM
   Willison, HJ
   Jacobs, BC
AF Leonhard, Sonja E.
   Mandarakas, Melissa R.
   Gondim, Francisco A. A.
   Bateman, Kathleen
   Ferreira, Maria L. B.
   Cornblath, David R.
   van Doorn, Pieter A.
   Dourado, Mario E.
   Hughes, Richard A. C.
   Islam, Badrul
   Kusunoki, Susumu
   Pardo, Carlos A.
   Reisin, Ricardo
   Sejvar, James J.
   Shahrizaila, Nortina
   Soares, Cristiane
   Umapathi, Thirugnanam
   Wang, Yuzhong
   Yiu, Eppie M.
   Willison, Hugh J.
   Jacobs, Bart C.
TI Diagnosis and management of Guillain-Barre syndrome in ten steps
SO NATURE REVIEWS NEUROLOGY
LA English
DT Review
ID INTRAVENOUS IMMUNOGLOBULIN; MECHANICAL VENTILATION; INFLUENZA
   VACCINATION; FISHER-SYNDROME; ELECTRODIAGNOSTIC CRITERIA;
   CLINICAL-FEATURES; VIRUS-INFECTION; UNITED-STATES; MORTALITY; FATIGUE
AB Guillain-Barre syndrome (GBS) is a rare, but potentially fatal, immune-mediated disease of the peripheral nerves and nerve roots that is usually triggered by infections. The incidence of GBS can therefore increase during outbreaks of infectious diseases, as was seen during the Zika virus epidemics in 2013 in French Polynesia and 2015 in Latin America. Diagnosis and management of GBS can be complicated as its clinical presentation and disease course are heterogeneous, and no international clinical guidelines are currently available. To support clinicians, especially in the context of an outbreak, we have developed a globally applicable guideline for the diagnosis and management of GBS. The guideline is based on current literature and expert consensus, and has a ten-step structure to facilitate its use in clinical practice. We first provide an introduction to the diagnostic criteria, clinical variants and differential diagnoses of GBS. The ten steps then cover early recognition and diagnosis of GBS, admission to the intensive care unit, treatment indication and selection, monitoring and treatment of disease progression, prediction of clinical course and outcome, and management of complications and sequelae.
C1 [Leonhard, Sonja E.; Mandarakas, Melissa R.; van Doorn, Pieter A.; Jacobs, Bart C.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands.
   [Gondim, Francisco A. A.] Univ Fed Ceara, Hosp Univ Walter Cantidio, Fortaleza, Ceara, Brazil.
   [Bateman, Kathleen] Univ Cape Town, Groote Schuur Hosp, Cape Town, South Africa.
   [Ferreira, Maria L. B.] Hosp Restauracao, Dept Neurol, Recife, PE, Brazil.
   [Cornblath, David R.; Pardo, Carlos A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Dourado, Mario E.] Univ Fed Rio Grande do Norte, Dept Integrat Med, Hosp Univ Onofre Lopes, Natal, RN, Brazil.
   [Hughes, Richard A. C.] UCL, UCL Queen Sq Inst Neurol, London, England.
   [Islam, Badrul] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh.
   [Kusunoki, Susumu] Kindai Univ, Fac Med, Osaka, Japan.
   [Reisin, Ricardo] Hosp Britanico, Buenos Aires, DF, Argentina.
   [Sejvar, James J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Shahrizaila, Nortina] Univ Malaya, Dept Neurol, Kuala Lumpur, Malaysia.
   [Soares, Cristiane] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Umapathi, Thirugnanam] Natl Neurosci Inst, Singapore, Singapore.
   [Wang, Yuzhong] Jining Med Univ, Affiliated Hosp, Dept Neurol, Jining, Shandong, Peoples R China.
   [Yiu, Eppie M.] Royal Childrens Hosp Melbourne, Dept Neurol, Melbourne, Vic, Australia.
   [Yiu, Eppie M.] Murdoch Childrens Res Inst, Neurosci Res, Melbourne, Vic, Australia.
   [Yiu, Eppie M.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Willison, Hugh J.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland.
   [Jacobs, Bart C.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands.
RP Jacobs, BC (corresponding author), Erasmus MC, Dept Neurol, Rotterdam, Netherlands.; Jacobs, BC (corresponding author), Erasmus MC, Dept Immunol, Rotterdam, Netherlands.
EM b.jacobs@erasmusmc.nl
RI SHAHRIZAILA, NORTINA/B-9402-2010; Gondim, Francisco de Assis/J-1463-2014
OI Gondim, Francisco de Assis/0000-0002-8957-5796; Bateman,
   Kathleen/0000-0002-0213-7102
FU European UnionEuropean Union (EU) [734584]; Wellcome Trust
   FoundationWellcome Trust; Prinses Beatrix Spierfonds; GBS/CIDP
   Foundation International; Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq); Prinses Beatrix Foundation; Ministry
   of Education, Culture, Sports, Science and Technology of JapanMinistry
   of Education, Culture, Sports, Science and Technology, Japan (MEXT)
   [18H02745]; Ministry of Health, Labour and Welfare of JapanMinistry of
   Health, Labour and Welfare, Japan; Malaysian Ministry of Education
   [FP043-2018A]; ALS Association; National Health and Medical Research
   Council of AustraliaNational Health and Medical Research Council of
   Australia
FX The authors thank Lisa Butler (Executive Director, GBS/CIDP Foundation
   International) for her contribution in reviewing the manuscript. C.A.P.,
   C.S., M.L.B.F., M.R.M., and S.E.L. are supported by a grant from the
   European Union (Horizon 2020, ZikaPLAN Grant Agreement No. 734584).
   H.J.W. is supported by a grant from the European Union (Horizon 2020,
   ZikaPLAN Grant Agreement No. 734584) and by the Wellcome Trust
   Foundation. B.C.J. is supported by a grant from the European Union
   (Horizon 2020, ZikaPLAN Grant Agreement No. 734584) and has received
   funding from Prinses Beatrix Spierfonds and GBS/CIDP Foundation
   International. F.d.A.A.G. is supported by a grant from the Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico. D.R.C. is on the
   Board of Directors for the Peripheral Nerve Society. P.A.v.D. received a
   grant from the Prinses Beatrix Foundation for the SID-GBS randomized
   controlled trial. S.K. is supported by a grant from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan
   (Grants-in-Aid for Scientific Research, 18H02745) and the Ministry of
   Health, Labour and Welfare of Japan (Health and Labour Sciences Research
   Grant). N.S. is supported by grants from the Malaysian Ministry of
   Education (FP043-2018A) and ALS Association. T.U. is supported by a
   grant from the GBS/CIDP Foundation International. E.M.Y. is supported by
   a grant from the National Health and Medical Research Council of
   Australia (Early Career Fellowship).
CR Annane D, 1997, ANN NEUROL, V41, P298
   [Anonymous], 1978, Ann Neurol, V3, P565
   Arsenault NS, 2016, PHYSIOTHER CAN, V68, P367, DOI 10.3138/ptc.2015-58
   ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707
   Berciano J, 2017, J NEUROL, V264, P221, DOI 10.1007/s00415-016-8204-2
   Bernsen RAJAM, 2010, MUSCLE NERVE, V41, P533, DOI 10.1002/mus.21536
   Bersano A, 2006, J NEUROL, V253, P214, DOI 10.1007/s00415-005-0958-x
   Blum S, 2013, J PERIPHER NERV SYST, V18, P316, DOI 10.1111/jns5.12045
   Branch DW, 2001, J ALLERGY CLIN IMMUN, V108, pS133, DOI 10.1067/mai.2001.117821
   Burwen DR, 2010, AM J PREV MED, V39, P296, DOI 10.1016/j.amepre.2010.05.022
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Chevret S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001798.pub3
   CORNBLATH DR, 1987, ANN NEUROL, V21, P32, DOI 10.1002/ana.410210107
   Davidson I, 2009, PHYSIOTHERAPY, V95, P157, DOI 10.1016/j.physio.2009.04.001
   Dhar R, 2008, J NEUROL SCI, V264, P121, DOI 10.1016/j.jns.2007.08.005
   Doets AY, 2018, BRAIN, V141, P2866, DOI 10.1093/brain/awy232
   Dominguez-Moreno R, 2014, REV NEUROLOGIA, V58, P4, DOI 10.33588/rn.5801.2013370
   Dourado ME, 2012, ACTA NEUROL SCAND, V125, P47, DOI 10.1111/j.1600-0404.2011.01503.x
   El-Bayoumi MA, 2011, CRIT CARE, V15, DOI 10.1186/cc10305
   Elrick MJ, 2019, JAMA PEDIATR, V173, P134, DOI 10.1001/jamapediatrics.2018.4890
   Farcas P, 1997, LANCET, V350, P1747, DOI 10.1016/S0140-6736(97)24050-X
   Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285
   Forsberg A, 2012, J NEUROL SCI, V317, P74, DOI 10.1016/j.jns.2012.02.026
   Gallardo E, 2015, CLIN NEUROPHYSIOL, V126, P810, DOI 10.1016/j.clinph.2014.06.051
   Garssen MPJ, 2006, J NEUROL, V253, P1143, DOI 10.1007/s00415-006-0163-6
   Garssen MPJ, 2004, NEUROLOGY, V63, P2393, DOI 10.1212/01.WNL.0000148589.87107.9C
   Gorson KC, 1996, NEUROLOGY, V47, P813, DOI 10.1212/WNL.47.3.813
   Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9
   Guillain G, 1916, B MEMOIRES SOCIETE M, V40, P1462
   Hadden RDM, 1998, ANN NEUROL, V44, P780, DOI 10.1002/ana.410440512
   Hiew FL, 2017, CLIN NEUROL NEUROSUR, V158, P114, DOI 10.1016/j.clineuro.2017.05.006
   Hiew FL, 2017, J NEUROL SCI, V375, P275, DOI 10.1016/j.jns.2017.02.024
   HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597
   Hopkins SE, 2019, JAMA PEDIATR, V173, P117, DOI 10.1001/jamapediatrics.2018.4896
   Hughes RAC, 2005, ARCH NEUROL-CHICAGO, V62, P1194, DOI 10.1001/archneur.62.8.1194
   HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2
   Hughes RAC, 2007, BRAIN, V130, P2245, DOI 10.1093/brain/awm004
   Ishaque T, 2017, J PERIPHER NERV SYST, V22, P121, DOI 10.1111/jns.12215
   Islam B, 2018, EUR J CLIN MICROBIOL, V37, P511, DOI 10.1007/s10096-018-3199-5
   Islam Md Badrul, 2017, Pilot Feasibility Stud, V3, P40, DOI 10.1186/s40814-017-0185-0
   Ito M, 2008, J NEUROL, V255, P674, DOI 10.1007/s00415-008-0775-0
   Ito M, 2011, J NEUROL NEUROSUR PS, V82, P294, DOI 10.1136/jnnp.2010.222836
   Jacobs BC, 2017, J PERIPHER NERV SYST, V22, P68, DOI 10.1111/jns.12209
   Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110
   Carod-Artal FJ, 2013, LANCET NEUROL, V12, P906, DOI 10.1016/S1474-4422(13)70150-9
   Jitraruch S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113609
   Juurlink DN, 2006, ARCH INTERN MED, V166, P2217, DOI 10.1001/archinte.166.20.2217
   Kanikannan MAK, 2014, J CRIT CARE, V29, P219, DOI 10.1016/j.jcrc.2013.10.026
   Kao JC, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0878-7
   KAPLAN JE, 1982, JAMA-J AM MED ASSOC, V248, P698, DOI 10.1001/jama.248.6.698
   KLEYWEG RP, 1991, J NEUROL NEUROSUR PS, V54, P957, DOI 10.1136/jnnp.54.11.957
   Korinthenberg R, 2007, NEUROPEDIATRICS, V38, P10, DOI 10.1055/s-2007-981686
   Korinthenberg R, 2005, PEDIATRICS, V116, P8, DOI 10.1542/peds.2004-1324
   Kuijf ML, 2005, J NEUROL SCI, V239, P37, DOI 10.1016/j.jns.2005.07.009
   Kuitwaard K, 2009, J PERIPHER NERV SYST, V14, P310, DOI 10.1111/j.1529-8027.2009.00243.x
   Kuwabara S, 2017, CLIN NEUROPHYSIOL, V128, P215, DOI 10.1016/j.clinph.2016.11.009
   Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501
   Lawn ND, 2001, ARCH NEUROL-CHICAGO, V58, P893, DOI 10.1001/archneur.58.6.893
   Maloney JA, 2015, AM J NEURORADIOL, V36, P245, DOI 10.3174/ajnr.A4188
   Mehta S, 2006, RESP CARE, V51, P1016
   Merkies ISJ, 1999, NEUROLOGY, V53, P1648, DOI 10.1212/WNL.53.8.1648
   MEULSTEE J, 1995, J NEUROL NEUROSUR PS, V59, P482, DOI 10.1136/jnnp.59.5.482
   Michon B, 2007, TRANSFUSION, V47, P1837, DOI 10.1111/j.1537-2995.2007.01405.x
   Misawa S, 2018, LANCET NEUROL, V17, P519, DOI 10.1016/S1474-4422(18)30114-5
   Mitsui Y, 2015, J NEUROL NEUROSUR PS, V86, P110, DOI 10.1136/jnnp-2013-306509
   Oczko-Walker Malgorzata, 2010, J Clin Neuromuscul Dis, V12, P55, DOI 10.1097/CND.0b013e3181f3dbbf
   Odaka M, 2003, BRAIN, V126, P2279, DOI 10.1093/brain/awg233
   Overell JR, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004761.pub2
   Pacheco LD, 2016, OBSTET GYNECOL, V128, P1105, DOI 10.1097/AOG.0000000000001716
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Peric S, 2014, J PERIPHER NERV SYST, V19, P317, DOI 10.1111/jns.12096
   Principi N, 2019, VACCINE, V37, P5544, DOI 10.1016/j.vaccine.2018.05.119
   Rajabally YA, 2015, J NEUROL NEUROSUR PS, V86, P115, DOI 10.1136/jnnp-2014-307815
   Raphael JC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001798.pub2
   Razali SNO, 2016, CLIN NEUROPHYSIOL, V127, P1652, DOI 10.1016/j.clinph.2015.06.030
   Roodbol J, 2011, NEUROLOGY, V76, P807, DOI 10.1212/WNL.0b013e31820e7b62
   Ropper A. H, 1991, GUILLAIN BARRE SYNDR, P155
   Rudant J, 2018, NEUROLOGY, V91, pE1220, DOI 10.1212/WNL.0000000000006246
   Ruts L, 2010, NEUROLOGY, V75, P1439, DOI 10.1212/WNL.0b013e3181f88345
   Ruts L, 2010, NEUROLOGY, V74, P1680, DOI 10.1212/WNL.0b013e3181e07d14
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   Sekiguchi Y, 2016, EUR J NEUROL, V23, P1058, DOI 10.1111/ene.12983
   Soysal A, 2011, ACTA NEUROL SCAND, V123, P181, DOI 10.1111/j.1600-0404.2010.01366.x
   THORNTON CA, 1991, NEUROLOGY, V41, P812, DOI 10.1212/WNL.41.6.812
   Tomimatsu T, 2016, EUR J OBSTET GYN R B, V201, P225, DOI 10.1016/j.ejogrb.2016.03.031
   Uchibori A, 2016, J NEUROIMMUNOL, V298, P172, DOI 10.1016/j.jneuroim.2016.07.021
   Uncini A, 2018, CLIN NEUROPHYSIOL, V129, P2586, DOI 10.1016/j.clinph.2018.09.025
   Uncini A, 2012, CLIN NEUROPHYSIOL, V123, P1487, DOI 10.1016/j.clinph.2012.01.025
   Uncini A, 2012, MUSCLE NERVE, V45, P464, DOI 10.1002/mus.22298
   van den Berg B, 2018, J NEUROL NEUROSUR PS, V89, P949, DOI 10.1136/jnnp-2018-317968
   van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121
   van den Berg B, 2014, NEUROLOGY, V82, P491, DOI 10.1212/WNL.0000000000000111
   van den Berg B, 2013, NEUROLOGY, V80, P1650, DOI 10.1212/WNL.0b013e3182904fcc
   Van den Bergh PYK, 2018, MUSCLE NERVE, V58, P23, DOI 10.1002/mus.26056
   van Koningsveld R, 2004, LANCET, V363, P192, DOI 10.1016/S0140-6736(03)15324-X
   Vellozzi C, 2014, CLIN INFECT DIS, V58, P1149, DOI 10.1093/cid/ciu005
   Verboon C, 2019, NEUROLOGY, V93, pE59, DOI 10.1212/WNL.0000000000007719
   Verboon C, 2017, J NEUROL NEUROSUR PS, V88, P346, DOI 10.1136/jnnp-2016-314862
   Vereninging Spierziekten Nederland Nederlandse Vereniging voor Neurologie & Nederlandse Vereniging van Revalidatieartsen [Dutch Association of Muscular Diseases & Dutch Society of Rehabilitation Specialists], 2011, MULT RICHTL GUILL BA
   Vucic S, 2004, CLIN NEUROPHYSIOL, V115, P2329, DOI 10.1016/j.clinph.2004.05.009
   Wakerley BR, 2016, J NEUROL SCI, V369, P43, DOI 10.1016/j.jns.2016.08.002
   Wakerley Benjamin R, 2015, Pract Neurol, V15, P90, DOI 10.1136/practneurol-2014-000937
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Walgaard C, 2011, NEUROLOGY, V76, P968, DOI 10.1212/WNL.0b013e3182104407
   Walgaard C, 2018, J PERIPHER NERV SYST, V23, P210, DOI 10.1111/jns.12286
   Walgaard C, 2017, NEUROCRIT CARE, V26, P6, DOI 10.1007/s12028-016-0311-5
   Walgaard C, 2010, ANN NEUROL, V67, P781, DOI 10.1002/ana.21976
   Wang YZ, 2017, EXP NEUROL, V291, P134, DOI 10.1016/j.expneurol.2017.02.010
   Wielanek AC, 2007, NEUROLOGY, V69, P2105, DOI 10.1212/01.wnl.0000277267.07220.88
   Wilder-Smith A, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1398485
   Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1
   Wong AHY, 2015, J PERIPHER NERV SYST, V20, P47, DOI 10.1111/jns.12104
   World Health Organization, 2016, ZIK SIT REP 5 FEBR 2
   Yikilmaz A, 2010, CHILD NERV SYST, V26, P1103, DOI 10.1007/s00381-010-1197-8
   Yoshikawa K, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000501
   Yuki N, 2001, Lancet Infect Dis, V1, P29
   Yuki N, 2012, J NEUROL, V259, P1181, DOI 10.1007/s00415-011-6330-4
   Zhang G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133520
NR 120
TC 34
Z9 34
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
EI 1759-4766
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD NOV
PY 2019
VL 15
IS 11
BP 671
EP 683
DI 10.1038/s41582-019-0250-9
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA JI9ZN
UT WOS:000493822500012
PM 31541214
OA Green Published, Other Gold, Green Accepted
DA 2020-12-09
ER

PT J
AU Marques, L
   Fregonezi, G
   Sarmento, A
   Marcelino, AA
   Vieira, R
   Viana, A
   Dourado, M
   Aliverti, A
   Resqueti, V
AF Marques, Layana
   Fregonezi, Guilherme
   Sarmento, Antonio
   Marcelino, Ana Aline
   Vieira, Rayane
   Viana, Andrezza
   Dourado-Junior, Mario
   Aliverti, Andrea
   Resqueti, Vanessa
TI Effects of position on thoracoabdominal asynchrony and paradoxical
   movement in subjects with DMD
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
CT European-Respiratory-Society (ERS) International Congress
CY SEP 28-OCT 02, 2019
CL Madrid, SPAIN
SP European Respiratory Soc
DE Neuromuscular diseases
C1 [Marques, Layana; Fregonezi, Guilherme; Sarmento, Antonio; Marcelino, Ana Aline; Vieira, Rayane; Viana, Andrezza; Resqueti, Vanessa] Univ Fed Rio Grande do Norte, Empresa Brasileira Serv Hosp EBSERH, Hosp Univ Onofre Lopes, PneumoCardioVasc Lab, Natal, RN, Brazil.
   [Marques, Layana; Fregonezi, Guilherme; Sarmento, Antonio; Marcelino, Ana Aline; Vieira, Rayane; Viana, Andrezza; Resqueti, Vanessa] Univ Fed Rio Grande do Norte, Dept Fisioterapia, Natal, RN, Brazil.
   [Marques, Layana; Fregonezi, Guilherme; Sarmento, Antonio; Marcelino, Ana Aline; Vieira, Rayane; Viana, Andrezza; Resqueti, Vanessa] Univ Fed Rio Grande do Norte, Dept Fisioterapia, Lab Inovacao Tecnol Reabilitacao, Natal, RN, Brazil.
   [Dourado-Junior, Mario] Univ Fed Rio Grande do Norte, Empresa Brasileira Serv Hosp EBSERH, Ambulatorio Neurol, Natal, RN, Brazil.
   [Dourado-Junior, Mario] Univ Fed Rio Grande do Norte, Dept Med Integrada, Natal, RN, Brazil.
   [Aliverti, Andrea] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
EM layanamarques@hotmail.com
RI Fregonezi, Guilherme/AAQ-1493-2020
OI Fregonezi, Guilherme/0000-0003-4938-7018
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 28
PY 2019
VL 54
SU 63
MA PA754
DI 10.1183/13993003.congress-2019.PA754
PG 2
WC Respiratory System
SC Respiratory System
GA KC7SG
UT WOS:000507372407350
DA 2020-12-09
ER

PT J
AU Silva, AMS
   Coimbra-Neto, AR
   Souza, PVS
   Winckler, PB
   Goncalves, MVM
   Cavalcanti, EBU
   Carvalho, AADS
   Sobreire, CFDR
   Camelo, CG
   Mendonca, RDH
   Estephan, EDP
   Reed, UC
   Machado-Costa, MC
   Dourado, MET
   Pereira, VC
   Cruzeiro, MM
   Helito, PVP
   Aivazoglou, LU
   Camargo, LVD
   Gomes, HH
   Camargo, AJSD
   Pinto, WBVDR
   Badia, BML
   Libardi, LH
   Yanagiura, MT
   Oliveira, ASB
   Nucci, A
   Saute, JAM
   Franca, MC
   Zanoteli, E
AF Silva, Andre M. S.
   Coimbra-Neto, Antonio R.
   Souza, Paulo Victor S.
   Winckler, Pablo B.
   Goncalves, Marcus V. M.
   Cavalcanti, Eduardo B. U.
   Carvalho, Alzira A. D. S.
   Sobreire, Claudia F. D. R.
   Camelo, Clara G.
   Mendonca, Rodrigo D. H.
   Estephan, Eduardo D. P.
   Reed, Umbertina C.
   Machado-Costa, Marcela C.
   Dourado-Junior, Mario E. T.
   Pereira, Vanessa C.
   Cruzeiro, Marcelo M.
   Helito, Paulo V. P.
   Aivazoglou, Lais U.
   Camargo, Leonardo V. D.
   Gomes, Hudson H.
   Camargo, Amaro J. S. D.
   Pinto, Wladimir B. V. D. R.
   Badia, Bruno M. L.
   Libardi, Luiz H.
   Yanagiura, Mario T.
   Oliveira, Acary S. B.
   Nucci, Anamarli
   Saute, Jonas A. M.
   Franca-Junior, Marcondes C.
   Zanoteli, Edmar
TI Clinical and molecular findings in a cohort of ANO5-related myopathy
SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
LA English
DT Article
ID MUSCULAR-DYSTROPHY; ANOCTAMIN 5; ANO5 MUTATIONS; MRI FINDINGS;
   PREVALENCE; VARIANTS; WEAKNESS; MYALGIA; PROTEIN
AB Objective ANO5-related myopathy is an important cause of limb-girdle muscular dystrophy (LGMD) and hyperCKemia. The main descriptions have emerged from European cohorts, and the burden of the disease worldwide is unclear. We provide a detailed characterization of a large Brazilian cohort of ANO5 patients. Methods A national cross-sectional study was conducted to describe clinical, histopathological, radiological, and molecular features of patients carrying recessive variants in ANO5. Correlation of clinical and genetic characteristics with different phenotypes was studied. Results Thirty-seven patients from 34 nonrelated families with recessive mutations of ANO5 were identified. The most common phenotype was LGMD, observed in 25 (67.5%) patients, followed by pseudometabolic presentation in 7 (18.9%) patients, isolated asymptomatic hyperCKemia in 4 (10.8%) patients, and distal myopathy in a single patient. Nine patients presented axial involvement, including one patient with isolated axial weakness. The most affected muscles according to MRI were the semimembranosus and gastrocnemius, but paraspinal and abdominal muscles, when studied, were involved in most patients. Fourteen variants in ANO5 were identified, and the c.191dupA was present in 19 (56%) families. Sex, years of disease, and the presence of loss-of-function variants were not associated with specific phenotypes. Interpretation We present the largest series of anoctaminopathy outside Europe. The most common European founder mutation c.191dupA was very frequent in our population. Gender, disease duration, and genotype did not determine the phenotype.
C1 [Silva, Andre M. S.; Camelo, Clara G.; Mendonca, Rodrigo D. H.; Estephan, Eduardo D. P.; Reed, Umbertina C.; Zanoteli, Edmar] Univ Sao Paulo, Fac Med, Dept Neurol, Sao Paulo, SP, Brazil.
   [Coimbra-Neto, Antonio R.; Nucci, Anamarli; Franca-Junior, Marcondes C.] Univ Estadual Campinas, Fac Ciencias Med, Dept Neurol, Campinas, SP, Brazil.
   [Souza, Paulo Victor S.; Pinto, Wladimir B. V. D. R.; Badia, Bruno M. L.; Libardi, Luiz H.; Yanagiura, Mario T.; Oliveira, Acary S. B.] Univ Fed Sao Paulo UNIFESP, Dept Neurol & Neurosurg, Div Neuromuscular Dis, Sao Paulo, SP, Brazil.
   [Winckler, Pablo B.; Saute, Jonas A. M.] HCPA, Neurol Serv, Porto Alegre, RS, Brazil.
   [Goncalves, Marcus V. M.] Univ Regiao Joinville UNIVILLE, Joinville, SC, Brazil.
   [Cavalcanti, Eduardo B. U.] Rede Sarah Hosp Reabilitacao, Brasilia, DF, Brazil.
   [Carvalho, Alzira A. D. S.] Fac Med ABC, Santo Andre, SP, Brazil.
   [Sobreire, Claudia F. D. R.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Neurociencias & Ciencias Comportamento, Ribeirao Preto, SP, Brazil.
   [Machado-Costa, Marcela C.] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [Dourado-Junior, Mario E. T.] Univ Fed Rio Grande do Norte, Dept Med Integrada, Natal, RN, Brazil.
   [Pereira, Vanessa C.] Univ Estadual Paulista Julio Mesquita, UNESP, Dept Neurol Psychol & Psychiat, Botucatu Sch Med, Botucatu, SP, Brazil.
   [Cruzeiro, Marcelo M.] Univ Fed Juiz de Fora UFJF, Hosp Univ, Dept Neurol & Neurosurg, Div Neuromuscular Dis, Juiz De Fora, MG, Brazil.
   [Helito, Paulo V. P.] Univ Sao Paulo, Fac Med, Dept Radiol, Sao Paulo, SP, Brazil.
   [Aivazoglou, Lais U.] Univ Fed Sao Paulo UNIFESP, Dept Diagnost Imaging, Sao Paulo, SP, Brazil.
   [Camargo, Leonardo V. D.; Gomes, Hudson H.] Pontificia Univ Catolica Parana, Londrina, Parana, Brazil.
   [Camargo, Amaro J. S. D.] Univ Sao Paulo, Fac Med, Inst Ortopedia, Sao Paulo, SP, Brazil.
   [Saute, Jonas A. M.] Univ Fed Rio Grande do Sul, Dept Internal Med, Porto Alegre, RS, Brazil.
   [Saute, Jonas A. M.] HCPA, Med Genet Serv, Porto Alegre, RS, Brazil.
RP Zanoteli, E (corresponding author), Av Dr Eneas de Carvalho Aguiar,255,5 Andar, BR-05403900 Sao Paulo, SP, Brazil.
EM edmar.zanoteli@usp.br
RI de Mattos Lombardi Badia, Bruno/AAO-4354-2020; Saute, Jonas Alex
   Morales/F-6635-2015; Estephan, Eduardo P/U-7659-2019; Cruzeiro,
   Marcelo/AAC-4009-2019
OI de Mattos Lombardi Badia, Bruno/0000-0001-7360-0494; Saute, Jonas Alex
   Morales/0000-0003-1141-6573; Estephan, Eduardo P/0000-0002-6807-1951;
   Cruzeiro, Marcelo/0000-0001-6898-2790; Silva, Andre Macedo Serafim
   da/0000-0002-5792-5878
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   [Anonymous], 2018, BROWSER GENOMES
   Bohlega S, 2015, NEUROSCIENCES, V20, P173, DOI 10.17712/nsj.2015.2.20140547
   Bolduc V, 2010, AM J HUM GENET, V86, P213, DOI 10.1016/j.ajhg.2009.12.013
   Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405
   de Camargo LV, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5069042
   Fischer D, 2008, NEUROLOGY, V71, P758, DOI 10.1212/01.wnl.0000324927.28817.9b
   gnomAD, 2018, GEN AGGR DAT
   Griffin DA, 2016, HUM MOL GENET, V25, P1900, DOI 10.1093/hmg/ddw063
   Guerreiro V, 2009, GENET MOL BIOL, V32, P1, DOI 10.1590/S1415-47572009005000001
   Guimaraes JB, 2017, AM J ROENTGENOL, V209, P1340, DOI 10.2214/AJR.17.17849
   Hartzell HC, 2009, J PHYSIOL-LONDON, V587, P2127, DOI 10.1113/jphysiol.2008.163709
   Hicks D, 2011, BRAIN, V134, P171, DOI 10.1093/brain/awq294
   Hu BL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012506
   Jagadeesh KA, 2016, NAT GENET, V48, P1581, DOI 10.1038/ng.3703
   Kadoya M, 2017, NEUROMUSCULAR DISORD, V27, P477, DOI 10.1016/j.nmd.2017.01.012
   Lahoria R, 2014, MUSCLE NERVE, V50, P610, DOI 10.1002/mus.24302
   Liewluck T, 2013, EUR J NEUROL, V20, P1383, DOI 10.1111/ene.12191
   Little AA, 2013, MUSCLE NERVE, V47, P287, DOI 10.1002/mus.23542
   Magri F, 2012, NEUROMUSCULAR DISORD, V22, P934, DOI 10.1016/j.nmd.2012.05.001
   Mercuri Eugenio, 2002, Eur J Paediatr Neurol, V6, P309, DOI 10.1053/ejpn.2002.0618
   Moura RR, AM J HUM BIOL, V27, P674
   Nallamilli BRR, 2018, ANN CLIN TRANSL NEUR, V5, P1574, DOI 10.1002/acn3.649
   Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601
   Papadopoulos C, 2017, MUSCLE NERVE, V56, P1096, DOI 10.1002/mus.25608
   Penttila S, 2012, NEUROLOGY, V78, P897, DOI 10.1212/WNL.0b013e31824c4682
   Rentzsch P, 2019, NUCLEIC ACIDS RES, V47, pD886, DOI 10.1093/nar/gky1016
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Sarkozy A, 2013, HUM MUTAT, V34, P1111, DOI 10.1002/humu.22342
   Sarkozy A, 2012, NEUROMUSCULAR DISORD, V22, pS122, DOI 10.1016/j.nmd.2012.05.012
   Savarese M, 2015, NEUROMUSCULAR DISORD, V25, P533, DOI 10.1016/j.nmd.2015.03.011
   Schessl J, 2012, MUSCLE NERVE, V45, P740, DOI 10.1002/mus.23281
   Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890
   Tsutsumi S, 2004, AM J HUM GENET, V74, P1255, DOI 10.1086/421527
   van der Kooi AJ, 2013, NEUROMUSCULAR DISORD, V23, P456, DOI 10.1016/j.nmd.2013.03.012
   Wahbi K, 2013, INT J CARDIOL, V168, P76, DOI 10.1016/j.ijcard.2012.09.070
   Witting N, 2013, J NEUROL, V260, P2084, DOI 10.1007/s00415-013-6934-y
NR 37
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2328-9503
J9 ANN CLIN TRANSL NEUR
JI Ann. Clin. Transl. Neurol.
PD JUL
PY 2019
VL 6
IS 7
BP 1225
EP 1238
DI 10.1002/acn3.50801
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA IK7JZ
UT WOS:000476766600008
PM 31353849
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Silva, IS
   Pedrosa, R
   Azevedo, IG
   Forbes, AM
   Fregonezi, HAF
   Dourado, MET
   Lima, SRH
   Ferreira, GMH
AF Silva, Ivanizia S.
   Pedrosa, Rafaela
   Azevedo, Ingrid G.
   Forbes, Anne-Marie
   Fregonezi, Herme A. F.
   Dourado Junior, Mario E. T.
   Lima, Suzianne R. H.
   Ferreira, Gardenia M. H.
TI Respiratory muscle training in children and adults with neuromuscular
   disease
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID AMYOTROPHIC-LATERAL-SCLEROSIS; DUCHENNE MUSCULAR-DYSTROPHY; FUNCTIONAL
   RATING-SCALE; PULMONARY-FUNCTION; HEALTH-STATUS; STRENGTH; EXERCISE;
   PRESSURE; PERFORMANCE; DISORDERS
AB Background
   Neuromuscular diseases (NMDs) are a heterogeneous group of diseases affecting the anterior horn cell of spinal cord, neuromuscular junction, peripheral nerves and muscles. NMDs cause physical disability usually due to progressive loss of strength in limb muscles, and some NMDs also cause respiratory muscle weakness. Respiratory muscle training (RMT) might be expected to improve respiratory muscle weakness; however, the effects of RMT are still uncertain. This systematic review will synthesize the available trial evidence on the effectiveness and safety of RMT in people with NMD, to inform clinical practice.
   Objectives
   To assess the effects of respiratory muscle training (RMT) for neuromuscular disease (NMD) in adults and children, in comparison to sham training, no training, standard treatment, breathing exercises, or other intensities or types of RMT.
   Search methods
   On 19 November 2018, we searched the Cochrane Neuromuscular Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase. On 23 December 2018, we searched the US National Institutes for Health Clinical Trials Registry (ClinicalTrials.gov), the World Health Organization International Clinical Trials Registry Platform, and reference lists of the included studies.
   Selection criteria
   We included randomized controlled trials (RCTs) and quasi-RCTs, including cross-over trials, of RMT in adults and children with a diagnosis of NMD of any degree of severity, who were living in the community, and who did not need mechanical ventilation. We compared trials of RMT (inspiratory muscle training (IMT) or expiratory muscle training (EMT), or both), with sham training, no training, standard treatment, different intensities of RMT, different types of RMT, or breathing exercises.
   Data collection and analysis
   We followed standard Cochrane methodological procedures.
   Main results
   We included 11 studies involving 250 randomized participants with NMDs: three trials (N = 88) in people with amyotrophic lateral sclerosis (ALS; motor neuron disease), six trials (N = 112) in Duchenne muscular dystrophy (DMD), one trial (N = 23) in people with Becker muscular dystrophy (BMD) or limb-girdle muscular dystrophy, and one trial (N = 27) in people with myasthenia gravis.
   Nine of the trials were at high risk of bias in at least one domain and many reported insufficient information for accurate assessment of the risk of bias. Populations, interventions, control interventions, and outcome measures were often different, which largely ruled out metaanalysis. All included studies assessed lung capacity, our primary outcome, but four did not provide data for analysis (1 in people with ALS and three cross-over studies in DMD). None provided long-term data (over a year) and only one trial, in ALS, provided information on adverse events. Unscheduled hospitalisations for chest infection or acute exacerbation of chronic respiratory failure were not reported and physical function and quality of life were reported in one (ALS) trial.
   Amyotrophic lateral sclerosis (ALS)
   Three trials compared RMT versus sham training in ALS. Short-term (8 weeks) effects of RMT on lung capacity in ALS showed no clear difference in the change of the per cent predicted forced vital capacity (FVC%) between EMT and sham EMT groups (mean difference (MD) 0.70, 95% confidence interval (CI) -8.48 to 9.88; N = 46; low-certainty evidence). The mean difference (MD) in FVC% after four months' treatment was 10.86% in favour of IMT (95% CI -4.25 to 25.97; 1 trial, N = 24; low-certainty evidence), which is larger than the minimal clinically important difference (MCID, as estimated in people with idiopathic pulmonary fibrosis). There was no clear difference between IMT and sham IMT groups, measured on the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALFRS; range of possible scores 0 = best to 40 = worst) (MD 0.85, 95% CI -2.16 to 3.85; 1 trial, N = 24; low-certainty evidence) or quality of life, measured on the EuroQol-5D (0 = worst to 100 = best) (MD 0.77, 95% CI -17.09 to 18.62; 1 trial, N = 24; low-certainty evidence) over the medium term (4 months). One trial report stated that the IMT protocol had no adverse effect (very low-certainty evidence).
   Duchenne muscular dystrophy (DMD)
   Two DMD trials compared RMT versus sham training in young males with DMD. In one study, the mean post-intervention (6-week) total lung capacity (TLC) favoured RMT (MD 0.45 L, 95% CI -0.24 to 1.14; 1 trial, N = 16; low-certainty evidence). In the other trial there was no clear difference in post-intervention (18 days) FVC between RMT and sham RMT (MD 0.16 L, 95% CI -0.31 to 0.63; 1 trial, N = 20; low-certainty evidence). One RCT and three cross-over trials compared a form of RMT with no training in males with DMD; the cross-over trials did not provide suitable data. Post-intervention (6-month) values showed no clear difference between the RMT and no training groups in per cent predicted vital capacity (VC%) (MD 3.50, 95% CI -14.35 to 21.35; 1 trial, N = 30; low-certainty evidence).
   Becker or limb-girdle muscular dystrophy
   One RCT (N = 21) compared 12 weeks of IMT with breathing exercises in people with Becker or limb-girdle muscular dystrophy. The evidence was of very low certainty and conclusions could not be drawn.
   Myasthenia gravis
   In myasthenia gravis, there may be no clear difference between RMT and breathing exercises on measures of lung capacity, in the short term (TLC MD -0.20 L, 95% CI -1.07 to 0.67; 1 trial, N = 27; low-certainty evidence). Effects of RMT on quality of life are uncertain (1 trial; N = 27).
   Some trials reported effects of RMT on inspiratory and/or expiratory muscle strength; this evidence was also of low or very low certainty.
   Authors' conclusions
   RMT may improve lung capacity and respiratory muscle strength in some NMDs. In ALS there may not be any clinically meaningful effect of RMT on physical functioning or quality of life and it is uncertain whether it causes adverse effects. Due to clinical heterogeneity between the trials and the small number of participants included in the analysis, together with the risk of bias, these results must be interpreted very cautiously.
C1 [Silva, Ivanizia S.] Univ Fed Rio Grande do Norte, Dept Phys Therapy, Ave Senador Salgado Filho 3000, BR-59072970 Natal, RN, Brazil.
   [Pedrosa, Rafaela] Univ Fed Paraiba, Dept Phys Therapy, Joao Pessoa, Paraiba, Brazil.
   [Azevedo, Ingrid G.] Ana Bezerra Univ Hosp, Phys Therapy, Natal, RN, Brazil.
   [Azevedo, Ingrid G.; Ferreira, Gardenia M. H.] Univ Fed Rio Grande do Norte, PhD Program Phys Therapy, Natal, RN, Brazil.
   [Forbes, Anne-Marie] Univ Tasmania, Sch Creat Arts & Media, Creat Arts & Hlth, Hobart, Tas, Australia.
   [Fregonezi, Herme A. F.] Brazilian Co Hosp Serv EBSERH, Onofre Lopes Univ Hosp, PneumoCardioVasc Lab, Natal, RN, Brazil.
   [Dourado Junior, Mario E. T.; Lima, Suzianne R. H.] Univ Fed Rio Grande do Norte, Integrated Med, Natal, RN, Brazil.
RP Silva, IS (corresponding author), Univ Fed Rio Grande do Norte, Dept Phys Therapy, Ave Senador Salgado Filho 3000, BR-59072970 Natal, RN, Brazil.
EM iziasoares@gmail.com
RI Azevedo, Ingrid/AAL-9413-2020
OI Azevedo, Ingrid/0000-0001-7305-7583
FU National Institute for Health Research (NIHR)National Institute for
   Health Research (NIHR); MRC Centre for Neuromuscular Disease; Motor
   Neurone Disease Association
FX This project was supported by the National Institute for Health Research
   (NIHR) via Cochrane Infrastructure funding to Cochrane Neuromuscular.
   Theviews and opinions expressed herein are those of the authors and do
   not necessarily reflect those of the Systematic Reviews Programme, NIHR,
   National Health Service (NHS) or the Department of Health. Cochrane
   Neuromuscular is also supported by the MRC Centre for Neuromuscular
   Disease and the Motor Neurone Disease Association.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Abe K, 1998, NEUROLOGY, V51, P641, DOI 10.1212/WNL.51.2.641
   Aboussouan L S, 2009, Chron Respir Dis, V6, P231, DOI 10.1177/1479972309345927
   Abresch RT, 2012, PHYS MED REH CLIN N, V23, P653, DOI 10.1016/j.pmr.2012.06.001
   ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771
   Ambrosino N, 2009, EUR RESPIR J, V34, P444, DOI 10.1183/09031936.00182208
   Anziska Y, 2013, MUSCLE NERVE, V48, P3, DOI 10.1002/mus.23771
   Aslan GK, 2014, CLIN REHABIL, V28, P573, DOI 10.1177/0269215513512215
   Benditt JO, 2006, RESPIR CARE, V51, P829
   Berlowitz D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008507.pub2
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Cedarbaum JM, 1997, J NEUROL SCI, V152, pS1, DOI 10.1016/S0022-510X(97)00237-2
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   Cheah B, 2009, 20 INT S ALS MND 200
   Cheah BC, 2009, AMYOTROPH LATERAL SC, V10, P384, DOI 10.3109/17482960903082218
   Cup EH, 2007, ARCH PHYS MED REHAB, V88, P1452, DOI 10.1016/j.apmr.2007.07.024
   D'Angelo MG, 2011, J NEUROL SCI, V306, P54, DOI 10.1016/j.jns.2011.03.045
   de Godoy VC, 2012, REV NEUROCINCIAS, V20, P138
   de la Loge C, 2016, CHRON OBSTR PULM DIS, V3, P519, DOI 10.15326/jcopdf.3.2.2015.0152
   DIMARCO AF, 1985, MUSCLE NERVE, V8, P284, DOI 10.1002/mus.880080404
   du Bois RM, 2011, AM J RESP CRIT CARE, V184, P1382, DOI 10.1164/rccm.201105-0840OC
   Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2
   Eidenberger M, 2014, NEUROREHABILITATION, V35, P349, DOI 10.3233/NRE-141148
   Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U
   Emery AEH, 1994, DIAGNOSTIC CRITERIA
   Enright SJ, 2011, PHYS THER, V91, P894, DOI 10.2522/ptj.20090413
   EPSTEIN SK, 1994, CLIN CHEST MED, V15, P619
   Estournet-Mathiaud B., 2003, PNEUMOLOGIE ENFANT, P273
   ESTRUP C, 1986, RESPIRATION, V50, P36
   Faber Jorge, 2014, Dental Press J. Orthod., V19, P27, DOI 10.1590/2176-9451.19.4.027-029.ebo
   Ferreira GD, 2016, PHYSIOTHERAPY, V102, P221, DOI 10.1016/j.physio.2016.01.002
   Finder JD, 2004, AM J RESP CRIT CARE, V170, P456, DOI 10.1164/rccm.200307-885ST
   Fitting JW, 2006, EUR RESPIR J, V27, P881, DOI 10.1183/09031936.06.00007906
   Fregonezi GA, 2010, CHEST, V138, p920A
   Fregonezi GA, 2003, EUROPEAN RESP J S45, V22, P2729
   Fregonezi GAD, 2005, CHEST, V128, P1524, DOI 10.1378/chest.128.3.1524
   Gozal D, 1999, MED SCI SPORT EXER, V31, P1522, DOI 10.1097/00005768-199911000-00005
   Gross D, 1993, Monaldi Arch Chest Dis, V48, P322
   HajGhanbari B, 2013, J STRENGTH COND RES, V27, P1643, DOI 10.1519/JSC.0b013e318269f73f
   Hannan LM, 2014, RESP MED, V108, P229, DOI 10.1016/j.rmed.2013.11.010
   HAPKE EJ, 1972, CHEST, V61, P41, DOI 10.1378/chest.61.1.41
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Hill K, 2004, AUST J PHYSIOTHER, V50, P169, DOI 10.1016/S0004-9514(14)60155-0
   Hoffman J., 2002, PHYSL ASPECTS SPORT
   Huang CH, 2011, J FORMOS MED ASSOC, V110, P518, DOI 10.1016/S0929-6646(11)60078-8
   Human A, 2017, NEUROMUSCULAR DISORD, V27, P503, DOI 10.1016/j.nmd.2017.03.009
   Illi SK, 2012, SPORTS MED, V42, P707, DOI 10.2165/11631670-000000000-00000
   INKLEY SR, 1974, AM J MED, V56, P297, DOI 10.1016/0002-9343(74)90611-1
   Jones Paul W, 2005, COPD, V2, P75
   JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702
   Landrigan PJ, 2005, CHILDRENS HLTH ENV G, P3
   LEITH DE, 1976, J APPL PHYSIOL, V41, P508
   Litchke LG, 2008, J SPINAL CORD MED, V31, P65, DOI 10.1080/10790268.2008.11753983
   MARTIN AJ, 1986, DEV MED CHILD NEUROL, V28, P314
   McConnell AK, 2009, J EXERC SCI FIT, V7, pS18, DOI 10.1016/S1728-869X(09)60019-8
   MCCOOL FD, 1995, PHYS THER, V75, P1006, DOI 10.1093/ptj/75.11.1006
   McDonald CM, 2002, AM J PHYS MED REHAB, V81, pS108, DOI 10.1097/00002060-200211001-00012
   McDonald CM, 2012, PHYS MED REH CLIN N, V23, P495, DOI 10.1016/j.pmr.2012.06.011
   Merkle M, 1993, EUROPEAN RESP J SUPP, V6, p310S
   Misuri G, 2000, CHEST, V117, P447, DOI 10.1378/chest.117.2.447
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Moodie Lisa H, 2011, BMC Res Notes, V4, P283, DOI 10.1186/1756-0500-4-283
   Nici L, 2006, AM J RESP CRIT CARE, V173, P1390, DOI 10.1164/rccm.200508-1211ST
   Nordic Cochrane Centre The Cochrane Collaboration, 2014, REV MAN 5 REVMAN 5 V
   OSSERMAN KE, 1971, MT SINAI J MED, V38, P497
   Page MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159267
   Park JH, 2010, YONSEI MED J, V51, P392, DOI 10.3349/ymj.2010.51.3.392
   Paschoal Ilma Aparecida, 2007, J. bras. pneumol., V33, P81, DOI 10.1590/S1806-37132007000100016
   Pedrosa R, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CDO11711, DOI 10.1002/14651858.CDO11711]
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Pine M, 2005, SPORTS COACH, V27, P1
   Pinto S, 2009, AMYOTROPHIC LATERAL, V10, P59
   Pinto S, 2014, NEURODEGENER DIS MAN, V4, P83, DOI [10.2217/nmt.13.74, 10.2217/NMT.13.74]
   Pinto S, 2013, AMYOTROPH LAT SCL FR, V14, P124, DOI 10.3109/17482968.2012.726227
   Pinto S, 2012, AMYOTROPH LATERAL SC, V13, P33, DOI 10.3109/17482968.2011.626052
   Plowman E, 2015, AMYOTROPHIC LATER S1, V16, P44, DOI [10.3109/21678421.2015.1089039/0065, DOI 10.3109/21678421.2015.1089039/0065]
   Plowman EK, 2014, AMYOTROPHIC LATERAL, V15, P206
   Plowman EK, 2019, MUSCLE NERVE, V59, P40, DOI 10.1002/mus.26292
   Plowman EK, 2016, MUSCLE NERVE, V54, P48, DOI 10.1002/mus.24990
   Pollock RD, 2013, INT J STROKE, V8, P124, DOI 10.1111/j.1747-4949.2012.00811.x
   Pontes Jaqueline Fernandes, 2012, Fisioter. mov., V25, P253, DOI 10.1590/S0103-51502012000200002
   Pustavoitau A, 2008, CRIT CARE CLIN, V24, P1, DOI 10.1016/j.ccc.2007.11.004
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Radunovic A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004427.pub4
   Ramirez-Sarmiento A, 2008, ARCH BRONCONEUMOL, V44, P119, DOI 10.1157/13116597
   Rassler B, 2014, ACTA PHYSIOL, V210, P138
   Rassler B, 2007, NEUROMUSCULAR DISORD, V17, P385, DOI 10.1016/j.nmd.2007.01.001
   Rassler B, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/808607
   Reed Umbertina C., 2002, J. Pediatr. (Rio J.), V78, pS89, DOI 10.1590/S0021-75572002000700012
   Reyes A, 2013, CHEST, V143, P1386, DOI 10.1378/chest.12-1442
   Rezania K, 2012, NEUROL CLIN, V30, P161, DOI 10.1016/j.ncl.2011.09.010
   Riebe D, 2014, ACSMS GUIDELINES EXE, P161
   Rietberg MB, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009424.pub2
   RODILLO E, 1989, ARCH DIS CHILD, V64, P736, DOI 10.1136/adc.64.5.736
   Rodriguez I, 2014, J BRAS PNEUMOL, V40, P626, DOI 10.1590/S1806-37132014000600006
   Romer LM, 2003, MED SCI SPORT EXER, V35, P237, DOI 10.1249/01.MSS.0000048642.58419.1E
   Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497
   Sartori R, 2008, J CYST FIBROS, V7, P313, DOI 10.1016/j.jcf.2007.12.003
   Savovic J, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16350
   Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.1016/j.ijsu.2011.09.004]
   Schunemann H, 2013, HDB GRADING QUALITY
   SMITH PEM, 1988, MUSCLE NERVE, V11, P784, DOI 10.1002/mus.880110716
   STERN LM, 1989, DEV MED CHILD NEUROL, V31, P494
   Suleman M, 2003, THORAX, V58, P77
   Thomas GD, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00381
   Timpani CA, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0652-y
   Topin N, 2002, NEUROMUSCULAR DISORD, V12, P576, DOI 10.1016/S0960-8966(02)00005-6
   TZELEPIS GE, 1994, J APPL PHYSIOL, V77, P795
   Tzelepis GE, 1999, EUR J APPL PHYSIOL O, V79, P467, DOI 10.1007/s004210050538
   Ungar D, 1996, Wien Med Wochenschr, V146, P213
   Van Houtte S, 2006, RESP MED, V100, P1886, DOI 10.1016/j.rmed.2006.02.029
   Vandervelde L, 2009, NEUROMUSCULAR DISORD, V19, P99, DOI 10.1016/j.nmd.2008.11.004
   WANKE T, 1994, CHEST, V105, P475, DOI 10.1378/chest.105.2.475
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Weiner P, 1998, CAN J NEUROL SCI, V25, P236, DOI 10.1017/S0317167100034077
   Wijdicks EF, 2009, NEUROLOGICAL COMPLIC, P59
   Wild M, 1995, ATEMWEG LUNGENKRANK, V21, P478
   Winkler G, 2000, MUSCLE NERVE, V23, P1257, DOI 10.1002/1097-4598(200008)23:8<1257::AID-MUS15>3.0.CO;2-M
   Wirth B, 1999, AM J HUM GENET, V64, P1340, DOI 10.1086/302369
   Xiao Y, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CDO09360.pub2, DOI 10.1002/14651858.CDO09360.PUB2]
   Yeldan I, 2008, CLIN REHABIL, V22, P741, DOI 10.1177/0269215508091203
   Zupan A, 2002, J NEUROL SCI, V199, pS32
NR 124
TC 3
Z9 3
U1 4
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2019
IS 9
AR CD011711
DI 10.1002/14651858.CD011711.pub2
PG 72
WC Medicine, General & Internal
SC General & Internal Medicine
GA KG7RQ
UT WOS:000510145900024
PM 31487757
OA Green Published
DA 2020-12-09
ER

PT J
AU Sarmento, A
   Fregonezi, G
   Dourado, MET
   Aliverti, A
   de Andrade, AD
   Parreira, VF
   Resqueti, V
AF Sarmento, Antonio
   Fregonezi, Guilherme
   Teixeira Dourado-Junior, Mario Emilio
   Aliverti, Andrea
   de Andrade, Armele Dornelas
   Parreira, Veronica Franco
   Resqueti, Vanessa
TI Thoracoabdominal asynchrony and paradoxical motion in middle stage
   amyotrophic lateral sclerosis
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE Chest wall volumes; Cough; Diaphragm impairment; Inspiratory paradox
   time; Phase angle; Quiet breathing
ID CHEST-WALL MOTION; RESPIRATORY MUSCLE STRENGTH; NASAL INSPIRATORY
   PRESSURE; RIB CAGE; NEUROMUSCULAR DISEASE; ABDOMINAL-MUSCLES; REFERENCE
   VALUES; MECHANICS; VOLUME; COUGH
AB Aim: To assess thoracoabdominal asynchrony (TAA) and the presence of paradoxical motion in middle stage amyotrophic lateral sclerosis (ALS) and its relationships with chest wall tidal volume (VT,cw), breathing pattern and cough peak flow (CPF).
   Methods: Phase angle (0) between upper (RCp) and lower ribcage (RCa) and abdomen (AB), as well as percentage of inspiratory time for the lower ribcage (IPnca) and abdomen (IPAB) moving in opposite directions were quantified using optoelectronic plethysmography in 12 ALS patients during quiet breathing and coughing. Paradoxical motion of the compartments was based on threshold values of 0 and IP, obtained in twelve age and sex matched healthy persons.
   Results: During quiet breathing, significantly higher RCa and AB 0 (p <.05), IPBca (p = 0.001) and IPAB (p < 0.05) were observed in ALS patients as compared to controls. In ALS patients, correlations between RCa and AB 0 with forced vital capacity (FVC) (r=-0.773, p < 0.01), vital capacity (r=-0.663, p < 0.05) and inspiratory capacity (IC) (r=-0.754, p < 0.01), as well as between RCp and RCa 0 with FVC (r=-0.608, p < 0.05) and CPF (r=-0.601, p < 0.05) were found. During coughing, correlations between RCp and AB 0 with CPF (r =-0.590, p < 0.05), IC (r = 0.748,p < 0.01) and VT,cw (r = -0.608, p < 0.05), as well as between RCa and AB 0 with CPF (r=-0.670, p < 0.05), IC (r=-0.713, p < 0.05) and peak expiratory flow (r=-0.727, p < 0.05) were also observed in ALS patients. ALS patients with paradoxical motion presented lower vital capacity and FVC%pred (p < 0.05) compared to those without paradoxical motion.
   Conclusions: Middle stage ALS patients exhibit TAA and paradoxical motion during quiet spontaneous breathing and coughing. In addition, diaphragmatic weakness (i.e. decrease in excursion of the RCa and AB compartments) was observed earlier in the lower ribcage rather than the abdominal compartment in this population.
C1 [Sarmento, Antonio; Fregonezi, Guilherme; Resqueti, Vanessa] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Empresa Brasileira Serv Hosp EBSERH, PneumoCardioVasc Lab, Natal, RN, Brazil.
   [Teixeira Dourado-Junior, Mario Emilio] Univ Fed Rio Grande do Norte, EBSERH, Ambulatario Neurol, Natal, RN, Brazil.
   [Aliverti, Andrea] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
   [de Andrade, Armele Dornelas] Univ Fed Pernambuco, Dept Fisioterapia, Recife, PE, Brazil.
   [Parreira, Veronica Franco] Univ Fed Minas Gerais, Dept Fisioterapia, Belo Horizonte, MG, Brazil.
RP Resqueti, V (corresponding author), Univ Fed Rio Grande do Norte UFRN, Dept Fisioterapia, Lab Desempenho PneumoCardioVasc & Musculos Resp, Campus Univ Lagoa Nova,Caixa Postal 1524, BR-59072970 Natal, RN, Brazil.
EM vanessaresqueti@hotmail.com
RI Andrea, Aliverti/A-3901-2015; Sarmento, Antonio/K-9999-2018; Fregonezi,
   Guilherme/AAQ-1493-2020; Fregonezi, Guilherme AF/B-2186-2019; PARREIRA,
   VERONICA/I-4236-2013
OI Andrea, Aliverti/0000-0002-2950-0231; Sarmento,
   Antonio/0000-0001-6391-5652; Fregonezi, Guilherme/0000-0003-4938-7018;
   Fregonezi, Guilherme AF/0000-0003-4938-7018; PARREIRA,
   VERONICA/0000-0003-0374-9319
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [PGCI 23.038.007514/2014-78, 054/2014]; CAPESCAPES [PROCAD -
   UFMG/UFRN/UFPE - 88881.068409/20140]; Conselho Nacional de
   Desenvolvimento Cientlfico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [307353/2015-0];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [310091/2015-2]
FX The study was funded by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES) - PGCI 23.038.007514/2014-78 and 054/2014; and
   CAPES - PROCAD - UFMG/UFRN/UFPE - 88881.068409/20140. Guilherme Augusto
   de Freitas Fregonezi is a Fellow of the Conselho Nacional de
   Desenvolvimento Cientlfico e Tecnologico (CNPq) number: 307353/2015-0
   and Vanessa Regiane Resqueti is also Fellow of CNPq number:
   310091/2015-2.
CR AGOSTONI E, 1966, J APPL PHYSIOL, V21, P1827
   Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518
   Aliverti A, 2000, AM J RESP CRIT CARE, V161, P1546, DOI 10.1164/ajrccm.161.5.9903024
   Aliverti A, 2002, J APPL PHYSIOL, V92, P1953, DOI 10.1152/japplphysiol.01222.2000
   Aliverti A, 2003, Monaldi Arch Chest Dis, V59, P12
   Aliverti A, 2009, EUR RESPIR J, V33, P49, DOI 10.1183/09031936.00141607
   Aliverti A, 2001, ANN BIOMED ENG, V29, P60, DOI 10.1114/1.1332084
   ALLEN JL, 1991, PEDIATR PULM, V11, P37, DOI 10.1002/ppul.1950110107
   ALLEN JL, 1990, AM REV RESPIR DIS, V141, P337, DOI 10.1164/ajrccm/141.2.337
   Allen J, 2010, PAEDIATR RESPIR REV, V11, P18, DOI 10.1016/j.prrv.2009.10.002
   Bach JR, 2008, AM J PHYS MED REHAB, V87, P720, DOI 10.1097/PHM.0b013e31817fb26f
   Balendra R, 2015, J NEUROL NEUROSUR PS, V86, P45, DOI 10.1136/jnnp-2013-306865
   BAYDUR A, 1991, CHEST, V99, P330, DOI 10.1378/chest.99.2.330
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Cala SJ, 1996, J APPL PHYSIOL, V81, P2680
   Carrie C, 2016, ULTRASOUND MED BIOL, V42, P143, DOI 10.1016/j.ultrasmedbio.2015.09.020
   Chihara K, 1996, J APPL PHYSIOL, V81, P437
   Cleary S, 2013, AMYOTROPH LAT SCL FR, V14, P111, DOI 10.3109/17482968.2012.720262
   Cohen J., 2013, STAT POWER ANAL BEHA
   CRAWFORD ABH, 1983, RESP PHYSIOL, V54, P197, DOI 10.1016/0034-5687(83)90057-9
   Crescimanno G, 2012, RESP MED, V106, P1478, DOI 10.1016/j.rmed.2012.05.013
   DETROYER A, 1983, J APPL PHYSIOL, V54, P465
   Detroyer A., 1995, THE THORAX, V85, P2177
   DIAZ CE, 1993, PEDIATR PULM, V16, P89, DOI 10.1002/ppul.1950160203
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   FERRIGNO G, 1994, J APPL PHYSIOL, V77, P1224
   Fregonezi G, 2015, RESP CARE, V60, P533, DOI 10.4187/respcare.03367
   Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338
   GIBSON GJ, 1977, AM REV RESPIR DIS, V115, P389
   GILMARTIN JJ, 1984, THORAX, V39, P264, DOI 10.1136/thx.39.4.264
   GOLDMAN MD, 1993, AM REV RESPIR DIS, V147, P1175, DOI 10.1164/ajrccm/147.5.1175
   Gordon PH, 2004, AMYOTROPH LATERAL SC, V5, P90, DOI 10.1080/17434470410019906
   Gregory SA, 2007, NEUROREHABILITATION, V22, P435
   Guedes K, 2010, ARQ NEURO-PSIQUIAT, V68, P44, DOI 10.1590/S0004-282X2010000100010
   Hammer J, 2009, PAEDIATR RESPIR REV, V10, P75, DOI 10.1016/j.prrv.2009.02.004
   Hardart MKM, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e24
   HERITIER F, 1994, AM J RESP CRIT CARE, V150, P1678, DOI 10.1164/ajrccm.150.6.7952632
   HIGENBOTTAM T, 1977, THORAX, V32, P589, DOI 10.1136/thx.32.5.589
   HILLMAN DR, 1986, AM REV RESPIR DIS, V133, P587
   IBANEZ J, 1982, INTENS CARE MED, V8, P173, DOI 10.1007/BF01725734
   Kang SW, 2000, CHEST, V118, P61, DOI 10.1378/chest.118.1.61
   KREITZER SM, 1978, AM J MED, V65, P89, DOI 10.1016/0002-9343(78)90697-6
   Lanini B, 2007, ACTA PHYSIOL, V190, P351, DOI 10.1111/j.1748-1716.2007.01701.x
   Lanini B, 2008, RESP PHYSIOL NEUROBI, V161, P62, DOI 10.1016/j.resp.2007.12.003
   Layton AM, 2016, MUSCLE NERVE, V54, P270, DOI 10.1002/mus.25043
   Lechtzin N, 2006, CHEST, V129, P1322, DOI 10.1378/chest.129.5.1322
   Lima INDF, 2014, RESP CARE, V59, P1101, DOI 10.4187/respcare.02651
   Llado J, 2006, NEUROBIOL DIS, V21, P110, DOI 10.1016/j.nbd.2005.06.019
   Lo Mauro A, 2010, EUR RESPIR J, V35, P1118, DOI 10.1183/09031936.00037209
   LoMauro A, 2014, PEDIATR PULM, V49, P357, DOI 10.1002/ppul.22836
   Lyall RA, 2001, BRAIN, V124, P2000, DOI 10.1093/brain/124.10.2000
   MIER A, 1985, J APPL PHYSIOL, V58, P1438
   Miscio G, 2006, J NEUROL SCI, V251, P10, DOI 10.1016/j.jns.2006.05.059
   MORTOLA JP, 1978, CLIN SCI MOL MED, V54, P25, DOI 10.1042/cs0540025
   MORTOLA JP, 1978, RESP PHYSIOL, V35, P201, DOI 10.1016/0034-5687(78)90022-1
   MORTOLA JP, 1979, AM REV RESPIR DIS, V119, P131
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   Orsini M, 2015, NEUROL INT, V7, DOI [10.4081/ni.2015.5885, 10.4081/ni.2015.5886]
   Park JH, 2010, YONSEI MED J, V51, P392, DOI 10.3349/ymj.2010.51.3.392
   Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
   Perez A, 1996, CHEST, V110, P454, DOI 10.1378/chest.110.2.454
   Polkey MI, 2017, AM J RESP CRIT CARE, V195, P86, DOI 10.1164/rccm.201604-0848OC
   Priori R, 2013, J APPL PHYSIOL, V114, P1066, DOI 10.1152/japplphysiol.00414.2012
   RINGEL ER, 1983, AM REV RESPIR DIS, V128, P607
   Roche JC, 2012, BRAIN, V135, P847, DOI 10.1093/brain/awr351
   Romer SH, 2017, EXP NEUROL, V287, P192, DOI 10.1016/j.expneurol.2016.05.033
   de Araujo PRS, 2012, J BRAS PNEUMOL, V38, P700, DOI 10.1590/S1806-37132012000600004
   Senent C, 2011, AMYOTROPH LATERAL SC, V12, P26, DOI 10.3109/17482968.2010.535541
   Shimizu T, 2010, AMYOTROPH LATERAL SC, V11, P57, DOI 10.1080/17482960903207385
   Similowski T, 2000, EUR RESPIR J, V15, P332, DOI 10.1034/j.1399-3003.2000.15b19.x
   Simon NG, 2014, ANN NEUROL, V76, P643, DOI 10.1002/ana.24273
   Smith JA, 2012, J PHYSIOL-LONDON, V590, P563, DOI 10.1113/jphysiol.2011.213157
   Stromberg NOT, 1998, CLIN PHYSIOL, V18, P447, DOI 10.1046/j.1365-2281.1998.00118.x
   Testa MBC, 2005, AM J PHYS MED REHAB, V84, P666, DOI 10.1097/01.phm.0000176362.24957.77
   VELLODY VP, 1978, J APPL PHYSIOL, V45, P581
   Vilke G M, 2000, Respir Care, V45, P407
   Vitacca M, 1997, EUR RESPIR J, V10, P1614, DOI 10.1183/09031936.97.10071614
   WARD ME, 1992, J APPL PHYSIOL, V72, P1338
   Warren RH, 1997, EUR RESPIR J, V10, P2295, DOI 10.1183/09031936.97.10102295
   YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101
   Zoumot Z, 2015, CHEST, V148, P185, DOI 10.1378/chest.14-2380
NR 81
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD JAN
PY 2019
VL 259
BP 16
EP 25
DI 10.1016/j.resp.2018.06.012
PG 10
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA HE4LW
UT WOS:000453339400002
PM 29969705
DA 2020-12-09
ER

PT J
AU Leonhard, S
   Barreira, A
   Van Doorn, P
   Amorelli, M
   Araujo, W
   Gondim, FDA
   Brito, M
   Tan, CY
   Cornblath, D
   Dourado, ME
   Fonseca, B
   Souza, DGB
   Islam, Z
   Maciel, E
   Marques, W
   Matos, L
   Mohammad, QD
   Osorio, L
   Pardo, C
   Parra, B
   Reisin, R
   Resende, G
   Dos Santos, D
   Sejvar, J
   Shahrizaila, N
   Mendonca, HS
   Solomon, T
   Thirugnanam, U
   Willison, H
   Jacobs, B
AF Leonhard, Sonja
   Barreira, Amilton
   Van Doorn, Pieter
   Amorelli, Manuela
   Araujo, Wildo
   Aquino Gondim, Francisco De Assis
   Brito, Maria
   Tan Cheng-Yin
   Cornblath, David
   Dourado, Mario Emilio
   Fonseca, Benedito
   Brum Souza, Doralina Guimaraes
   Islam, Zhahirul
   Maciel, Ernane
   Marques, Wilson
   Matos, Luiza
   Mohammad, Quazi Deen
   Osorio, Lyda
   Pardo, Carlos
   Parra, Beatriz
   Reisin, Ricardo
   Resende, Glaucia
   Dos Santos, Diogo
   Sejvar, James
   Shahrizaila, Nortina
   Mendonca, Helena Silva
   Solomon, Tom
   Thirugnanam, Umapathi
   Willison, Hugh
   Jacobs, Bart
TI International Zika virus related Guillain-Barre Syndrome Outcome Study
   (IGOS-Zika): Update of a case-controlled study
SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
LA English
DT Meeting Abstract
CT Annual Meeting of the Peripheral-Nerve-Society
CY JUL 21-25, 2018
CL Baltimore, MD
SP Peripheral Nerve Soc
DE Inflammatory; Other
C1 [Leonhard, Sonja; Van Doorn, Pieter; Jacobs, Bart] Erasmus MC, Dept Neurol, Rotterdam, Netherlands.
   [Barreira, Amilton; Marques, Wilson] Univ Sao Paulo, Med Sch, Dept Neurosci, Ribeirao Preto, Brazil.
   [Amorelli, Manuela] Secretary State Fed Dist, Dept Infect Dis, Brasilia, DF, Brazil.
   [Araujo, Wildo] Univ Brasilia, Ceilandia Fac, Dept Epidemiol, Brasilia, DF, Brazil.
   [Aquino Gondim, Francisco De Assis] Hosp Univ Walter Cantidio Fortaleza, Fortaleza, Ceara, Brazil.
   [Brito, Maria] Hosp Restauracao, Recife, PE, Brazil.
   [Tan Cheng-Yin; Shahrizaila, Nortina] Univ Malaya, Dept Neurol, Kuala Lumpur, Malaysia.
   [Cornblath, David; Pardo, Carlos] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Dourado, Mario Emilio] Hosp Univ Onofre Lopes, Natal, RN, Brazil.
   [Fonseca, Benedito] Med Sch Ribeirao Preto, Dept Virol, Ribeirao Preto, Brazil.
   [Brum Souza, Doralina Guimaraes] Hosp Clin Fac Med Botucatu, Botucatu, SP, Brazil.
   [Islam, Zhahirul] Icddr B, Lab Sci & Serv Div, Dhaka, Bangladesh.
   [Maciel, Ernane; Matos, Luiza] Hosp Base Dist Fed, Brasilia, DF, Brazil.
   [Mohammad, Quazi Deen] Inst Neurosci & Hosp NINS, Dhaka, Bangladesh.
   [Osorio, Lyda; Parra, Beatriz] Univ Valle, Cali, Colombia.
   [Reisin, Ricardo] Hosp Britanico, Buenas Aires, Argentina.
   [Resende, Glaucia] Hosp Municipal Odilon Behrens MG, Belo Horizonte, MG, Brazil.
   [Dos Santos, Diogo] Hosp Clin Univ Fed Oberlandia, Oberlandia, Brazil.
   [Sejvar, James] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Mendonca, Helena Silva] Univ Fed Goias, Goiania, Go, Brazil.
   [Solomon, Tom] Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
   [Thirugnanam, Umapathi] Natl Neurosci Inst, Singapore, Singapore.
   [Willison, Hugh] Univ Glasgow, Dept Neurol, Glasgow, Lanark, Scotland.
RI Tan, Cheng-Yin/AAX-1763-2020; Araujo, Wildo Navegantes/AAD-9163-2020;
   Marques, Wilson/G-4240-2012; Fonseca, Benedito/U-1154-2019; Pardo,
   Carlos A./A-5192-2008
OI Araujo, Wildo Navegantes/0000-0002-6856-4094; Marques,
   Wilson/0000-0002-4589-2749; Pardo, Carlos A./0000-0002-4128-5335
FU European Union's Horizon 2020 research and innovation programme [734584]
FX This project has received funding from the European Union's Horizon 2020
   research and innovation programme under grant agreement No 734584
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1085-9489
EI 1529-8027
J9 J PERIPHER NERV SYST
JI J. Peripher. Nerv. Syst.
PD DEC
PY 2018
VL 23
IS 4
BP 321
EP 322
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA HD8EO
UT WOS:000452787700182
DA 2020-12-09
ER

PT J
AU Dourado, MET
   Fernandes, UT
   Ramos, ES
   Vital, ALF
   Urbano, JCC
   Queiroz, JW
   Jeronimo, SMB
AF Dourado Junior, Mario E. T.
   Fernandes, Ugor T.
   Ramos, Eugenio S.
   Vital, Ana L. F.
   Urbano, Joao C. C.
   Queiroz, Jose W.
   Jeronimo, Selma M. B.
TI Egos has a reduced capacity to predicts GBS prognosis in Northeast
   Brazil
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Editorial Material
DE Guillain-Barre syndrome; Nerve Conduction Study; neuropathies;
   peripheral neuropathies; prognosis
ID GUILLAIN-BARRE-SYNDROME; PATHOGENESIS; INFECTIONS
AB ObjectiveThe Erasmus Guillain Barre Outcome Score (EGOS) is a prognostic model that predicts the chance of being able to walk independently at 6months after Guillain Barre syndrome (GBS). This study was conducted aiming to determine the validity of EGOS in a Brazilian population.
   Material and MethodsData collected from GBS patients in Rio Grande do Norte, Brazil, were used to determine the validity of EGOS. GBS disability score was assessed in the second week of disease and at 6months.
   ResultsA total of 206 subjects were studied. The Brazilian patients were younger, with a more severe clinical presentation, with higher percentage of cranial nerve involvement and upper respiratory infection. There was no difference relative to sex or presence of anti-gangliosides antibodies. The demyelinating variant was more common (73.9%). However, only 24% of the Brazilians with EGOS 5.5-7 were not able to walk after 6months, compared to 52% to European Group. Nine patients (3.8%) presented nodopathies, of these four had an EGOS >5, but only one of the latter group was unable to walk after 6months of GBS.
   ConclusionsErasmus Guillain Barre Outcome Score was not a good predictor for the ability to walk after 6months of GBS in Rio Grande do Norte, Brazil. Differences could be that the Brazilian GBS were younger, or alternatively, it could be due to a different infection profile or in the incidence of nodopathies.
C1 [Dourado Junior, Mario E. T.] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Natal, RN, Brazil.
   [Dourado Junior, Mario E. T.] Univ Fed Rio Grande do Norte, Dept Integrat Med, Av Nilo Pecanha, BR-59012300 Natal, RN, Brazil.
   [Dourado Junior, Mario E. T.; Fernandes, Ugor T.; Ramos, Eugenio S.; Vital, Ana L. F.; Urbano, Joao C. C.; Queiroz, Jose W.; Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, Inst Trop Med Rio Grande do Norte, Natal, RN, Brazil.
   [Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, Dept Biochem, Natal, RN, Brazil.
   [Jeronimo, Selma M. B.] Natl Inst Sci & Technol Trop Dis, Natal, RN, Brazil.
RP Dourado, MET (corresponding author), Univ Fed Rio Grande do Norte, Dept Integrat Med, Av Nilo Pecanha, BR-59012300 Natal, RN, Brazil.
EM medourado@ufrnet.br
RI Jeronimo, Selma/AAY-4033-2020
OI Jeronimo, Selma/0000-0002-4784-9904
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [CNPQ-440893/2016-0]
FX This work was supported in part with funds from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPQ-440893/2016-0). The
   funder had no role in the study design.
CR ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707
   Dourado ME, 2012, ACTA NEUROL SCAND, V125, P47, DOI 10.1111/j.1600-0404.2011.01503.x
   Draak THP, 2016, J PERIPHER NERV SYST, V21, P74, DOI 10.1111/jns.12167
   FEASBY TE, 1993, J NEUROL SCI, V116, P185, DOI 10.1016/0022-510X(93)90324-R
   da Silva IRF, 2017, JAMA NEUROL, V74, P1190, DOI 10.1001/jamaneurol.2017.1703
   Hadden RDM, 1998, ANN NEUROL, V44, P780, DOI 10.1002/ana.410440512
   Hadden RDM, 2001, NEUROLOGY, V56, P758, DOI 10.1212/WNL.56.6.758
   HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597
   Islam Z, 2011, EMERG INFECT DIS, V17, P1317, DOI [10.3201/eid1707.102031, 10.3201/eid1707.101999]
   Jacobs BC, 2017, J PERIPHER NERV SYST, V22, P68, DOI 10.1111/jns.12209
   Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110
   Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802760370736
   Rivera-Lillo G, 2016, J PERIPHER NERV SYST, V21, P339, DOI 10.1111/jns.12182
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Uncini A, 2015, J NEUROL NEUROSUR PS, V86, P1186, DOI 10.1136/jnnp-2014-310097
   van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121
   van Doorn PA, 2008, LANCET NEUROL, V7, P939, DOI 10.1016/S1474-4422(08)70215-1
   van Koningsveld R, 2007, LANCET NEUROL, V6, P589, DOI 10.1016/S1474-4422(07)70130-8
   Willison H.J., 2016, LANCET, V6736, P1, DOI DOI 10.1016/S0140-6736(16)00339-1.ELSEVIER
   Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101
NR 20
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD NOV
PY 2018
VL 138
IS 5
BP 459
EP 462
DI 10.1111/ane.12995
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA GW0JK
UT WOS:000446549700011
PM 30003535
DA 2020-12-09
ER

PT J
AU Marques, L
   Fregonezi, G
   Santos, P
   Sarmento, A
   Marcelino, A
   Lopes, N
   Aliverti, A
   Dourado, ME
   Resqueti, V
   Medeiros, J
AF Marques, Layana
   Fregonezi, Guilherme
   Santos, Priscila
   Sarmento, Antonio
   Marcelino, Ana
   Lopes, Natalia
   Aliverti, Andrea
   Dourado, Mario Emilio, Jr.
   Resqueti, Vanessa
   Medeiros, Jessica
TI Effects of posture on peak cough flow and respiratory muscle activation
   in Duchenne muscular dystrophy
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
CT 28th International Congress of the European-Respiratory-Society (ERS)
CY SEP 15-19, 2018
CL Paris, FRANCE
SP European Respiratory Soc
C1 [Marques, Layana; Fregonezi, Guilherme; Santos, Priscila; Sarmento, Antonio; Marcelino, Ana; Lopes, Natalia; Resqueti, Vanessa; Medeiros, Jessica] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Empresa Brasileira Serv Hosp EBSERH, PneumoCardioVasc Lab,Dept Fisioterapia, Natal, RN, Brazil.
   [Aliverti, Andrea] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
   [Dourado, Mario Emilio, Jr.] Univ Fed Rio Grande do Norte, Dept Med Interna, Natal, RN, Brazil.
   [Dourado, Mario Emilio, Jr.] Univ Fed Rio Grande do Norte, Setor Neurofisiol, Natal, RN, Brazil.
RI Fregonezi, Guilherme AF/B-2186-2019; Fregonezi, Guilherme/AAQ-1493-2020;
   Sarmento, Antonio/K-9999-2018; Andrea, Aliverti/A-3901-2015
OI Fregonezi, Guilherme AF/0000-0003-4938-7018; Fregonezi,
   Guilherme/0000-0003-4938-7018; Sarmento, Antonio/0000-0001-6391-5652;
   Andrea, Aliverti/0000-0002-2950-0231
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 15
PY 2018
VL 52
SU 62
MA PA3898
DI 10.1183/13993003.congress-2018.PA3898
PG 2
WC Respiratory System
SC Respiratory System
GA HH2RV
UT WOS:000455567105030
DA 2020-12-09
ER

PT J
AU Santos, IP
   Lira, M
   Da Fonseca, JDM
   Marques, L
   Marcelino, A
   Dourado, M
   Fregonezi, G
   Resqueti, V
AF Santos, Ilsa Priscila
   Lira, Maria
   Medeiros Da Fonseca, Jessica Danielle
   Marques, Layana
   Marcelino, Ana
   Emilio Dourado-Junior, Mario
   Fregonezi, Guilherme
   Resqueti, Vanessa
TI Analysis of maximum relaxation rate in patients with Duchenne Muscular
   Distrophy compared to healthy subjects
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
CT 28th International Congress of the European-Respiratory-Society (ERS)
CY SEP 15-19, 2018
CL Paris, FRANCE
SP European Respiratory Soc
C1 [Santos, Ilsa Priscila; Lira, Maria; Medeiros Da Fonseca, Jessica Danielle; Marques, Layana; Marcelino, Ana; Fregonezi, Guilherme; Resqueti, Vanessa] Univ Rio Grande do Norte UFRN, Empresa Brasileira Serv Hosp EBSERH, Hosp Univ Onofre Lopes, PneumoCardioVasc Lab,Dept Fisioterapia, Natal, RN, Brazil.
   [Emilio Dourado-Junior, Mario] Univ Rio Grande do Norte UFRN, Empresa Brasileira Serv Hosp EBSERH, Hosp Univ Onofre Lopes, Dept Med Integrada, Natal, RN, Brazil.
RI Fregonezi, Guilherme AF/B-2186-2019; Fregonezi, Guilherme/AAQ-1493-2020
OI Fregonezi, Guilherme AF/0000-0003-4938-7018; Fregonezi,
   Guilherme/0000-0003-4938-7018
NR 0
TC 0
Z9 0
U1 0
U2 2
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 15
PY 2018
VL 52
SU 62
MA PA1715
DI 10.1183/13993003.congress-2018.PA1715
PG 2
WC Respiratory System
SC Respiratory System
GA HH2RV
UT WOS:000455567102124
DA 2020-12-09
ER

PT J
AU Sarmento, A
   Aliverti, A
   Marques, L
   Pennati, F
   Medeiros, J
   Dourado, ME
   Fregonezi, G
   Resqueti, V
AF Sarmento, Antonio
   Aliverti, Andrea
   Marques, Layana
   Pennati, Francesca
   Medeiros, Jessica
   Dourado-Junior, Mario Emilio
   Fregonezi, Guilherme
   Resqueti, Vanessa
TI Multiparametric analysis of sniff nasal inspiratory pressure test in
   middle stage amyotrophic lateral sclerosis
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
CT 28th International Congress of the European-Respiratory-Society (ERS)
CY SEP 15-19, 2018
CL Paris, FRANCE
SP European Respiratory Soc
C1 [Sarmento, Antonio; Marques, Layana; Medeiros, Jessica; Fregonezi, Guilherme; Resqueti, Vanessa] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Empresa Brasileira Serv Hosp EBSERH, PneumoCardioVasc Lab,Dept Fisioterapia, Natal, RN, Brazil.
   [Aliverti, Andrea; Pennati, Francesca] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
   [Dourado-Junior, Mario Emilio] Univ Fed Rio Grande do Norte, Dept Med Integrada, EBSERH, Ambulatorio Neurol, Natal, RN, Brazil.
RI Sarmento, Antonio/K-9999-2018; Andrea, Aliverti/A-3901-2015; Fregonezi,
   Guilherme AF/B-2186-2019; Fregonezi, Guilherme/AAQ-1493-2020; Pennati,
   Francesca/K-5287-2016
OI Sarmento, Antonio/0000-0001-6391-5652; Andrea,
   Aliverti/0000-0002-2950-0231; Fregonezi, Guilherme
   AF/0000-0003-4938-7018; Fregonezi, Guilherme/0000-0003-4938-7018;
   Pennati, Francesca/0000-0001-8896-8224
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 15
PY 2018
VL 52
SU 62
MA PA3897
DI 10.1183/13993003.congress-2018.PA3897
PG 2
WC Respiratory System
SC Respiratory System
GA HH2RV
UT WOS:000455567105029
OA Green Published
DA 2020-12-09
ER

PT J
AU de Andrade, HMT
   Cintra, VP
   de Albuquerque, M
   Piccinin, CC
   Bonadia, LC
   Couteiro, RED
   de Oliveira, DS
   Claudino, R
   Goncalves, MVM
   Dourado, MET
   de Souza, LC
   Teixeira, AL
   Prado, LDR
   Tumas, V
   Oliveira, ASB
   Nucci, A
   Lopes-Cendes, I
   Marques, W
   Franca, MC
AF Tavares de Andrade, Helen Maia
   Cintra, Vivian Pedigone
   de Albuquerque, Milena
   Piccinin, Camila Callegari
   Bonadia, Luciana Cardoso
   Duarte Couteiro, Rafael Esteves
   de Oliveira, Daniel Sabino
   Claudino, Rinaldo
   Magno Goncalves, Marcos Vinicius
   Teixeira Dourado Jr, Mario Emilio
   de Souza, Leonardo Cruz
   Teixeira, Antonio Lucio
   Rousseff Prado, Laura de Godoy
   Tumas, Vitor
   Bulle Oliveira, Acary Souza
   Nucci, Anamarli
   Lopes-Cendes, Iscia
   Marques Jr, Wilson
   Franca Jr, Marcondes C.
TI Intermediate-length CAG repeat in ATXN2 is associated with increased
   risk for amyotrophic lateral sclerosis in Brazilian patients
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE ALS; ATXN2 gene; Brazilian patients; Risk factor
ID SPINOCEREBELLAR ATAXIA TYPE-2; POLYGLUTAMINE EXPANSIONS; HEXANUCLEOTIDE
   REPEAT; ALS; MUTATIONS; GENE; PROTEIN; C9ORF72; ONSET; FTD
AB Intermediate-length cytosine-adenine-guanine nucleotide repeat expansions in the ATXN2 gene (which encodes for the protein Ataxin-2) have been linked to increased risk for amyotrophic lateral sclerosis (ALS) in different populations. There is no such study in the Brazilian population, which has a mixed ethnic background. We have thus selected 459 patients with ALS (372 Sporadic ALS and 87 Familial ALS) and 468 control subjects from 6 Brazilian centers to investigate this point. We performed polymerase chain reaction to determine the length of the ATXN2 alleles. Polymerase chain reaction products were resolved using capillary electrophoresis on ABI 3500 x l capillary sequencer. We found that ATXN2 intermediate-length expansions (larger than 26 repeats) were associated with an increased risk for ALS (odds ratio = 2.56, 95% confidence interval: 1.29-5.08, p = 0.005). Phenotype in patients with and without ATXN2 expansions was similar. Our findings support the hypothesis that ATXN2 plays an important role in the pathogenesis of ALS also in the Brazilian population. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Tavares de Andrade, Helen Maia; de Albuquerque, Milena; Piccinin, Camila Callegari; Nucci, Anamarli; Franca Jr, Marcondes C.] Univ Estadual Campinas, Sch Med, Dept Neurol, UNICAMP, Campinas, SP, Brazil.
   [Cintra, Vivian Pedigone; Duarte Couteiro, Rafael Esteves; de Oliveira, Daniel Sabino; Tumas, Vitor; Marques Jr, Wilson] Univ Sao Paulo HCFMRP USP, Ribeirao Preto Sch Med, Dept Neurosci & Behav Sci, Ribeirao Preto, SP, Brazil.
   [Bonadia, Luciana Cardoso; Lopes-Cendes, Iscia] Univ Estadual Campinas, Sch Med, Dept Med Genet, UNICAMP, Campinas, SP, Brazil.
   [Claudino, Rinaldo; Magno Goncalves, Marcos Vinicius] Univ Fed Santa Catarina, Dept Neurol, Campus Univ Reitor Joao David Ferreira Lima, Trindade, Brazil.
   [Teixeira Dourado Jr, Mario Emilio] Univ Fed Rio Grande do Norte, Dept Neurol, Campus Univ Lagoa Nova, Natal, RN, Brazil.
   [de Souza, Leonardo Cruz; Teixeira, Antonio Lucio] Univ Fed Minas Gerais, Dept Internal Med, Fac Med, Belo Horizonte, MG, Brazil.
   [de Souza, Leonardo Cruz; Teixeira, Antonio Lucio; Rousseff Prado, Laura de Godoy] Univ Fed Minas Gerais, Programa Posgrad Neurociencias, Belo Horizonte, MG, Brazil.
   [Bulle Oliveira, Acary Souza] Univ Fed Sao Paulo, Dept Neurol, Neuromuscular Disorders Unit, Sao Paulo, SP, Brazil.
RP Franca, MC (corresponding author), Univ Estadual Campinas, UNICAMP, Dept Neurol, Cidade Univ Zeferino Vaz, BR-13083887 Campinas, SP, Brazil.
EM mcfrancajr@uol.com.br
RI Lopes-Cendes, Iscia/B-9416-2013; de Souza, Leonardo C/C-1833-2016;
   Marques, Wilson/G-4240-2012; Teixeira, Antonio L/N-3315-2014
OI Lopes-Cendes, Iscia/0000-0002-6221-6822; de Souza, Leonardo
   C/0000-0001-5027-9722; Marques, Wilson/0000-0002-4589-2749; Teixeira,
   Antonio L/0000-0002-9621-5422; Maia Tavares de Andrade,
   Helen/0000-0003-2662-6223
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESPs
   [2013/01766-7]; Conselho Nacional de Pesquisa CNPqNational Council for
   Scientific and Technological Development (CNPq) [470428/2011-2]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo-FAPESPs (grant #2013/01766-7) and Conselho Nacional de
   Pesquisa CNPq (grant #470428/2011-2).
CR Becker LA, 2017, NATURE, V544, P367, DOI 10.1038/nature22038
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Cady J, 2015, ANN NEUROL, V77, P100, DOI 10.1002/ana.24306
   Chadi G, 2017, AMYOTROPH LAT SCL FR, V18, P249, DOI 10.1080/21678421.2016.1254245
   DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011
   Elden AC, 2010, NATURE, V466, P1069, DOI 10.1038/nature09320
   Highley JR, 2016, NEUROPATH APPL NEURO, V42, P377, DOI 10.1111/nan.12254
   Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285
   Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066
   Lastres-Becker I, 2008, CEREBELLUM, V7, P115, DOI 10.1007/s12311-008-0019-y
   Lee T, 2011, HUM MOL GENET, V20, P1697, DOI 10.1093/hmg/ddr045
   Lu HP, 2015, NEUROBIOL AGING, V36, DOI 10.1016/j.neurobiolaging.2014.10.015
   Narain P, 2017, NEUROBIOL AGING, V56, DOI 10.1016/j.neurobiolaging.2017.04.011
   Neuenschwander AG, 2014, JAMA NEUROL, V71, P1529, DOI 10.1001/jamaneurol.2014.2082
   Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108
   Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287
   Ostrowski LA, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060157
   Pena SDJ, 2009, BRAZ J MED BIOL RES, V42, P870, DOI 10.1590/S0100-879X2009005000026
   Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269
   Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Sambrook J, 2012, MOL CLONING LAB MANU, P1
   Soong BW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2014.05.008
   Sproviero W, 2017, NEUROBIOL AGING, V51, DOI 10.1016/j.neurobiolaging.2016.11.010
   van Es MA, 2017, LANCET, V390, P2084, DOI 10.1016/S0140-6736(17)31287-4
   Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942
   Vucic S, 2014, TRENDS NEUROSCI, V37, P433, DOI 10.1016/j.tins.2014.05.006
   Wang MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105534
   Yamashita S, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0036-y
NR 29
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD SEP
PY 2018
VL 69
AR 292.e15
DI 10.1016/j.neurobiolaging.2018.04.020
PG 4
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA GO0SW
UT WOS:000439651000032
PM 29934271
DA 2020-12-09
ER

PT J
AU Cintra, VP
   Bonadia, LC
   Andrade, HMT
   de Albuquerque, M
   Eusebio, MF
   de Oliveira, DS
   Claudino, R
   Goncalves, MVM
   Teixeira, AL
   Prado, LDR
   de Souza, LC
   Dourado, MET
   Oliveira, ASB
   Tumas, V
   Franca, MC
   Marques, W
AF Cintra, Vivian Pedigone
   Bonadia, Luciana Cardoso
   Andrade, Helen Maia T.
   de Albuquerque, Milena
   Eusebio, Mayara Ferreira
   de Oliveira, Daniel Sabino
   Claudino, Rinaldo
   Magno Goncalves, Marcus Vinicius
   Teixeira, Antonio Lucio, Jr.
   Rousseff Prado, Laura de Godoy
   de Souza, Leonardo Cruz
   Teixeira Dourado, Mario Emilio, Jr.
   Bulle Oliveira, Acary Souza
   Tumas, Vitor
   Franca, Marcondes C., Jr.
   Marques, Wilson, Jr.
TI The frequency of the C9orf72 expansion in a Brazilian population
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE C9orf72; G(4)C(2) repeat expansion; Amyotrophic lateral sclerosis;
   Frontotemporal dementia; Neurodegenerative diseases; Frequency
ID FRONTOTEMPORAL LOBAR DEGENERATION; HEXANUCLEOTIDE REPEAT EXPANSION;
   SPASTIC PARAPLEGIA; EPIDEMIOLOGY; DIAGNOSIS; DEMENTIA; SPECTRUM; ALS
AB G(4)C(2) hexanucleotide repeat expansions in the C9orf72 gene seem to be the cause of numerous cases of amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD). In this study, we investigated the presence of the G(4)C(2) repeat expansion in 463 Brazilian probands, of whom 404 had ALS/motor neuron disease and 67 FTD, and in 63 healthy controls in the southeastern region of Brazil. The highest frequencies of the C9orf72 mutation were in the ALS-FTD group (50% of familial and 17.6% of sporadic cases), although it was also present in 5% of pure ALS/motor neuron disease patients (11.8% of familial and 3.6% of sporadic cases) and in 7.1% of pure familial FTD. Among G(4)C(2) repeat mutation carriers, 68.8% of the subjects who developed dementia symptoms were females. This frequency was significantly higher than the percentage reached by men with C9orf72 expansion who had this phenotype (p = 0.047). No abnormal repeat expansion was found in control groups. Inclusion of the C9orf72 genetic test in the molecular panels for Brazilian populations with these neurodegenerative diseases should be strongly considered. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Cintra, Vivian Pedigone; de Oliveira, Daniel Sabino; Tumas, Vitor; Marques, Wilson, Jr.] Univ Sao Paulo, FMRP, Sao Paulo, Brazil.
   [Bonadia, Luciana Cardoso; Andrade, Helen Maia T.; de Albuquerque, Milena; Eusebio, Mayara Ferreira; Franca, Marcondes C., Jr.] Univ Estadual Campinas UNICAMP, FCC, Campinas, Brazil.
   [Claudino, Rinaldo] Univ Fed Santa Catarina, Dept Neurol, Florianopolis, SC, Brazil.
   [Magno Goncalves, Marcus Vinicius] Univ Regiao Joinville UNIVILLE, Dept Neurol, Joinville, Brazil.
   [Teixeira, Antonio Lucio, Jr.; Rousseff Prado, Laura de Godoy; de Souza, Leonardo Cruz] Univ Fed Minas Gerais, Dept Med Interna, Belo Horizonte, MG, Brazil.
   [Teixeira Dourado, Mario Emilio, Jr.] Univ Fed Rio Grande Norte UFRN, Dept Neurol, Natal, RN, Brazil.
   [Bulle Oliveira, Acary Souza] Univ Fed Sao Paulo UNIFESP, Dept Neurol & Neurocirurgia, Sao Paulo, Brazil.
RP Marques, W (corresponding author), Univ Sao Paulo, FMRP, Sao Paulo, Brazil.
EM wmjunior@fmrp.usp.br
RI de Souza, Leonardo C/C-1833-2016; Cintra, Vivian/M-9780-2018; Marques,
   Wilson/G-4240-2012; Teixeira, Antonio L/N-3315-2014
OI de Souza, Leonardo C/0000-0001-5027-9722; Cintra,
   Vivian/0000-0002-4908-9320; Marques, Wilson/0000-0002-4589-2749;
   Teixeira, Antonio L/0000-0002-9621-5422
FU Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [4019942010-4]; Comissao de Aperfeicoamento de
   Pessoal do Nivel Superior-CAPES (USP/RPMedicine-Neurology)
   [33002029012P3]; Fundacao de Apoio ao Ensino, Pesquisa e
   Assistencia-FAEPA, Brazil
FX The authors are grateful to all study participants for their cooperation
   and support. The authors also thank Sandra Elisabete Marques and Daiana
   Oliveira Souza for technical assistance. This work was supported by
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq
   (4019942010-4), Comissao de Aperfeicoamento de Pessoal do Nivel
   Superior-CAPES (USP/RPMedicine-Neurology: 33002029012P3), and Fundacao
   de Apoio ao Ensino, Pesquisa e Assistencia-FAEPA, Brazil.
CR Almeida MR, 2016, NEUROBIOL AGING, V40, DOI 10.1016/j.neurobiolaging.2015.12.015
   Boeve BF, 2012, BRAIN, V135, P765, DOI 10.1093/brain/aws004
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Chadi G., 2016, AMYOTROPH LATERAL SC, V18, P1
   Chester C, 2013, AMYOTROPH LAT SCL FR, V14, P70, DOI 10.3109/17482968.2012.690418
   DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011
   Gijselinck I, 2012, LANCET NEUROL, V11, P54, DOI 10.1016/S1474-4422(11)70261-7
   Hubers A, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.11.034
   Itzcovich T, 2016, NEUROBIOL AGING, V40, DOI 10.1016/j.neurobiolaging.2016.02.001
   Lillo P, 2009, J CLIN NEUROSCI, V16, P1131, DOI 10.1016/j.jocn.2009.03.005
   Luo YY, 2014, J NEUROL SCI, V347, P104, DOI 10.1016/j.jns.2014.09.028
   Majounie E, 2012, LANCET NEUROL, V11, P323, DOI 10.1016/S1474-4422(12)70043-1
   Morris Jerry, 2015, Neurodiagn J, V55, P180
   Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546
   Nielsen TT, 2014, SPINAL CORD, V52, P77, DOI 10.1038/sc.2013.116
   Onyike CU, 2013, INT REV PSYCHIATR, V25, P130, DOI 10.3109/09540261.2013.776523
   Rabinovici GD, 2010, CNS DRUGS, V24, P375, DOI 10.2165/11533100-000000000-00000
   Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010
   Ringholz GM, 2005, NEUROLOGY, V65, P586, DOI 10.1212/01.wnl.0000172911.39167.b6
   Smith BN, 2013, EUR J HUM GENET, V21, P102, DOI 10.1038/ejhg.2012.98
   Takada LT, 2012, ARCH NEUROL-CHICAGO, V69, P1149, DOI 10.1001/archneurol.2012.650
   van der Zee J, 2013, HUM MUTAT, V34, P363, DOI 10.1002/humu.22244
   van Rheenen W, 2012, NEUROLOGY, V79, P878, DOI 10.1212/WNL.0b013e3182661d14
   Williams KL, 2013, J NEUROL NEUROSUR PS, V84, P931, DOI 10.1136/jnnp-2012-304529
NR 24
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUN
PY 2018
VL 66
AR 179.e1
DI 10.1016/j.neurobiolaging.2018.01.007
PG 4
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA GE1WA
UT WOS:000431006300024
PM 29449030
DA 2020-12-09
ER

PT J
AU Sarmento, A
   Aliverti, A
   Marques, L
   Pennati, F
   Dourado, ME
   Fregonezi, G
   Resqueti, V
AF Sarmento, Antonio
   Aliverti, Andrea
   Marques, Layana
   Pennati, Francesca
   Dourado-Junior, Mario Emilio
   Fregonezi, Guilherme
   Resqueti, Vanessa
TI Multiparametric Analysis of Sniff Nasal Inspiratory Pressure Test in
   Middle Stage Amyotrophic Lateral Sclerosis
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE amyotrophic lateral sclerosis; forced vital capacity; inspiratory muscle
   weakness; relaxation rates; respiratory subscore; sniff nasal
   inspiratory pressure
ID FUNCTIONAL RATING-SCALE; MAXIMAL RELAXATION RATE; SLOW VITAL CAPACITY;
   MUSCLE-RELAXATION; RESPIRATORY-FAILURE; ALSFRS-R; VOLUNTARY
   CONTRACTIONS; DIAPHRAGMATIC FATIGUE; DISEASE PROGRESSION;
   CYSTIC-FIBROSIS
AB The relaxation rates and contractile properties of inspiratory muscles are altered with inspiratory muscle weakness and fatigue. This fact plays an important role in neuromuscular disorders patients and had never been extensively studied in amyotrophic lateral sclerosis (ALS). In this cross-sectional study, these parameters were investigated non-invasively through nasal inspiratory sniff pressure test (SNIP) in 39 middle stage spinal onset ALS subjects and compared with 39 healthy controls. ALS patients were also divided into three subgroups according to a decline in their percentage of predicted forced vital capacity (FVC%pred) as well as a decline in the ALS functional rating scale score and its respiratory subscore (R-subscore) in order to determine the best parameter linked to early respiratory muscle weakness. When compared with healthy subjects, middle stage ALS subjects exhibited a significantly lower (p < 0.0001) maximum relaxation rate and maximum rate of pressure development (MRPD), as well as a significantly higher (p < 0.0001) tau (tau), contraction time, and half-relaxation time. The results from receiver operating characteristic curves showed that MRPD (AUC 0.735, p < 0.001) and FVC%pred (AUC 0.749, p = 0.009) were the best discriminator parameters between ALS patients with <= 30 and > 30 points in the ALS functional rating scale. In addition, 1/2RT (AUC 0.720, p = 0.01), FVC%pred (AUC 0.700, p = 0.03), tau (AUC 0.824, p < 0.0001), and MRPD (AUC 0.721, p = 0.01) were the parameters more sensitive in detecting a fall of three points in the R-subscore. On the other hand, MRPD (AUC 0.781, p < 0.001), tau (AUC 0.794, p = 0.0001), and percentage of predicted of SNIP (AUC 0.769, p = 0.002) were the parameters able to detect a fall in 30% of the FVC%pred in middle stage ALS patients. The contractile properties and relaxation rates of the diaphragm are altered in middle stage spinal onset ALS when compared with healthy subjects. These parameters are able to discriminate between those middle stage ALS subjects with early decline in inspiratory muscle function and those who not.
C1 [Sarmento, Antonio; Marques, Layana; Fregonezi, Guilherme; Resqueti, Vanessa] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Empresa Brasileira Serv Hosp EBSERH, Dept Fisioterapia,PneumoCardioVasc Lab, Natal, RN, Brazil.
   [Aliverti, Andrea; Pennati, Francesca] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
   [Dourado-Junior, Mario Emilio] Univ Fed Rio Grande do Norte, Dept Med Integrada, Empresa Brasileira Serv Hosp EBSERH, Ambulatorio Neurol, Natal, RN, Brazil.
RP Resqueti, V (corresponding author), Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Empresa Brasileira Serv Hosp EBSERH, Dept Fisioterapia,PneumoCardioVasc Lab, Natal, RN, Brazil.
EM vanessaresqueti@hotmail.com
RI Andrea, Aliverti/A-3901-2015; Fregonezi, Guilherme/AAQ-1493-2020;
   Pennati, Francesca/K-5287-2016; Sarmento, Antonio/K-9999-2018
OI Andrea, Aliverti/0000-0002-2950-0231; Fregonezi,
   Guilherme/0000-0003-4938-7018; Pennati, Francesca/0000-0001-8896-8224;
   Sarmento, Antonio/0000-0001-6391-5652
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [PGCI 23.038.007514/2014-78, 054/2014]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [307353/2015-0];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [310091/2015-2]
FX The study was funded by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES)-PGCI 23.038.007514/2014-78 and 054/2014. GF is
   Fellow from Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) number: 307353/2015-0 and VR is Fellow from CNPq
   number: 310091/2015-2.
CR Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518
   Andrews JA, 2018, JAMA NEUROL, V75, P58, DOI 10.1001/jamaneurol.2017.3339
   Bauer M, 2012, RESPIRATION, V84, P306, DOI 10.1159/000339415
   BEHM DG, 1993, J APPL PHYSIOL, V74, P359
   BELLEMARE F, 1986, J APPL PHYSIOL, V61, P1153
   Benicio K, 2016, BRAZ J PHYS THER, V20, P96, DOI 10.1590/bjpt-rbf.2014.0101
   BIGLANDRITCHIE B, 1983, J NEUROPHYSIOL, V50, P313
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Capozzo R, 2015, J NEUROL, V262, P593, DOI 10.1007/s00415-014-7613-3
   Castrillo-Viguera C, 2010, AMYOTROPH LATERAL SC, V11, P178, DOI 10.3109/17482960903093710
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   Chen R, 1996, J NEUROL NEUROSUR PS, V60, P455, DOI 10.1136/jnnp.60.4.455
   Chio A, 2013, NEUROEPIDEMIOLOGY, V41, P118, DOI 10.1159/000351153
   Cohen J., 2013, STAT POWER ANAL BEHA
   Coirault C, 1999, J APPL PHYSIOL, V87, P1243
   Czaplinski A, 2006, MUSCLE NERVE, V34, P702, DOI 10.1002/mus.20658
   Dassios T, 2015, PEDIATR RES, V77, P541, DOI 10.1038/pr.2015.2
   Dassios TG, 2013, RESP CARE, V58, P474, DOI 10.4187/respcare.01930
   DAWSON MJ, 1980, J PHYSIOL-LONDON, V299, P465, DOI 10.1113/jphysiol.1980.sp013137
   deCarvalho M, 1996, J NEUROL SCI, V139, P117, DOI 10.1016/0022-510X(96)00089-5
   Detroyer A., 1995, THE THORAX, V85, P2177
   ESAU SA, 1983, J APPL PHYSIOL, V55, P731
   ESAU SA, 1983, J APPL PHYSIOL, V54, P1353
   Evangelista MD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177318
   Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338
   Garcia-Rio F, 2006, RESPIRATION, V73, P474, DOI 10.1159/000091804
   GOLDSTONE JC, 1994, THORAX, V49, P54, DOI 10.1136/thx.49.1.54
   Gordon PH, 2007, AMYOTROPH LATERAL SC, V8, P270, DOI 10.1080/17482960701547958
   GRASSINO A, 1984, ANNU REV MED, V35, P625, DOI 10.1146/annurev.med.35.1.625
   Guedes K, 2010, ARQ NEURO-PSIQUIAT, V68, P44, DOI 10.1590/S0004-282X2010000100010
   HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707
   HERITIER F, 1994, AM J RESP CRIT CARE, V150, P1678, DOI 10.1164/ajrccm.150.6.7952632
   Kaufmann P, 2005, NEUROLOGY, V64, P38, DOI 10.1212/01.WNL.0000148648.38313.64
   Kollewe K, 2008, J NEUROL SCI, V275, P69, DOI 10.1016/j.jns.2008.07.016
   KOULOURIS N, 1989, AM REV RESPIR DIS, V139, P1213, DOI 10.1164/ajrccm/139.5.1213
   Kwon S, 2015, CLIN NEUROPHYSIOL, V126, P1421, DOI 10.1016/j.clinph.2014.10.006
   KYROUSSIS D, 1994, THORAX, V49, P1127, DOI 10.1136/thx.49.11.1127
   LAROCHE CM, 1988, AM REV RESPIR DIS, V138, P598, DOI 10.1164/ajrccm/138.3.598
   LEVY RD, 1984, AM REV RESPIR DIS, V130, P38
   MADOR MJ, 1992, CHEST, V102, P1767, DOI 10.1378/chest.102.6.1767
   Magnus T, 2002, MUSCLE NERVE, V25, P709, DOI 10.1002/mus.10090
   Marin B, 2017, INT J EPIDEMIOL, V46, P57, DOI 10.1093/ije/dyw061
   MATTHEWS AW, 1975, CLIN SCI MOL MED, V49, P57, DOI 10.1042/cs0490057
   MILLER JM, 1985, CLIN SCI, V69, P91, DOI 10.1042/cs0690091
   Morgan RK, 2005, AM J RESP CRIT CARE, V171, P269, DOI 10.1164/rccm.200403-314OC
   MULVEY DA, 1991, AM REV RESPIR DIS, V144, P803, DOI 10.1164/ajrccm/144.4.803
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   Park JS, 2017, CLIN NEUROPHYSIOL, V128, P1625, DOI 10.1016/j.clinph.2017.06.039
   Pereira CA, 2002, J PNEUMOL, V29, P207
   Pinto S, 2017, AMYOTROPH LAT SCL FR, V18, P86, DOI 10.1080/21678421.2016.1249486
   Pinto S, 2014, NEURODEGENER DIS MAN, V4, P83, DOI [10.2217/nmt.13.74, 10.2217/NMT.13.74]
   Pinto S, 2009, CLIN NEUROPHYSIOL, V120, P2082, DOI 10.1016/j.clinph.2009.08.025
   Polkey MI, 1996, AM J RESP CRIT CARE, V154, P1146, DOI 10.1164/ajrccm.154.4.8887619
   Polkey MI, 2017, AM J RESP CRIT CARE, V195, P86, DOI 10.1164/rccm.201604-0848OC
   Roche JC, 2012, BRAIN, V135, P847, DOI 10.1093/brain/awr351
   ROCHESTER DF, 1985, J CLIN INVEST, V75, P1397, DOI 10.1172/JCI111841
   Romer LM, 2004, EUR J APPL PHYSIOL, V91, P167, DOI 10.1007/s00421-003-0984-2
   Romer LM, 2003, MED SCI SPORT EXER, V35, P237, DOI 10.1249/01.MSS.0000048642.58419.1E
   de Araujo PRS, 2012, J BRAS PNEUMOL, V38, P700, DOI 10.1590/S1806-37132012000600004
   SCHIFFMAN PL, 1989, AM REV RESPIR DIS, V139, P1418, DOI 10.1164/ajrccm/139.6.1418
   SMITH J, 1987, J APPL PHYSIOL, V62, P1893
   Tomczak M., 2014, TRENDS SPORT SCI, V1, P19, DOI DOI 10.7326/0003-4819-159-3-201308060-00005
   Tzelepis GE, 1999, EUR J APPL PHYSIOL O, V79, P467, DOI 10.1007/s004210050538
   WILCOX PG, 1988, J APPL PHYSIOL, V65, P675
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 65
TC 2
Z9 2
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAY 2
PY 2018
VL 9
AR 306
DI 10.3389/fneur.2018.00306
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA GE4RM
UT WOS:000431204400002
PM 29770120
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Dourado, ME
AF Dourado, Mario Emilio
TI Guillain, Barraquer and I
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE history of medicine; autoimmune diseases of the nervous system;
   Guillain-Barre syndrome; polyradiculoneuropathy; Zika virus infection
ID ZIKA VIRUS OUTBREAK; BARRE-SYNDROME; BRAZIL
AB The year 2016 was the centennial anniversary of the recognition of the Guillain-Barre syndrome, which was first described by George Guillain, Jean-Alexandre Barre and Andre Strohl. In celebration of the centennial, this historical review describes aspects of the contributions of Guillain and the Spanish neurologist, Barraquer-Bordas and a brief account of the Fourth International Neurological Congress, which brought together Guillain and Barraquer-Bordas. There were many outstanding Brazilian physicians at that meeting. Finally, the author describes his interaction with Barraquer-Bordas and provides an account of his influence in shaping a generation of Brazilian neurologists, including himself.
C1 [Dourado, Mario Emilio] Hosp Univ Onofre Lopes, Natal, RN, Brazil.
RP Dourado, ME (corresponding author), Rua Nilo Pecanha 620, BR-59012300 Natal, RN, Brazil.
EM medourado@ufrnet.br
CR Aarli JA, 2014, HIST WORLD FEDERATIO
   [Anonymous], 1949, J NEUROL NEUROSUR PS, V12, P77
   Araujo LM, 2016, ARQ NEURO-PSIQUIAT, V74, P253, DOI 10.1590/0004-282X20160035
   Dourado ME, 2012, ACTA NEUROL SCAND, V125, P47, DOI 10.1111/j.1600-0404.2011.01503.x
   Heukelbach J, 2016, J INFECT DEV COUNTR, V10, P116, DOI 10.3855/jidc.8217
   Lange O., 1957, ARQ NEURO-PSIQUIAT, V15, P91
   Maranhao P, 2015, ARQ NEURO-PSIQUIAT, V73, P140, DOI 10.1590/0004-282X20140215
   Pritchard J, 2004, LANCET, V363, P2186, DOI 10.1016/S0140-6736(04)16512-4
   RUTZ-LARA R, 1952, Arq Neuropsiquiatr, V10, P127
   Sociedad Espanola de Neurologia, 2010, EXP LB BORD SOC ESP
   Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD FEB
PY 2018
VL 76
IS 2
BP 113
EP 116
DI 10.1590/0004-282X20170177
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA FX9TT
UT WOS:000426450500011
PM 29489966
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Barros, ANAB
   Dourado, MET
   Pedrosa, LDC
   Leite-Lais, L
AF Barros, Acsa Nara A. B.
   Dourado, Mario Emilio T., Jr.
   Pedrosa, Lucia de Fatima C.
   Leite-Lais, Lucia
TI Association of Copper Status with Lipid Profile and Functional Status in
   Patients with Amyotrophic Lateral Sclerosis
SO JOURNAL OF NUTRITION AND METABOLISM
LA English
DT Article
ID OXIDATIVE STRESS; RATING-SCALE; DISEASE SEVERITY; TRACE-ELEMENTS; SERUM
   COPPER; KNEE HEIGHT; RISK; DIETARY; POPULATION; PROGNOSIS
AB Oxidative stress is one of the main mechanisms associated with the pathogenesis of amyotrophic lateral sclerosis (ALS). Copper can affect cellular oxidation and lipid metabolism. The aim of this study was to evaluate the association of copper status with lipid profile and functional status in patients with ALS. A cross-sectional study was carried out including 27 patients with ALS (case group) and 26 healthy individuals (control group). Copper status was evaluated by habitual dietary copper intake, plasma copper, and serum ceruloplasmin concentrations. The lipid profile included analysis of serum total cholesterol (TC), LDL-cholesterol (LDL-c), HDL-cholesterol (HDL-c), and triglycerides (TGL). The functional status of patients with ALS was assessed by the ALS Functional Rating Scale-Revised (ALSFRS-R). In the case group, plasma copper was lower compared with the control group (133.9 versus 164.1 mu g/dL, p = 0.0001) and was positively correlated with HDL-c (r(s) = 0.398, p = 0.044). In the control group, plasma copper was positively correlated with serum ceruloplasmin (r(s) = 0.646, p < 0.001), TC (r(s) = 0.446, p = 0.025), LDL-c (r(s) = 0.445, p = 0.029), and HDL-c (r(s) = 0.479, p = 0.015), and serum ceruloplasmin was positively correlated only with LDL-c (r(s) = 0.407, p = 0.043). In the case group, dietary copper intake (B = -0.373, p < 0.001), plasma copper (B = -0.005, p = 0.033), and TC (B = -0.312, p = 0.001) were inversely associated with the functional status of patients with ALS. In contrast, serum ceruloplasmin (B = 0.016, p = 0.044), LDL-c (B = 0.314, p = 0.001), HDL-c (B = 0.308, p = 0.001), and TGL (B = 0.062; p = 0.001) were positively associated with their functional status. In conclusion, this study suggests a disturbance of copper status and its connection with the lipid profile in patients with ALS. Furthermore, copper status and lipid profile may influence the functional status of patients with ALS, standing out as potential biomarkers of disease severity.
C1 [Barros, Acsa Nara A. B.; Pedrosa, Lucia de Fatima C.; Leite-Lais, Lucia] Univ Fed Rio Grande do Norte, Dept Nutr, Natal, RN, Brazil.
   [Dourado, Mario Emilio T., Jr.] Univ Fed Rio Grande do Norte, Dept Med, Natal, RN, Brazil.
RP Leite-Lais, L (corresponding author), Univ Fed Rio Grande do Norte, Dept Nutr, Natal, RN, Brazil.
EM ludl10@hotmail.com
RI Pedrosa, Lucia Fatima Campos/N-7343-2019; LEITE-LAIS, LUCIA/K-3204-2013
OI Pedrosa, Lucia Fatima Campos/0000-0002-5436-5115; LEITE-LAIS,
   LUCIA/0000-0002-8061-7048
FU Foundation for Research Support from the State of Rio Grande do Norte
   (FAPERN); Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES [006/2014]
FX This work was supported in part by the Foundation for Research Support
   from the State of Rio Grande do Norte (FAPERN) and Coordination for the
   Improvement of Higher Education Personnel (CAPES), Grant no. 006/2014.
CR Ahuja A, 2015, J TRACE ELEM MED BIO, V29, P11, DOI 10.1016/j.jtemb.2014.05.003
   Al-khateeb E, 2014, J ALZHEIMERS DIS, V41, P203, DOI 10.3233/JAD-132180
   Bergomi M, 2002, ENVIRON RES, V89, P116, DOI 10.1006/enrs.2002.4361
   Bo S, 2008, J NUTR, V138, P305
   Bost M, 2016, J TRACE ELEM MED BIO, V35, P107, DOI 10.1016/j.jtemb.2016.02.006
   Bozzo F, 2017, NEUROSCI LETT, V636, P3, DOI 10.1016/j.neulet.2016.04.065
   Brown RH, 2017, NEW ENGL J MED, V377, P162, DOI [10.1056/NEJMra1603471, 10.1056/NEJMc1710379]
   Burkhead J. L., 2013, LIPID METABOLISM, P39, DOI DOI 10.5772/51819
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   Chio A, 2009, NEUROLOGY, V73, P1681, DOI 10.1212/WNL.0b013e3181c1df1e
   CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x
   CHUMLEA WMC, 1994, J AM DIET ASSOC, V94, P1385, DOI 10.1016/0002-8223(94)92540-2
   Crisponi G, 2010, COORDIN CHEM REV, V254, P876, DOI 10.1016/j.ccr.2009.12.018
   Curti MLR, 2011, J OBES, V2011, DOI 10.1155/2011/497401
   Dorst J, 2011, J NEUROL, V258, P613, DOI 10.1007/s00415-010-5805-z
   Forte G, 2017, NEUROL SCI, V38, P1609, DOI 10.1007/s10072-017-3018-2
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gil-Bea FJ, 2017, EXPERT REV MOL MED, V19, DOI 10.1017/erm.2017.9
   Guedes K, 2010, ARQ NEURO-PSIQUIAT, V68, P44, DOI 10.1590/S0004-282X2010000100010
   Gutierrez-Garcia R, 2013, BIOMETALS, V26, P1033, DOI 10.1007/s10534-013-9680-9
   Huang R, 2015, AMYOTROPH LAT SCL FR, V16, P359, DOI 10.3109/21678421.2015.1047454
   Huster D, 2007, MOL BIOSYST, V3, P816, DOI 10.1039/b711118p
   Ikawa M, 2015, NEUROLOGY, V84, P2033, DOI 10.1212/WNL.0000000000001588
   Ikeda K, 2012, INTERNAL MED, V51, P1501, DOI 10.2169/internalmedicine.51.7465
   Institute of Medicine, 2002, DIET REF INT VIT A V
   Lima SCVC, 2006, BIOL TRACE ELEM RES, V114, P19, DOI 10.1385/BTER:114:1:19
   Liu Y, 2014, TURK J GASTROENTEROL, V25, P116, DOI 10.5152/tjg.2014.5064
   Lutsenko S, 2010, CURR OPIN CHEM BIOL, V14, P211, DOI 10.1016/j.cbpa.2010.01.003
   Morrell A, 2017, IUBMB LIFE, V69, P263, DOI 10.1002/iub.1613
   Ngo ST, 2014, J NEUROL SCI, V340, P5, DOI 10.1016/j.jns.2014.02.035
   Nusser SM, 1996, J AM STAT ASSOC, V91, P1440, DOI 10.2307/2291570
   Osredkar J., 2011, J CLIN TOXICOL, V3, P1, DOI [10.4172/2161-0495.S3-001, DOI 10.4172/2161-0495.S3-001]
   Park Y, 2015, NUTRITION, V31, P1362, DOI 10.1016/j.nut.2015.05.025
   Peters TL, 2016, NEUROTOXICOLOGY, V54, P119, DOI 10.1016/j.neuro.2016.03.022
   Petrov D, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00068
   Rafiq MK, 2015, AMYOTROPH LAT SCL FR, V16, P478, DOI 10.3109/21678421.2015.1062517
   Rai KN, 2013, J CLIN DIAGN RES, V7, P1314, DOI 10.7860/JCDR/2013/6127.3124
   Roos PM, 2013, BIOL TRACE ELEM RES, V151, P159, DOI 10.1007/s12011-012-9547-x
   Sedlak E, 2007, BIOCHEMISTRY-US, V46, P9638, DOI 10.1021/bi700715e
   Sutedja NA, 2011, J NEUROL NEUROSUR PS, V82, P638, DOI 10.1136/jnnp.2010.236752
   Tasic NM, 2015, VOJNOSANIT PREGL, V72, P801, DOI 10.2298/VSP140417074T
   THOMPSON FE, 1994, J NUTR, V124, pS2245, DOI 10.1093/jn/124.suppl_11.2245s
   Tokuda E, 2015, NEUROTHERAPEUTICS, V12, P461, DOI 10.1007/s13311-015-0346-x
   Torsdottir G, 2000, PHARMACOL TOXICOL, V87, P126, DOI 10.1111/j.0901-9928.2000.870305.x
   Tsuboi A, 2014, ASIA PAC J CLIN NUTR, V23, P239, DOI 10.6133/apjcn.2014.23.2.04
   Uriu-Adams Janet Y., 2005, Molecular Aspects of Medicine, V26, P268, DOI 10.1016/j.mam.2005.07.015
   White AR, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00127
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   World Health Organization, 1995, TECHNICAL REPORT SER
   Wuolikainen A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113619
   YOUNG DS, 1987, ANN INTERN MED, V106, P114, DOI 10.7326/0003-4819-106-1-114
   Zheng Y, 2014, CLIN LIPIDOL, V9, P417, DOI 10.2217/CLP.14.30
NR 52
TC 5
Z9 5
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-0724
EI 2090-0732
J9 J NUTR METAB
JI J. Nutr. Metab.
PY 2018
VL 2018
AR 5678698
DI 10.1155/2018/5678698
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA GP0LT
UT WOS:000440502200001
PM 30116640
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Sarmento, A
   Resqueti, V
   Dourado, M
   Saturnino, L
   Aliverti, A
   Fregonezi, G
   de Andrade, AD
AF Sarmento, Antonio
   Resqueti, Vanessa
   Dourado-Junior, Mario, Jr.
   Saturnino, Lailane
   Aliverti, Andrea
   Fregonezi, Guilherme
   de Andrade, Armele Dornelas
TI Effects of Air Stacking Maneuver on Cough Peak Flow and Chest Wall
   Compartmental Volumes of Subjects With Amyotrophic Lateral Sclerosis
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Amyotrophic lateral sclerosis; Rehabilitation; Vital capacity
ID MECHANICAL INSUFFLATION-EXSUFFLATION; RESPIRATORY MUSCLE STRENGTH; NASAL
   INSPIRATORY PRESSURE; RIB CAGE; PULMONARY-FUNCTION; LUNG-VOLUME; VITAL
   CAPACITY; COMPRESSION; KINEMATICS; VOLUNTARY
AB Objectives: To assess the acute effects of air stacking on cough peak flow (CPF) and chest wall compartmental volumes of persons with amyotrophic lateral sclerosis (ALS) versus healthy subjects positioned at 45 degrees body inclination.& para;& para;Design: Cross-sectional study with a matched-pair design.& para;& para;Setting: University hospital.& para;& para;Participants: Persons (N=24) with ALS (n=12) and age-matched healthy subjects (n=12).& para;& para;Main Outcomes Measures: CPF, chest wall compartmental inspiratory capacity, chest wall vital capacity, chest wall tidal volume and operational volumes, breathing pattern, and percentage of contribution of the compartments to the inspired volume were measured by optoelectronic plethysmography.& para;& para;Results: Compared with healthy subjects, significantly lower CPF (P=.007), chest wall compartmental inspiratory capacity (P<.001), chest wall vital capacity (P<.001), and chest wall tidal volume (P<.001) were found in subjects with ALS. Immediately after air stacking, CPF (P<.001) and chest wall compartmental inspiratory capacity (P<.001) significantly increased in both groups, with values returning to basal only in healthy subjects. After air stacking, the abdominal compartment (P=.004) was determined to be responsible for the inspired volume in subjects with ALS. Significantly higher chest wall vital capacity (P=.05) was observed in subjects with ALS 5 minutes after air stacking, with the rib cage compartment (P=.049) being responsible for volume change. No differences were found in chest wall vital capacity and compartmental volumes of healthy subjects. Chest wall tidal volume (P<.001) significantly increased during the protocol in the healthy subjects, mainly because of end-inspiratory (P<.001) and abdominal volumes (P=.008). No significant differences were observed in percentage of contribution of the compartments to the inspired volume and end-expiratory volume of both groups. No significant differences were found in chest wall tidal volume, operational volume, and breathing pattern in persons with ALS.& para;& para;Conclusions: Air stacking is effective in increasing CPF, chest wall compartmental inspiratory capacity, and chest wall vital capacity of persons with ALS with no hyperinflation. Differences in compartmental volume contributions are probably because of lung and chest wall physiological changes. (C) 2016 by the American Congress of Rehabilitation Medicine
C1 [Sarmento, Antonio; Resqueti, Vanessa; Saturnino, Lailane; Fregonezi, Guilherme] Univ Fed Rio Grande do Norte, PneumoCardioVasc Lab, HUOL, Empresa Brasileira Serv Hosp, Natal, RN, Brazil.
   [Sarmento, Antonio; Resqueti, Vanessa; Saturnino, Lailane; Fregonezi, Guilherme] Univ Fed Rio Grande do Norte, Dept Fisioterapia, PneumoCardioVasc Lab, Natal, RN, Brazil.
   [Dourado-Junior, Mario, Jr.] Univ Fed Rio Grande do Norte, Ambulatorio Neurol, Empresa Brasileira Serv Hosp, Natal, RN, Brazil.
   [Aliverti, Andrea] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
   [de Andrade, Armele Dornelas] Univ Fed Pernambuco, Dept Fisioterapia, Recife, PE, Brazil.
RP Resqueti, V (corresponding author), Univ Fed Rio Grande do Norte, Lab Desempenho PneumoCardioVasc & Musculos Resp, Dept Fisioterapia, Campus Univ Lagoa Nova,Caixa Postal 1524, BR-59072970 Natal, RN, Brazil.
EM vanessaresqueti@hotmail.com
RI Fregonezi, Guilherme/AAQ-1493-2020; Sarmento, Antonio/K-9999-2018;
   Fregonezi, Guilherme AF/B-2186-2019; Andrea, Aliverti/A-3901-2015
OI Fregonezi, Guilherme/0000-0003-4938-7018; Sarmento,
   Antonio/0000-0001-6391-5652; Fregonezi, Guilherme
   AF/0000-0003-4938-7018; Andrea, Aliverti/0000-0002-2950-0231
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [307353/2015-0, 310091/2015-2]
FX Supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (grant nos. 307353/2015-0 and 310091/2015-2).
CR AGOSTONI E, 1960, J APPL PHYSIOL, V15, P1087
   Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518
   Aliverti A, 2000, AM J RESP CRIT CARE, V161, P1546, DOI 10.1164/ajrccm.161.5.9903024
   Aliverti A, 2004, THORAX, V59, P210, DOI 10.1136/thorax.2003.011494
   Aliverti A, 2002, J APPL PHYSIOL, V92, P1953, DOI 10.1152/japplphysiol.01222.2000
   Aliverti A, 2003, Monaldi Arch Chest Dis, V59, P12
   Aliverti A, 2001, ANN BIOMED ENG, V29, P60, DOI 10.1114/1.1332084
   Bach JR, 2007, AM J PHYS MED REHAB, V86, P295, DOI 10.1097/PHM.0b013e318038d1ce
   Bach JR, 2008, AM J PHYS MED REHAB, V87, P720, DOI 10.1097/PHM.0b013e31817fb26f
   BACH JR, 1993, CHEST, V104, P1553, DOI 10.1378/chest.104.5.1553
   Balendra R, 2015, J NEUROL NEUROSUR PS, V86, P45, DOI 10.1136/jnnp-2013-306865
   Brito MF, 2009, J BRAS PNEUMOL, V35, P973, DOI 10.1590/S1806-37132009001000005
   Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536
   Cala SJ, 1996, J APPL PHYSIOL, V81, P2680
   Marques TBC, 2014, J BRAS PNEUMOL, V40, P528, DOI 10.1590/S1806-37132014000500009
   Chaudri MB, 2002, EUR RESPIR J, V19, P434, DOI 10.1183/09031936.02.00082702
   Chiou M, 2017, J REHABIL MED, V49, P49, DOI 10.2340/16501977-2144
   Cohen J., 2013, STAT POWER ANAL BEHA
   Desport JC, 2005, AMYOTROPH LATERAL SC, V6, P88, DOI 10.1080/14660820410021258a
   Dohna-Schwake C, 2006, PEDIATR PULM, V41, P551, DOI 10.1002/ppul.20406
   Fitting JW, 2006, EUR RESPIR J, V27, P881, DOI 10.1183/09031936.06.00007906
   FUGLMEYER AR, 1974, RESPIRATION, V31, P240
   GRIMBY G, 1976, J APPL PHYSIOL, V41, P739
   HERITIER F, 1994, AM J RESP CRIT CARE, V150, P1678, DOI 10.1164/ajrccm.150.6.7952632
   INKLEY SR, 1974, AM J MED, V56, P297, DOI 10.1016/0002-9343(74)90611-1
   Ishikawa Y, 2008, AM J PHYS MED REHAB, V87, P726, DOI 10.1097/PHM.0b013e31817f99a8
   Jeong JH, 2015, J PHYS THER SCI, V27, P1951, DOI 10.1589/jpts.27.1951
   Kang SW, 2006, YONSEI MED J, V47, P307, DOI 10.3349/ymj.2006.47.3.307
   Kang SW, 2000, CHEST, V118, P61, DOI 10.1378/chest.118.1.61
   Kang SW, 2000, AM J PHYS MED REHAB, V79, P222, DOI 10.1097/00002060-200005000-00002
   Kang SW, 2005, YONSEI MED J, V46, P233, DOI 10.3349/ymj.2005.46.2.233
   KONNO K, 1968, J APPL PHYSIOL, V24, P544
   Lanini B, 2007, ACTA PHYSIOL, V190, P351, DOI 10.1111/j.1748-1716.2007.01701.x
   Lanini B, 2008, RESP PHYSIOL NEUROBI, V161, P62, DOI 10.1016/j.resp.2007.12.003
   Lechtzin N, 2006, CHEST, V129, P1322, DOI 10.1378/chest.129.5.1322
   Lee LJ, 2010, RESP PHYSIOL NEUROBI, V170, P236, DOI 10.1016/j.resp.2010.01.001
   Lo Mauro A, 2010, EUR RESPIR J, V35, P1118, DOI 10.1183/09031936.00037209
   MCCOOL FD, 1995, PHYS THER, V75, P1006, DOI 10.1093/ptj/75.11.1006
   NAVA S, 1993, THORAX, V48, P702, DOI 10.1136/thx.48.7.702
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   Orsini M, 2015, ARQ NEURO-PSIQUIAT, V73, P873, DOI 10.1590/0004-282X20150132
   Orsini M, 2015, NEUROL INT, V7, DOI [10.4081/ni.2015.5885, 10.4081/ni.2015.5886]
   Panitch HB, 2006, CURR OPIN PEDIATR, V18, P277, DOI 10.1097/01.mop.0000193297.40388.19
   Park JH, 2010, YONSEI MED J, V51, P392, DOI 10.3349/ymj.2010.51.3.392
   Park KH, 2016, J CLIN NEUROL, V12, P361, DOI 10.3988/jcn.2016.12.3.361
   Pereira CA, 2002, J PNEUMOL, V29, P207
   Roche JC, 2012, BRAIN, V135, P847, DOI 10.1093/brain/awr351
   Romei M, 2010, RESP PHYSIOL NEUROBI, V172, P184, DOI 10.1016/j.resp.2010.05.018
   de Araujo PRS, 2012, J BRAS PNEUMOL, V38, P700, DOI 10.1590/S1806-37132012000600004
   Sarmento A, 2017, EUR J APPL PHYSIOL, V117, P189, DOI 10.1007/s00421-016-3511-y
   Sarmento A, 2017, RESP CARE, V62, P432, DOI 10.4187/respcare.05189
   Schmidt EP, 2006, MUSCLE NERVE, V33, P127, DOI 10.1002/mus.20450
   SHARP JT, 1975, J APPL PHYSIOL, V39, P608
   Simon NG, 2014, ANN NEUROL, V76, P643, DOI 10.1002/ana.24273
   Simonds AK, 2013, EUR RESPIR REV, V22, P325, DOI 10.1183/09059180.00003113
   Smith JA, 2012, J PHYSIOL-LONDON, V590, P563, DOI 10.1113/jphysiol.2011.213157
   SMITH PEM, 1987, NEW ENGL J MED, V316, P1197, DOI 10.1056/NEJM198705073161906
   Torres-Castro R, 2014, SPINAL CORD, V52, P354, DOI 10.1038/sc.2014.19
   Toussaint M, 2009, RESP CARE, V54, P359
   Winck JC, 2004, CHEST, V126, P774, DOI 10.1378/chest.126.3.774
NR 60
TC 5
Z9 5
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD NOV
PY 2017
VL 98
IS 11
BP 2237
EP 2246
DI 10.1016/j.apmr.2017.04.015
PG 10
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA FL5KK
UT WOS:000414275500017
PM 28526483
DA 2020-12-09
ER

PT J
AU da Silva, HFL
   Brito, AND
   de Freitas, EPS
   Dourado, MET
   de Sena-Evangelista, KCM
   Leite-Lais, L
AF Lopes da Silva, Heloisa Fernanda
   de Araujo Brito, Acsa Nara
   Silva de Freitas, Erika Paula
   Dourado Junior, Mario Emilio Teixeira
   Mauricio de Sena-Evangelista, Karine Cavalcanti
   Leite-Lais, Lucia
TI Dietary intake and zinc status in amyotrophic lateral sclerosis patients
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Amyotrophic lateral sclerosis.; Dietary intake; Zinc; Nutntional status
ID ATOMIC-ABSORPTION SPECTROPHOTOMETRY; BODY-MASS INDEX;
   ENERGY-EXPENDITURE; ALS PATIENTS; SURVIVAL; NUTRITION; NUTRIENT; METALS;
   PLASMA
AB Background: There is considerable evidence that abnormal zinc homeostasis is related to amyotrophic lateral sclerosis (ALS) pathogenesis, and malnutrition is an independent prognostic factor for worsened survival of ALS patients.
   Objective: To evaluate the dietary intake and zinc status in patients with ALS, treated in a specialized outpatient facility in Natal, Brazil.
   Methods: Twenty patients with ALS (case group) and 37 healthy subjects (control group) were included. Clinical and anthropometric assessments were carried out and dietary intake was obtained from two 24-hour recalls. Plasma and urinary zinc concentrations were determined by atomic absorption spectrophotometry.
   Results: Most of the participants were eutrophic. Mean energy, protein, carbohydrate and fat intake was significantly lower for the case group. There was greater prevalence of inadequate zinc intake in the case group (35%) compared to controls (27%). Mean plasma zinc was significantly lower in the case group than in controls (77.13 +/- 22.21 vs 87.84 +/- 17.44 mu gZn/dI). Urinary zinc did not differ significantly between cases and controls. In the case group, plasma and urinary zinc concentrations were below reference values in 50.0% and 52.6% of patients, respectively.
   Conclusion: A large portion of patients with ALS exhibited poor dietary intake and changes in body zinc status. The zinc deficiency found in half of the ALS patients may contribute to a worsened prognosis and should be the target of nutritional intervention that aims to correct this deficiency.
C1 [Lopes da Silva, Heloisa Fernanda; de Araujo Brito, Acsa Nara; Silva de Freitas, Erika Paula; Mauricio de Sena-Evangelista, Karine Cavalcanti; Leite-Lais, Lucia] Univ Fed Rio Grande do Norte, Dept Nutr, Campus Univ, BR-59078900 Natal, RN, Brazil.
   [Dourado Junior, Mario Emilio Teixeira] Univ Fed Rio Grande do Norte, Dept Med, Natal, RN, Brazil.
RP Leite-Lais, L (corresponding author), Univ Fed Rio Grande do Norte, Dept Nutr, Campus Univ, BR-59078900 Natal, RN, Brazil.
EM ludl10@hotmail.com
FU Foundation for Research Support of Rio Grande do Norte (FAPERN), Brazil
FX This work was supported in part by the Foundation for Research Support
   of Rio Grande do Norte (FAPERN), Brazil.
CR BEATON GH, 1994, AM J CLIN NUTR, V59, p253S, DOI 10.1093/ajcn/59.1.253S
   Brito ANA, 2014, REV BRAS CIENC SAUDE, V18, P79
   Desport JC, 1999, NEUROLOGY, V53, P1059, DOI 10.1212/WNL.53.5.1059
   Dupuis L, 2011, LANCET NEUROL, V10, P75, DOI 10.1016/S1474-4422(10)70224-6
   Food and Nutrition Board: Institute of Medicine, 2001, DIET REF INT VIT VIT
   Genton L, 2011, CLIN NUTR, V30, P553, DOI 10.1016/j.clnu.2011.06.004
   Gibson R.S, 2005, PRINCIPLES NUTR ASSE, V1, P683
   Guedes K, 2010, ARQ NEURO-PSIQUIAT, V68, P44, DOI 10.1590/S0004-282X2010000100010
   Iacone R, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0152-2
   International Zinc Nutrition Consultative Group (IZiNCG), 2004, Food Nutr Bull, V25, pS99
   Kasarskis EJ, 2014, AM J CLIN NUTR, V99, P792, DOI 10.3945/ajcn.113.069997
   KIILERICH S, 1980, CLIN CHIM ACTA, V105, P231, DOI 10.1016/0009-8981(80)90465-9
   King JC, 2016, J NUTR, V146, p858S, DOI 10.3945/jn.115.220079
   King JC, 2011, AM J CLIN NUTR, V94, p679S, DOI 10.3945/ajcn.110.005744
   Lasiene J, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/718987
   Leite LD, 2012, REV BRAS NUTR CLIN, V27, P87
   Marin B, 2011, J NEUROL NEUROSUR PS, V82, P628, DOI 10.1136/jnnp.2010.211474
   Mattson MP, 2007, NEUROMOL MED, V9, P17, DOI 10.1385/NMM:9:1:17
   Mitchell JD, 2007, LANCET, V369, P2031, DOI 10.1016/S0140-6736(07)60944-1
   Ngo ST, 2014, J NEUROL SCI, V340, P5, DOI 10.1016/j.jns.2014.02.035
   Nicoletti A, 2016, EUR J NEUROL, V23, P964, DOI 10.1111/ene.12973
   Nucleo de Estudos e Pesquisas em Alimentacao-NEPA, 2011, TAB BRAS COMP AL TAC
   Paganoni S, 2011, MUSCLE NERVE, V44, P20, DOI 10.1002/mus.22114
   Peters TL, 2016, NEUROTOXICOLOGY, V54, P119, DOI 10.1016/j.neuro.2016.03.022
   Philippi ST, 2001, TABELA COMPOSICAO AL
   RODRIGUEZ MP, 1989, ATOM SPECTROSC, V10, P68
   Rooney J, 2015, J NEUROL NEUROSUR PS, V86, P496, DOI 10.1136/jnnp-2014-309601
   Roos PM, 2013, BIOL TRACE ELEM RES, V151, P159, DOI 10.1007/s12011-012-9547-x
   Rothstein JD, 2009, ANN NEUROL, V65, pS3, DOI 10.1002/ana.21543
   Slater B, 2004, REV SAUDE PUBL, V38, P599, DOI [10.1590/S0034-89102004000400019, 10.1590/s0034-89102004000400019]
   Smith AP, 2007, AMYOTROPH LATERAL SC, V8, P131, DOI 10.1080/17482960701249241
   Szewczyk B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00033
   THOMPSON FE, 1994, J NUTR, V124, pS2245, DOI 10.1093/jn/124.suppl_11.2245s
   Tyszka-Czochara M, 2014, ACTA POL PHARM, V71, P369
   U.S. Department of Agriculture Agricultural Research Service, 2012, USDA NAT NUTR DAT ST
   WHO, 2000, WHO TECHN REP SER, V894
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Wood RJ, 2000, J NUTR, V130, p1350S, DOI 10.1093/jn/130.5.1350S
NR 38
TC 1
Z9 1
U1 1
U2 4
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
EI 1699-5198
J9 NUTR HOSP
JI Nutr. Hosp.
PD NOV-DEC
PY 2017
VL 34
IS 6
BP 1361
EP 1367
DI 10.20960/nh.1004
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA FT6FD
UT WOS:000423248800016
PM 29280652
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Sarmento, A
   Resqueti, VR
   Dourado, MET
   Aliverti, A
   Fregonezi, GAD
   de Andrade, AD
AF Sarmento, Antonio
   Regiane Resqueti, Vanessa
   Teixeira Dourado-Junior, Mario Emilio
   Aliverti, Andrea
   de Freitas Fregonezi, Guilherme Augusto
   Dornelas de Andrade, Armele
TI Effects of air stacking maneuver on cough peak flow and chest wall
   compartmental volumes of amyotrophic lateral sclerosis subjects
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
CT European-Respiratory-Society (ERS) International Congress
CY SEP 09-13, 2017
CL Milan, ITALY
SP European Respiratory Soc
RI Fregonezi, Guilherme AF/B-2186-2019; Sarmento, Antonio/K-9999-2018;
   Fregonezi, Guilherme/AAQ-1493-2020; Andrea, Aliverti/A-3901-2015
OI Fregonezi, Guilherme AF/0000-0003-4938-7018; Sarmento,
   Antonio/0000-0001-6391-5652; Fregonezi, Guilherme/0000-0003-4938-7018;
   Andrea, Aliverti/0000-0002-2950-0231
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2017
VL 50
SU 61
MA PA2224
DI 10.1183/1393003.congress-2017.PA2224
PG 1
WC Respiratory System
SC Respiratory System
GA GF2DO
UT WOS:000431748901631
DA 2020-12-09
ER

PT J
AU Dourado, ME
   Fernandes, U
   Vital, AL
   Ramos, E
   Urbano, JC
   Sena, A
   Fraiman, PHA
   Luz, K
   Queiroz, JW
   Jeronimo, SMB
AF Dourado, M. E.
   Fernandes, U.
   Vital, A. L.
   Ramos, E.
   Urbano, J. C.
   Sena, A.
   Fraiman, P. H. A.
   Luz, K.
   Queiroz, J. W.
   Jeronimo, S. M. B.
TI HIGH INCIDENCE OF GUILLAIN-BARRE SYNDROME AFTER ZIKA VIRUS INFECTION IN
   THE STATE RIO GRANDE DO NORTE, IN NORTHEAST BRAZIL
SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
LA English
DT Meeting Abstract
CT Peripheral-Nerve-Society Meeting
CY JUL 08-12, 2017
CL Sitges, SPAIN
SP Peripheral Nerve Soc, Alnylam Pharmaceut Inc, CSL Behring, Grifols S A, Kedr S p A, Pfizer Inc Rare Dis, Terumo BCT Inc, Shire Plc, GBS CIDP Fdn Int, Octapharma AG, Acceleron Pharma Inc, Ionis Pharmaceut Inc, LFB Biomedicaments, Mayo Med Labs, Pharnext SA, Hereditary Neuropathy Fdn, Syntimmune Inc, UCB Biosciences Inc
C1 [Dourado, M. E.; Fernandes, U.; Vital, A. L.; Ramos, E.; Urbano, J. C.; Sena, A.; Fraiman, P. H. A.; Luz, K.; Queiroz, J. W.; Jeronimo, S. M. B.] Univ Fed Rio Grande do Norte, Natal, RN, Brazil.
RI Jeronimo, Selma/AAY-4033-2020
OI Jeronimo, Selma/0000-0002-4784-9904
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1085-9489
EI 1529-8027
J9 J PERIPHER NERV SYST
JI J. Peripher. Nerv. Syst.
PD SEP
PY 2017
VL 22
IS 3
BP 275
EP 276
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA FF8CU
UT WOS:000409243500125
DA 2020-12-09
ER

PT J
AU Dourado, ME
   Fernandes, U
   Vital, AL
   Ramos, E
   Urbano, JC
   Sena, A
   Queiroz, JW
   Jeronimo, SMB
AF Dourado, M. E.
   Fernandes, U.
   Vital, A. L.
   Ramos, E.
   Urbano, J. C.
   Sena, A.
   Queiroz, J. W.
   Jeronimo, S. M. B.
TI EGOS DID NOT HAVE A GOOD CAPACITY TO PROGNOSIS IN GBS IN RIO GRANDE DO
   NORTE, BRAZIL
SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
LA English
DT Meeting Abstract
CT Peripheral-Nerve-Society Meeting
CY JUL 08-12, 2017
CL Sitges, SPAIN
SP Peripheral Nerve Soc, Alnylam Pharmaceut Inc, CSL Behring, Grifols S A, Kedr S p A, Pfizer Inc Rare Dis, Terumo BCT Inc, Shire Plc, GBS CIDP Fdn Int, Octapharma AG, Acceleron Pharma Inc, Ionis Pharmaceut Inc, LFB Biomedicaments, Mayo Med Labs, Pharnext SA, Hereditary Neuropathy Fdn, Syntimmune Inc, UCB Biosciences Inc
C1 [Dourado, M. E.; Fernandes, U.; Vital, A. L.; Ramos, E.; Urbano, J. C.; Sena, A.; Queiroz, J. W.; Jeronimo, S. M. B.] Univ Fed Rio Grande do Norte, Natal, RN, Brazil.
RI Jeronimo, Selma/AAY-4033-2020
OI Jeronimo, Selma/0000-0002-4784-9904
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1085-9489
EI 1529-8027
J9 J PERIPHER NERV SYST
JI J. Peripher. Nerv. Syst.
PD SEP
PY 2017
VL 22
IS 3
BP 275
EP 275
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA FF8CU
UT WOS:000409243500124
DA 2020-12-09
ER

PT J
AU Evangelista, MD
   Dias, FAL
   Dourado, ME
   do Nascimento, GC
   Sarmento, A
   Gualdi, LP
   Aliverti, A
   Resqueti, V
   Fregonezi, GAD
AF Evangelista, Morgana de Araujo
   Lavezzo Dias, Fernando Augusto
   Teixeira Dourado Junior, Mario Emilio
   do Nascimento, George Carlos
   Sarmento, Antonio
   Gualdi, Lucien Peroni
   Aliverti, Andrea
   Resqueti, Vanessa
   de Freitas Fregonezi, Guilherme Augusto
TI Noninvasive assessment of respiratory muscle strength and activity in
   Myotonic dystrophy
SO PLOS ONE
LA English
DT Article
ID RELAXATION RATE; DIAPHRAGMATIC FATIGUE; IMPAIRMENT; PRESSURES; TESTS
AB Objective
   To evaluate sensitivity/specificity of the maximum relaxation rate (MRR) of inspiratory muscles, amplitude of electromyographic activity of the sternocleidomastoid (SCM), scalene (SCA), parasternal (2nd IS) and rectus abdominis (RA) muscles; lung function and respiratory muscle strength in subjects with Myotonic dystrophy type 1 (DM1) compared with healthy subjects.
   Design and methods
   Quasi-experimental observational study with control group. MRR of inspiratory muscles, lung function and amplitude of the electromyographic activity of SCM, SCA, 2nd IS and RA muscles during maximum inspiratory pressure (PImax), maximum expiratory pressure (PEmax) and sniff nasal inspiratory pressure (SNIP) tests were assessed in eighteen DM1 subjects and eleven healthy.
   Results
   MRR was lower in DM1 group compared to healthy (P = 0.001) and was considered sensitive and specific to identify disease in DM1 and discard it in controls, as well as SNIP% (P = 0.0026), PImax% (P = 0.0077) and PEmax% (P = 0.0002). Contraction time of SCM and SCA was higher in DM1 compared to controls, respectively, during PImax (P = 0.023 and P = 0.017) and SNIP (P = 0.015 and P =.0004). The DM1 group showed lower PImax (P =.0006), PEmax (P = 0.0002), SNIP (P = 0.0014), and higher electromyographic activity of the SCM (P = 0.002) and SCA (P = 0.004) at rest; of 2nd IS (P = 0.003) during PEmax and of SCM (P = 0.02) and SCA (P = 0.03) during SNIP test.
   Conclusions
   MD1 subjects presented restrictive pattern, reduced respiratory muscle strength, muscular electrical activity and MRR when compared to higher compared to controls. In addition, the lower MRR found in MD1 subjects showed to be reliable to sensitivity and specificity in identifying the delayed relaxation of respiratory muscles.
C1 [Evangelista, Morgana de Araujo; Sarmento, Antonio; Gualdi, Lucien Peroni; Resqueti, Vanessa; de Freitas Fregonezi, Guilherme Augusto] Univ Fed Rio Grande do Norte, Dept Fisioterapia, PneumoCardioVasc Lab, Natal, RN, Brazil.
   [Evangelista, Morgana de Araujo; Sarmento, Antonio; Gualdi, Lucien Peroni; Resqueti, Vanessa; de Freitas Fregonezi, Guilherme Augusto] Univ Fed Rio Grande do Norte, Empresa Brasileira Serv Hosp EBSERH, PneumoCardioVasc Lab HUOL, Natal, RN, Brazil.
   [Lavezzo Dias, Fernando Augusto] Univ Fed Parana, Dept Fisiol, Curitiba, Parana, Brazil.
   [Teixeira Dourado Junior, Mario Emilio] Univ Fed Rio Grande do Norte, Dept Med Integrada, Natal, RN, Brazil.
   [do Nascimento, George Carlos] Univ Fed Rio Grande do Norte, Dept Engn Biomed, Natal, RN, Brazil.
   [Gualdi, Lucien Peroni] Univ Fed Rio Grande do Norte, Fac Ciencias Saude Trairi, Santa Cruz, RN, Brazil.
   [Aliverti, Andrea] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.
RP Fregonezi, GAD (corresponding author), Univ Fed Rio Grande do Norte, Dept Fisioterapia, PneumoCardioVasc Lab, Natal, RN, Brazil.; Fregonezi, GAD (corresponding author), Univ Fed Rio Grande do Norte, Empresa Brasileira Serv Hosp EBSERH, PneumoCardioVasc Lab HUOL, Natal, RN, Brazil.
EM fregonezi@ufrnet.br
RI Fregonezi, Guilherme AF/B-2186-2019; Gualdi, Lucien/ABF-2712-2020;
   Fregonezi, Guilherme/AAQ-1493-2020; Andrea, Aliverti/A-3901-2015;
   Sarmento, Antonio/K-9999-2018; Dias, Fernando AL/D-7126-2013
OI Fregonezi, Guilherme AF/0000-0003-4938-7018; Fregonezi,
   Guilherme/0000-0003-4938-7018; Andrea, Aliverti/0000-0002-2950-0231;
   Sarmento, Antonio/0000-0001-6391-5652; Dias, Fernando
   AL/0000-0003-3951-2604; Peroni Gualdi, Lucien/0000-0002-6907-7335
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [PROCAD 2013 88881.068409/2014-01]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq) [400316/2012-9]; Guilherme Augusto de
   Freitas Fregonezi is fellow from CNPq [307353/2015-0]; Vanessa Resqueti
   is fellow from CNPqNational Council for Scientific and Technological
   Development (CNPq) [310091/2015-2]
FX The study received financial support of Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES), PROCAD 2013 88881.068409/2014-01,
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   processo: 400316/2012-9. Guilherme Augusto de Freitas Fregonezi is
   fellow from CNPq number 307353/2015-0 and Vanessa Resqueti is fellow
   from CNPq number 310091/2015-2. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 1999, J ELECTROMYOGR KINES, V9, pIII
   Ashizawa Tetsuo, 2011, Handb Clin Neurol, V101, P193, DOI 10.1016/B978-0-08-045031-5.00015-3
   Begin P, 1997, AM J RESP CRIT CARE, V156, P133, DOI 10.1164/ajrccm.156.1.9509041
   BENAIM S, 1954, Med Illus, V8, P221
   Cohen J., 2013, STAT POWER ANAL BEHA
   de Die-Smulders CEM, 1998, BRAIN, V121, P1557, DOI 10.1093/brain/121.8.1557
   Duiverman ML, 2004, J APPL PHYSIOL, V96, P1723, DOI 10.1152/japplphysiol.00914.2003
   Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U
   ESAU SA, 1983, J APPL PHYSIOL, V55, P731
   ESAU SA, 1983, J APPL PHYSIOL, V54, P1353
   ESTENNE M, 1984, AM REV RESPIR DIS, V130, P681
   FITTING JW, 1989, AM REV RESPIR DIS, V140, P1442, DOI 10.1164/ajrccm/140.5.1442
   Flanigan KM, 2012, SEMIN NEUROL, V32, P255, DOI 10.1055/s-0032-1329199
   Fregonezi G, 2015, RESP CARE, V60, P533, DOI 10.4187/respcare.03367
   Garcia-Rio F, 2006, RESPIRATION, V73, P474, DOI 10.1159/000091804
   GILLAM P M, 1964, Thorax, V19, P112, DOI 10.1136/thx.19.2.112
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Harris AD, 2004, CLIN INFECT DIS, V38, P1586, DOI 10.1086/420936
   Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4
   JAMMES Y, 1985, MUSCLE NERVE, V8, P586, DOI 10.1002/mus.880080708
   Kendall FP, 2007, MUSCULOS PROVAS E FU
   KILBURN KH, 1959, NEW ENGL J MED, V261, P1089, DOI 10.1056/NEJM195911262612201
   KOULOURIS N, 1989, AM REV RESPIR DIS, V139, P1213, DOI 10.1164/ajrccm/139.5.1213
   KYROUSSIS D, 1994, THORAX, V49, P1127, DOI 10.1136/thx.49.11.1127
   Mathieu J, 1999, NEUROLOGY, V52, P1658, DOI 10.1212/WNL.52.8.1658
   Mathieu J, 2001, NEUROLOGY, V56, P336, DOI 10.1212/WNL.56.3.336
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Moraes Klyvia Juliana Rocha de, 2012, Rev. CEFAC, V14, P918, DOI 10.1590/s1516-18462011005000133
   MULVEY DA, 1991, J APPL PHYSIOL, V70, P2173
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
   Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
   Poussel M, 2015, NEUROMUSCULAR DISORD, V25, P403, DOI 10.1016/j.nmd.2015.02.006
   Poussel M, 2014, RESP PHYSIOL NEUROBI, V193, P43, DOI 10.1016/j.resp.2014.01.006
   RIMMER KP, 1993, AM REV RESPIR DIS, V148, P1018, DOI 10.1164/ajrccm/148.4_Pt_1.1018
   de Araujo PRS, 2012, J BRAS PNEUMOL, V38, P700, DOI 10.1590/S1806-37132012000600004
   Smith AE, 2014, AM J PHYS MED REHAB, V93, P387, DOI 10.1097/PHM.0000000000000032
   Smorto M P, 1972, Riv Neurobiol, V18, P48
   Steier J, 2007, THORAX, V62, P975, DOI 10.1136/thx.2006.072884
   Turner C, 2010, J NEUROL NEUROSUR PS, V81, P358, DOI 10.1136/jnnp.2008.158261
   WILES CM, 1979, CLIN SCI MOL MED, V56, P47, DOI 10.1042/cs0560047
NR 41
TC 7
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 8
PY 2017
VL 12
IS 6
AR e0177318
DI 10.1371/journal.pone.0177318
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX0PL
UT WOS:000402923200010
PM 28594857
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Dourado, ME
   Ferreira, LC
   Freire-Neto, FP
   Jeronimo, SMB
AF Dourado Junior, Mario Emilio
   Ferreira, Leonardo Capistrano
   Freire-Neto, Francisco Paulo
   Jeronimo, Selma M. B.
TI No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barre
   Syndrome in a Brazilian population
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE Guillain-Barre Syndrome; FCGR; Polymorphism; Genetics
ID FC-RECEPTOR POLYMORPHISMS; ZIKA VIRUS OUTBREAK; CAMPYLOBACTER-JEJUNI;
   ANTIGANGLIOSIDE ANTIBODIES; INFECTION; IIA; SUSCEPTIBILITY;
   POLYNEUROPATHY; IMMUNOGLOBULIN; SEVERITY
AB The pathogenesis of Guillain-Barre Syndrome (GBS) is not entirely understood, but includes infection-induced aberrant immune responses. Genetic polymorphisms in Fc gamma receptor genes (FCGR) have been associated with GBS. We assessed whether polymorphisms rs1801274 in FCGR2A and rs396991 in FCGR3A were associated with GBS in a Brazilian population. We genotyped 141 GBS cases and 364 healthy controls from Brazil for both polymorphisms. The FCGR genotypes and alleles frequencies did not differ significantly between GBS and controls. In addition, there was no genetic association with either severity or clinical outcomes. We conclude that these FCGR polymorphisms are not associated with susceptibility to Guillain-Barre Syndrome in this Brazilian population. (C) 2016 Published by Elsevier B.V.
C1 [Dourado Junior, Mario Emilio] Univ Fed Rio Grande do Norte, Dept Integrat Med, Natal, RN, Brazil.
   [Dourado Junior, Mario Emilio; Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Hlth Postgrad Program, Natal, RN, Brazil.
   [Ferreira, Leonardo Capistrano; Freire-Neto, Francisco Paulo; Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, Dept Biochem, Biosci Ctr, Natal, RN, Brazil.
   [Jeronimo, Selma M. B.] Univ Fed Rio Grande do Norte, Inst Trop Med Rio Grande Norte, Natal, RN, Brazil.
   [Jeronimo, Selma M. B.] Inst Sci & Technol Trop Dis, Salvador, BA, Brazil.
RP Jeronimo, SMB (corresponding author), Univ Fed Rio Grande do Norte, Inst Trop Med Rio Grande Norte, Dept Biochem, Natal, RN, Brazil.
EM smbj@cb.ufrn.br
RI Jeronimo, Selma M.B./M-8672-2014; Jeronimo, Selma/AAY-4033-2020;
   Ferreira, Leonardo Capistrano/D-7097-2019
OI Jeronimo, Selma M.B./0000-0002-4784-9904; Jeronimo,
   Selma/0000-0002-4784-9904; Ferreira, Leonardo
   Capistrano/0000-0001-9268-4881
FU Brazilian Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [482017/2009-0]
FX We thank John Donelson, PhD (University of Iowa, Iowa City, IA, USA) and
   Cleni M Marzocchi-Machado, PhD (FCFRP-USP, Ribeirao Preto, Brazil) for
   their helpful revision of this manuscript. This study was supported by a
   grant 482017/2009-0 from the Brazilian Research Council (CNPq).
CR Araujo LM, 2016, ARQ NEURO-PSIQUIAT, V74, P253, DOI 10.1590/0004-282X20160035
   ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Vigato-Ferreira ICC, 2014, AUTOIMMUNITY, V47, P451, DOI 10.3109/08916934.2014.921809
   Dalakas MC, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.6_Suppl_5.S2
   Dourado ME, 2012, ACTA NEUROL SCAND, V125, P47, DOI 10.1111/j.1600-0404.2011.01503.x
   Dourado ME, 2003, ACTA NEUROL SCAND, V108, P102, DOI 10.1034/j.1600-0404.2003.00103.x
   Ettinger NA, 2009, ANN HUM GENET, V73, P304, DOI 10.1111/j.1469-1809.2009.00510.x
   FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201
   Gillis C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00254
   Godschalk PCR, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-32
   GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390
   He L, 2015, J NEUROSCI, V35, P6770, DOI 10.1523/JNEUROSCI.4926-14.2015
   HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597
   Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9
   HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2
   Kuwano ST, 2000, TRANSFUSION, V40, P1388, DOI 10.1046/j.1537-2995.2000.40111388.x
   McCarthy N, 2001, AM J EPIDEMIOL, V153, P610, DOI 10.1093/aje/153.6.610
   Moriya H, 2014, BIOMED REP, V2, P265, DOI 10.3892/br.2013.210
   Nachamkin I, 2008, J INFECT DIS, V198, P226, DOI 10.1086/589624
   Odaka M, 2001, J NEUROL NEUROSUR PS, V70, P50, DOI 10.1136/jnnp.70.1.50
   Rodrigues F.N., 2016, PLOS CURR, V8
   SALMON JE, 1995, J CLIN INVEST, V95, P2877, DOI 10.1172/JCI117994
   SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566
   Sheikh KA, 1998, NEUROLOGY, V51, P371, DOI 10.1212/WNL.51.2.371
   Sinha S, 2010, ACTA NEUROL SCAND, V122, P21, DOI 10.1111/j.1600-0404.2009.01229.x
   Siqueira JF, 2011, J ENDODONT, V37, P1345, DOI 10.1016/j.joen.2011.06.025
   Siqueira JF, 2009, J ENDODONT, V35, P1186, DOI 10.1016/j.joen.2009.05.006
   Susuki K, 2007, J NEUROSCI, V27, P3956, DOI 10.1523/JNEUROSCI.4401-06.2007
   Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856
   van der Pol WL, 2000, NEUROLOGY, V54, P1661, DOI 10.1212/WNL.54.8.1661
   van Doorn PA, 2008, LANCET NEUROL, V7, P939, DOI 10.1016/S1474-4422(08)70215-1
   van Sorge NM, 2005, J NEUROIMMUNOL, V162, P157, DOI 10.1016/j.jneuroim.2005.01.016
   van Sorge NM, 2003, ANN NEUROL, V53, P570, DOI 10.1002/ana.10503
   VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705
   Vedeler CA, 2000, NEUROLOGY, V55, P705, DOI 10.1212/WNL.55.5.705
   Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101
   YUKI N, 1990, NEUROLOGY, V40, P1900, DOI 10.1212/WNL.40.12.1900
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
   Zhang G., 2014, PLOS ONE, V11
NR 40
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD SEP 15
PY 2016
VL 298
BP 160
EP 164
DI 10.1016/j.jneuroim.2016.07.020
PG 5
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DW8WQ
UT WOS:000383936600023
PM 27609290
DA 2020-12-09
ER

PT J
AU Nascimento, OJM
   Ferreira, MLB
   Dourado, MET
   Ferreira, ACA
   Coelho, GE
   Silva, IRF
   Lebeis, K
   Pupe, CCB
AF Nascimento, O. J. M.
   Ferreira, M. L. B.
   Dourado Jr, M. E. T.
   Ferreira, A. C. A.
   Coelho, G. E.
   Silva, I. R. F.
   Lebeis, K.
   Pupe, C. C. B.
TI INCREASED INCIDENCE OF GBS AND ITS VARIANTS: A CURRENT PHOTOGRAPH OF THE
   BRAZILIAN SCENARIO
SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
LA English
DT Meeting Abstract
CT Inflammatory Neuropathy Consortium and GBS 100 Centenary Symposium and
   Ceilidh
CY JUN 21-24, 2016
CL Univ Glasgow, Glasgow, SCOTLAND
SP Baxalta, CSL Behring, Grifols, Kedrion S p A, GBS CIDP Fdn Int, Guillain Barre Associated Inflammatory Neuropathies, LFB Biomedicaments, Octapharma, TEVA
HO Univ Glasgow
C1 [Nascimento, O. J. M.; Ferreira, A. C. A.; Silva, I. R. F.; Lebeis, K.; Pupe, C. C. B.] Univ Fed Fluminense, Rio De Janeiro, Brazil.
   [Ferreira, M. L. B.] Hosp Restauracao, Recife, PE, Brazil.
   [Dourado Jr, M. E. T.] Univ Fed Rio Grande do Norte, Natal, RN, Brazil.
   [Coelho, G. E.] Minist Saude Brasil, Brasilia, DF, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1085-9489
EI 1529-8027
J9 J PERIPHER NERV SYST
JI J. Peripher. Nerv. Syst.
PD SEP
PY 2016
VL 21
IS 3
BP 194
EP 194
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DW7TY
UT WOS:000383856200109
DA 2020-12-09
ER

PT J
AU Fregonezi, G
   Evangelista, MA
   Dias, F
   Dourado, ME
   Lima, INDF
   Resqueti, V
   Aliverti, A
AF Fregonezi, Guilherme
   Evangelista, Morgana Araujo
   Dias, Fernando
   Dourado, Mario Emilio, Jr.
   Lima, Illia Nadine Dantas Florentino
   Resqueti, Vanessa
   Aliverti, Andrea
TI Noninvasive assessment of respiratory muscle strenght and activity in
   myotonic dystrophy
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
DE Physiology; Respiratory muscle; Physiological diagnostic services
RI Fregonezi, Guilherme/AAQ-1493-2020; Fregonezi, Guilherme AF/B-2186-2019;
   Andrea, Aliverti/A-3901-2015; Dias, Fernando AL/D-7126-2013
OI Fregonezi, Guilherme/0000-0003-4938-7018; Fregonezi, Guilherme
   AF/0000-0003-4938-7018; Andrea, Aliverti/0000-0002-2950-0231; Dias,
   Fernando AL/0000-0003-3951-2604
NR 0
TC 0
Z9 0
U1 0
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2016
VL 48
SU 60
MA PA5040
DI 10.1183/13993003.congress-2016.PA5040
PG 1
WC Respiratory System
SC Respiratory System
GA VF5GZ
UT WOS:000443059706289
DA 2020-12-09
ER

PT J
AU Llerena, JC
   Nascimento, OJM
   Oliveira, ASB
   Dourado, MET
AF Llerena, Juan Clinton
   Nascimento, Osvaldo J. M.
   Oliveira, Acary Souza B.
   Dourado, Mario Emilio T.
TI Guidelines for the diagnosis, treatment and clinical monitoring of
   patients with juvenile and adult Pompe disease (vol 74, pg 166, 2016)
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA Portuguese
DT Correction
CR Llerena JC, 2016, ARQ NEURO-PSIQUIAT, V74, P166, DOI 10.1590/0004-282X20150194
NR 1
TC 0
Z9 0
U1 0
U2 3
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD FEB
PY 2016
VL 74
IS 2
BP VI
EP VI
DI 10.1590/0004-282X20150194errata
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DG7TP
UT WOS:000372286900001
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Llerena, JC
   Nascimento, OJM
   Oliveira, ASB
   Dourado, MET
   Marrone, CD
   Siqueira, HH
   Sobreira, CFR
   Dias-Tosta, E
   Werneck, LC
AF Llerena Junior, Juan Clinton
   Nascimento, Osvaldo J. M.
   Oliveira, Acary Souza B.
   Dourado Junior, Mario Emilio T.
   Marrone, Carlo D.
   Siqueira, Heloise Helena
   Sobreira, Claudia F. R.
   Dias-Tosta, Elza
   Werneck, Lineu Cesar
TI Guidelines for the diagnosis, treatment and clinical monitoring of
   patients with juvenile and adult Pompe disease
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Review
DE Pompe disease; glycogen storage disease type II; acid alpha-glucosidase;
   muscular weakness; dyspnea; GAA gene; rhGAA
ID ENZYME REPLACEMENT THERAPY; LYSOSOMAL STORAGE DISEASES; TANDEM
   MASS-SPECTROMETRY; MUSCLE INVOLVEMENT; BLOOD SPOTS; EXPERIENCE;
   MANAGEMENT; PREGNANCY; CONSENSUS; LESSONS
AB Pompe disease (PD) is a potentially lethal illness involving irreversible muscle damage resulting from glycogen storage in muscle fiber and activation of autophagic pathways. A promising therapeutic perspective for PD is enzyme replacement therapy (ERT) with the human recombinant enzyme acid alpha-glucosidase (Myozyme (R)). The need to organize a diagnostic flowchart, systematize clinical follow-up, and establish new therapeutic recommendations has become vital, as ERT ensures greater patient longevity. A task force of experienced clinicians outlined a protocol for diagnosis, monitoring, treatment, genetic counseling, and rehabilitation for PD patients. The study was conducted under the coordination of REBREPOM, the Brazilian Network for Studies of PD. The meeting of these experts took place in October 2013, at L'Hotel Port Bay in Sao Paulo, Brazil. In August 2014, the text was reassessed and updated. Given the rarity of PD and limited high-impact publications, experts submitted their views.
C1 [Llerena Junior, Juan Clinton] Inst Fernandes Figueira FIOCRUZ, Dept Med Genet, Rio De Janeiro, RJ, Brazil.
   [Nascimento, Osvaldo J. M.] Univ Fed Fluminense, Dept Neurol & NeuroUPC, BR-22031171 Rio De Janeiro, RJ, Brazil.
   [Oliveira, Acary Souza B.] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo, SP, Brazil.
   [Dourado Junior, Mario Emilio T.] Univ Fed Rio Grande do Norte, Dept Neurol, Caiaco, RN, Brazil.
   [Marrone, Carlo D.] Clin Marrone, Porto Alegre, RS, Brazil.
   [Siqueira, Heloise Helena] Univ Cuiaba, Dept Neurol, Cuiaba, MT, Brazil.
   [Sobreira, Claudia F. R.] Univ Sao Paulo, Dept Neurociencias, BR-14049 Ribeirao Preto, SP, Brazil.
   [Dias-Tosta, Elza] Hosp Base Dist Fed, Serv Neurol, Brasilia, DF, Brazil.
   [Werneck, Lineu Cesar] Univ Fed Parana, Serv Doencas Neuromusculares, BR-80060000 Curitiba, Parana, Brazil.
RP Nascimento, OJM (corresponding author), Univ Fed Fluminense, Dept Neurol, Rua Siqueira Campos 53,1204, BR-22031171 Rio De Janeiro, RJ, Brazil.
EM osvaldo_nascimento@hotmail.com
RI Werneck, Lineu/Y-4038-2019
OI Siqueira, Heloise/0000-0002-5586-3933; Llerena, Juan/0000-0002-4308-3841
CR Al-Lozi MI, 2009, MUSCLE NERVE, V40, P149, DOI [10.1002/21393, 10.1002/mus.21393]
   Alejaldre A, 2012, NEUROMUSCULAR DISORD, V22, pS148, DOI 10.1016/j.nmd.2012.05.011
   Angelini C, 2012, MUSCLE NERVE, V45, P831, DOI 10.1002/mus.23340
   Bali DS, 2012, AM J MED GENET C, V160C, P40, DOI 10.1002/ajmg.c.31319
   Carlier RY, 2011, NEUROMUSCULAR DISORD, V21, P791, DOI 10.1016/j.nmd.2011.06.748
   Case LE, 2006, GENET MED, V8, P318, DOI 10.1097/01.gim.0000217789.14470.c5
   Cupler EJ, 2012, MUSCLE NERVE, V45, P319, DOI 10.1002/mus.22329
   de Vries JM, 2011, MOL GENET METAB, V104, P552, DOI 10.1016/j.ymgme.2011.09.012
   Desnick RJ, 2012, ANNU REV GENOM HUM G, V13, P307, DOI 10.1146/annurev-genom-090711-163739
   Dubrovsky A, 2011, MUSCLE NERVE, V44, P897, DOI 10.1002/mus.22202
   Forsha D, 2011, GENET MED, V13, P625, DOI 10.1097/GIM.0b013e3182142966
   Fuller DD, 2013, RESP PHYSIOL NEUROBI, V189, P241, DOI 10.1016/j.resp.2013.06.007
   Gauderer MWL, 2002, CLIN NUTR, V21, P103, DOI 10.1054/clnu.2001.0533
   Gungor D, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-34
   Gungor D, 2013, MOL GENET METAB, V109, P371, DOI 10.1016/j.ymgme.2013.05.021
   Gungor D, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-49
   Hagemans MLC, 2005, NEUROLOGY, V64, P2139, DOI 10.1212/01.WNL.0000165979.46537.56
   Hirschhorn R, 2001, METABOLIC MOL BASES, P3389
   Hobson-Webb LD, 2013, NEUROMUSCULAR DISORD, V23, P319, DOI 10.1016/j.nmd.2012.12.003
   Hoeksma M, 2007, EUR J PEDIATR, V166, P871, DOI 10.1007/s00431-006-0315-9
   Karabul N, 2014, MOL GENET METAB, V112, P148, DOI 10.1016/j.ymgme.2014.03.010
   Kishnani PS, 2010, MOL GENET METAB, V99, P26, DOI 10.1016/j.ymgme.2009.08.003
   Kroos M, 2012, AM J MED GENET C, V160C, P59, DOI [10.1002/ajmc.31318, 10.1002/ajmg.c.31318]
   Laforet P, 2010, NEUROMUSCULAR DISORD, V20, P128, DOI 10.1016/j.nmd.2009.11.006
   Lehberger J, 2012, ANAESTHESIST, V61, P229, DOI 10.1007/s00101-012-1998-0
   Liao HC, 2014, CLIN CHIM ACTA, V431, P80, DOI 10.1016/j.cca.2014.01.030
   Llerena JC, 2009, J PEDIATR-US, V155, pS47, DOI 10.1016/j.jpeds.2009.07.006
   Mellies U, 2005, NEUROLOGY, V64, P1465, DOI 10.1212/01.WNL.0000158682.85052.C0
   Mellies U, 2009, RESP MED, V103, P477, DOI 10.1016/j.rmed.2008.12.009
   Messinger YH, 2012, GENET MED, V14, P135, DOI 10.1038/gim.2011.4
   Muller KB, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-65
   Muller-Felber W, 2007, NEUROMUSCULAR DISORD, V17, P698, DOI 10.1016/j.nmd.2007.06.002
   Norwood FR, 2012, NEUROMUSCULAR DISORD, V22, P183, DOI DOI 10.1016/J.NMD.2011.05.009
   Oba-Shinjo SM, 2009, J NEUROL, V256, P1881, DOI 10.1007/s00415-009-5219-y
   Patel TT, 2012, MOL GENET METAB, V106, P301, DOI 10.1016/j.ymgme.2012.04.027
   Ploeg AT, 2010, NEW ENGL J MED, V362, P1396, DOI [10.1056/NEJMoa0909859, DOI 10.1056/NEJMOA0909859]
   Politei JM, 2010, J OBSTET GYNAECOL RE, V36, P428, DOI 10.1111/j.1447-0756.2009.01164.x
   Raben N, 2010, MOL GENET METAB, V101, P324, DOI 10.1016/j.ymgme.2010.08.001
   Ravaglia S, 2010, J NEURO-OPHTHALMOL, V30, P389, DOI 10.1097/WNO.0b013e3181f9a923
   Roberts M, 2011, MOL GENET METAB, V104, P574, DOI 10.1016/j.ymgme.2011.08.011
   Sacconi S, 2010, J NEUROL, V257, P1730, DOI 10.1007/s00415-010-5618-0
   Scott CR, 2013, J PEDIATR-US, V163, P498, DOI 10.1016/j.jpeds.2013.01.031
   Terzis G, 2011, MOL GENET METAB, V104, P279, DOI 10.1016/j.ymgme.2011.05.013
   Toscano A, 2013, J NEUROL, V260, P951, DOI 10.1007/s00415-012-6636-x
   Van der Beek NAME, 2009, NEUROMUSCULAR DISORD, V19, P113, DOI 10.1016/j.nmd.2008.11.007
   van der Beek NAME, 2012, J INHERIT METAB DIS, V35, P335, DOI 10.1007/s10545-011-9396-3
   van der Ploeg AT, 2008, LANCET, V372, P1342, DOI 10.1016/S0140-6736(08)61555-X
   Vissing J, 2013, JAMA NEUROL, V70, P923, DOI 10.1001/2013.jamaneurol.486
   Vries JM, 2012, ORPHANET J RARE DIS, V7, P73, DOI [10.1186/1750-1172-7-73, DOI 10.1186/1750-1172-7-73]
   Wang RY, 2011, GENET MED, V13, P457, DOI 10.1097/GIM.0b013e318211a7e1
   Wens SCA, 2014, J INHERIT METAB DIS, V37, P391, DOI 10.1007/s10545-013-9667-2
   Werneck LC, 2013, ARQ NEURO-PSIQUIAT, V71, P284, DOI 10.1590/0004-282X20130022
   Winchester B, 2008, MOL GENET METAB, V93, P275, DOI 10.1016/j.ymgme.2007.09.006
   World Health Organization, 2001, INT CLASS FUNCT DIS
   Zagnoli F, 2013, NEUROMUSCULAR DISORD, V23, P180, DOI 10.1016/j.nmd.2012.11.006
NR 55
TC 11
Z9 14
U1 0
U2 6
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD FEB
PY 2016
VL 74
IS 2
BP 166
EP 176
DI 10.1590/0004-282X20150194
PG 11
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DG7TP
UT WOS:000372286900017
PM 26690841
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Laurentino, M
   Melo, C
   Loureiro, C
   Camilo, A
   Linard, V
   Jose, J
   Godeiro, C
   Santiago, P
   Dourado, ME
   Correia, CE
   Marinho, M
AF Laurentino, M.
   Melo, C.
   Loureiro, C.
   Camilo, A.
   Linard, V.
   Jose, J.
   Godeiro, C.
   Santiago, P.
   Dourado, M. E.
   Correia, C. E.
   Marinho, M.
TI Reversible cerebral vasoconstriction syndrome as a cause of
   simultaneously ischemic and hemorrhagic stroke
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Meeting Abstract
CT 22nd World Congress of Neurology (WCN)
CY OCT 31-NOV 05, 2015
CL Santiago, CHILE
C1 [Laurentino, M.; Melo, C.; Loureiro, C.; Camilo, A.; Linard, V.; Jose, J.; Godeiro, C.; Santiago, P.; Dourado, M. E.; Correia, C. E.; Marinho, M.] Huol Ufrn, Neurol, Natal, RN, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD OCT 15
PY 2015
VL 357
SU 1
MA 1335
BP E389
EP E389
DI 10.1016/j.jns.2015.08.1383
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DX8JV
UT WOS:000384634802201
OA Bronze
DA 2020-12-09
ER

PT J
AU Laurentino, M
   Afonso, COM
   Rocha, TAF
   Silva, JJ
   Melo, JFN
   Dourado, MET
   Godeiro, CO
   Brito, PSM
   Figueiredo, MM
   Correia, CER
AF Laurentino, M.
   Afonso, C. O. M.
   Rocha, T. A. F.
   Silva, J. J.
   Melo, J. F. N.
   Dourado, M. E. T.
   Godeiro Junior, C. O.
   Brito, P. S. M.
   Figueiredo, M. M.
   Correia, C. E. R.
TI Indirect carotid cavernous fistula type c: a case report
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Meeting Abstract
CT 22nd World Congress of Neurology (WCN)
CY OCT 31-NOV 05, 2015
CL Santiago, CHILE
C1 [Laurentino, M.; Afonso, C. O. M.; Dourado, M. E. T.; Godeiro Junior, C. O.; Brito, P. S. M.; Figueiredo, M. M.; Correia, C. E. R.] HUOL, Neurol, Natal, RN, Brazil.
   [Rocha, T. A. F.; Silva, J. J.; Melo, J. F. N.] HUOL, Neurosurg, Natal, RN, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD OCT 15
PY 2015
VL 357
SU 1
MA 554
BP E180
EP E181
DI 10.1016/j.jns.2015.08.622
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DX8JV
UT WOS:000384634800463
DA 2020-12-09
ER

PT J
AU da Silva, AE
   Barreira, AA
   Oliveira, ASB
   Dourado, MET
   De Marco, SPG
   Marques, W
AF da Silva, A. E.
   Barreira, A. A.
   Oliveira, A. S. B.
   Dourado Jr, M. E. T.
   De Marco, S. P. G.
   Marques Jr, W.
TI GENOTYPIC EVALUATION OF PATIENTS WITH INITIAL DIAGNOSIS OF CHRONIC
   INFLAMMATORY DEMYELINATING POLYNEUROPATHY
SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
LA English
DT Meeting Abstract
CT Biennial Meeting of the Peripheral-Nerve-Society
CY JUN 27-JUL 02, 2015
CL Quebec, CANADA
SP Peripheral Nerve Soc
C1 [da Silva, A. E.; Barreira, A. A.; De Marco, S. P. G.; Marques Jr, W.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Oliveira, A. S. B.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Dourado Jr, M. E. T.] Univ Fed Rio Grande do Norte, BR-59072970 Natal, RN, Brazil.
RI Marques, Wilson/G-4240-2012
OI Marques, Wilson/0000-0002-4589-2749
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1085-9489
EI 1529-8027
J9 J PERIPHER NERV SYST
JI J. Peripher. Nerv. Syst.
PD JUN
PY 2015
VL 20
IS 2
BP 122
EP 122
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CP9LC
UT WOS:000360214600093
DA 2020-12-09
ER

PT J
AU Fregonezi, G
   Azevedo, IG
   Resqueti, VR
   De Andrade, AD
   Gualdi, LP
   Aliverti, A
   Dourado, MET
   Parreira, VF
AF Fregonezi, Guilherme
   Azevedo, Ingrid G.
   Resqueti, Vanessa R.
   De Andrade, Armele D.
   Gualdi, Lucien P.
   Aliverti, Andrea
   Dourado-Junior, Mario E. T.
   Parreira, Veronica F.
TI Muscle Impairment in Neuromuscular Disease Using an
   Expiratory/Inspiratory Pressure Ratio
SO RESPIRATORY CARE
LA English
DT Article
DE respiratory muscle strength; respiratory muscle imbalance; neuromuscular
   diseases; respiratory therapy; P-Emax/P-Imax ratio
ID RESPIRATORY CARE; PATTERN
AB BACKGROUND: Neuromuscular diseases (NMDs) lead to different weakness patterns, and most patients with NMDs develop respiratory failure. Inspiratory and expiratory muscle strength can be measured by maximum static inspiratory pressure (P-Imax) and maximum static expiratory pressure (P-Emax), and the relationship between them has not been well described in healthy subjects and subjects with NMDs. Our aim was to assess expiratory/inspiratory muscle strength in NMDs and healthy subjects and calculate P-Emax/P-Imax ratio for these groups. METHODS: Seventy (35 males) subjects with NMDs (amyotrophic lateral sclerosis, myasthenia gravis, and myotonic dystrophy), and 93 (47 males) healthy individuals 20-80 y of age were evaluated for anthropometry, pulmonary function, P-Imax, and P-Emax, respectively. RESULTS: Healthy individuals showed greater values for PImax and P-Emax when compared with subjects with NMDs. P-Emax/PImax ratio for healthy subjects was 1.31 +/- 0.26, and P-Emax%/P-Imax% was 1.04 +/- 0.05; for subjects with NMDs, P-Emax/PImax ratio was 1.45 +/- 0.65, and P-Emax%/PImax% ratio was 1.42 +/- 0.67. We found that P-Emax%/PImax% for myotonic dystrophy was 0.93 +/- 0.24, for myasthenia gravis 1.94 +/- 0.6, and for amyotrophic lateral sclerosis 1.33 +/- 0.62 when we analyzed them separately. All healthy individuals showed higher P-Emax compared with P-Imax. For subjects with NMDs, the impairment of P-Emax and P-Imax is different among the 3 pathologies studied (P < .001). CONCLUSIONS: Healthy individuals and subjects with NMDs showed higher P-Emax in comparison to P-Imax regarding the P-Emax/P-Imax ratio. Based on the ratio, it is possible to state that NMDs show different patterns of respiratory muscle strength loss. P-Emax/P-Imax ratio is a useful parameter to assess the impairment of respiratory muscles in a patient and to customize rehabilitation and treatment.
C1 [Fregonezi, Guilherme; Azevedo, Ingrid G.; Resqueti, Vanessa R.; Gualdi, Lucien P.] Univ Fed Rio Grande do Norte, Phys Therapy Dept, BR-59072970 Natal, RN, Brazil.
   [Azevedo, Ingrid G.] Univ Fed Pernambuco, Phys Therapy Dept, Recife, PE, Brazil.
   [Aliverti, Andrea] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, I-20133 Milan, Italy.
   [Dourado-Junior, Mario E. T.] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, BR-59072970 Natal, RN, Brazil.
   [Parreira, Veronica F.] Univ Fed Minas Gerais, Phys Therapy Dept, Belo Horizonte, MG, Brazil.
RP Fregonezi, G (corresponding author), Univ Fed Rio Grande do Norte, Dept Fisioterapia, Lab Desempenho PneumoCardioVasc & Musculos Resp, Campus Univ Lagoa Nova,Caixa Postal 1524, BR-59072970 Natal, RN, Brazil.
EM fregonezi@ufrnet.br
RI Andrea, Aliverti/A-3901-2015; Gualdi, Lucien/ABF-2712-2020; Resqueti,
   Vanessa R/I-3604-2015; Fregonezi, Guilherme AF/B-2186-2019; Azevedo,
   Ingrid/AAL-9413-2020; Parreira, Veronica F/I-4236-2013; Fregonezi,
   Guilherme/AAQ-1493-2020
OI Andrea, Aliverti/0000-0002-2950-0231; Fregonezi, Guilherme
   AF/0000-0003-4938-7018; Azevedo, Ingrid/0000-0001-7305-7583; Parreira,
   Veronica F/0000-0003-0374-9319; Fregonezi,
   Guilherme/0000-0003-4938-7018; Peroni Gualdi, Lucien/0000-0002-6907-7335
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   grant Programa Nacional de Cooperacao Academica (PROCAD) 764/2010 from
   Universidade Federal do Rio Grande do Norte/Universidade Federal de
   Pernambuco/Universidade Federal de Minas Gerais [764/2010]; CAPESCAPES
FX This research was supported by Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES) grant Programa Nacional de Cooperacao
   Academica (PROCAD) 764/2010 from Universidade Federal do Rio Grande do
   Norte/Universidade Federal de Pernambuco/Universidade Federal de Minas
   Gerais, as well as a postdoctoral scholarship to Dr Fregonezi from
   CAPES. The authors have disclosed no other conflicts of interest.
CR Ambrosino N, 2009, EUR RESPIR J, V34, P444, DOI 10.1183/09031936.00182208
   Association WM, 2002, J POSTGRAD MED, P158
   BLACK LF, 1969, AM REV RESPIR DIS, V99, P696
   D'Angelo MG, 2011, J NEUROL SCI, V306, P54, DOI 10.1016/j.jns.2011.03.045
   KEENAN SP, 1995, EUR RESPIR J, V8, P1130, DOI 10.1183/09031936.95.08071130
   Misuri G, 2000, CHEST, V117, P447, DOI 10.1378/chest.117.2.447
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   Park JH, 2010, YONSEI MED J, V51, P7
   Pereira CAC, 2007, J BRAS PNEUMOL, V33, P9
   Qureshi MM, 2006, AMYOTROPH LATERAL SC, V7, P173, DOI 10.1080/14660820600640596
   Racca F, 2010, MINERVA ANESTESIOL, V76, P51
   Simonds AK, 2006, CHEST, V130, P1879, DOI 10.1378/chest.130.6.1879
   Sociedade Brasileira de Pneumologia e Tisiologia, 2002, J PNEUMOL, V28, P237
   Society ATSER, 2002, AM J RESP CRIT CARE, V15, P106
   Troosters T, 2005, EUR RESP MON, V31, P14
   VEALE D, 1995, EUR RESPIR J, V8, P815
   Weiner P, 1998, CAN J NEUROL SCI, V25, P236, DOI 10.1017/S0317167100034077
   World Health Organization, GLOB DAT BOD MASS IN
NR 18
TC 12
Z9 15
U1 0
U2 1
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD APR
PY 2015
VL 60
IS 4
BP 533
EP 539
DI 10.4187/respcare.03367
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CH7BQ
UT WOS:000354191000018
PM 25587161
OA Bronze
DA 2020-12-09
ER

PT J
AU Fregonezi, G
   Araujo, PRS
   Macedo, TLF
   Dourado, ME
   Resqueti, VR
   de Andrade, ADD
AF Fregonezi, Guilherme
   Saldanha Araujo, Palomma Russelly
   Ferreira Macedo, Tathiana Lindemberg
   Dourado Junior, Mario Emilio
   Resqueti, Vanessa Regiane
   Dornelas de Andrade, Armele de Fatima
TI Monitoring respiratory muscle strength assists in early diagnosis of
   respiratory dysfunction as opposed to the isolated use of pulmonary
   function evaluation in amyotrophic lateral sclerosis
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE muscle weakness; neuromuscular diseases; pulmonary function test;
   respiratory muscles
ID NASAL INSPIRATORY PRESSURE; MOTOR-NEURON DISEASE; SPIROMETRY; SNIFF;
   DEATH; VENTILATION; WEAKNESS; VALUES; TESTS; ALS
AB Objective: It was study the relationship between respiratory muscle strength and forced vital capacity (FVC) in patients with amyotrophic lateral sclerosis (ALS) versus healthy subjects. Methods: Pulmonary function and respiratory muscle strength [maximal inspiratory (PImax), maximal expiratory (PEmax) and sniff nasal inspiratory pressure (SNIP)] were assessed in patients with ALS and healthy subjects, matched using cutoffs established in the literature for impaired pulmonary function and respiratory muscle weakness. Results: Twenty-eight ALS patients and 28 healthy subjects were studied. We found sensitivity and specificity for Plmax, PEmax and SNIP of 75/58%, 81/67% and 75/67%. The Receiver Operating Characteristic curve (ROC curve) indicated that the variables Plmax, PEmax and SNIP can identify differences in respiratory muscle strength between ALS and healthy individuals at 0.89, 0.9 and 0.82, respectively. A positive correlation was recorded between FVC (%) versus SNIP, Plmax and PEmax. Conclusion: In ALS, monitoring respiratory muscle strength assists in early diagnosis of respiratory dysfunction as opposed to the isolated use of FVC.
C1 [Fregonezi, Guilherme; Saldanha Araujo, Palomma Russelly; Ferreira Macedo, Tathiana Lindemberg] Fed Univ Rio Grande Norte UFRN, Dept Phys Therapy, Natal, RN, Brazil.
   [Dourado Junior, Mario Emilio] Univ Fed Rio Grande do Norte, Onofre Lopes Univ Hosp, Natal, RN, Brazil.
   [Resqueti, Vanessa Regiane; Dornelas de Andrade, Armele de Fatima] Fed Univ Pernambuco UFPE, Dept Physiotherapy, Lab Cardiopulm Physiotherapy, Pernambuco, PE, Brazil.
RP Fregonezi, G (corresponding author), Univ Fed Rio Grande do Norte, Dept Fisioterapia, Campus Univ Lagoa Nova Caixa Postal 1524, BR-59072970 Natal, RN, Brazil.
EM fregonezi@ufrnet.br
RI Fregonezi, Guilherme/AAQ-1493-2020; Resqueti, Vanessa R/I-3604-2015;
   Fregonezi, Guilherme AF/B-2186-2019
OI Fregonezi, Guilherme/0000-0003-4938-7018; Fregonezi, Guilherme
   AF/0000-0003-4938-7018
FU CNPq BrazilNational Council for Scientific and Technological Development
   (CNPq) [301661/2009-0]; Programs Nacional de Cooperacao Academics - Acao
   Novas Fronteiras (Procad-NF) [764/2010-UFRN-UFMG-UFPE]
FX This work was supported by the CNPq Brazil (number: 301661/2009-0) and
   Programs Nacional de Cooperacao Academics - Acao Novas Fronteiras
   (Procad-NF) number 764/2010-UFRN-UFMG-UFPE.
CR Araujo PRS, MAXIMAL SNI IN PRESS
   Azevedo IG, 2010, TER MAN, V8, P224
   BLACK LF, 1969, AM REV RESPIR DIS, V99, P696
   Corcia P, 2008, AMYOTROPH LATERAL SC, V9, P59, DOI 10.1080/17482960701656940
   Silva LBD, 2008, ARQ NEURO-PSIQUIAT, V66, P354, DOI 10.1590/S0004-282X2008000300014
   FALLAT RJ, 1979, ARCH NEUROL-CHICAGO, V36, P74, DOI 10.1001/archneur.1979.00500380044004
   Fregonezi GAF, 2011, EUR RESP J, V239
   Lima NMFV, 2011, ARQ NEURO-PSIQUIAT, V69, P170, DOI 10.1590/S0004-282X2011000200005
   Hart N, 2003, J NEUROL NEUROSUR PS, V74, P1685, DOI 10.1136/jnnp.74.12.1685
   Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3
   Katagiri M, 2003, RESP MED, V97, P1027, DOI 10.1016/S0954-6111(03)00133-1
   Kurian KM, 2009, J NEUROL NEUROSUR PS, V80, P84, DOI 10.1136/jnnp.2008.149708
   Lechtzin N, 2002, CHEST, V121, P436, DOI 10.1378/chest.121.2.436
   Lofaso F, 2006, EUR RESPIR J, V27, P980, DOI 10.1183/09031936.06.00121305
   Almeida SRM, 2010, ARQ NEURO-PSIQUIAT, V68, P258, DOI 10.1590/S0004-282X2010000200020
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   NAVA S, 1993, THORAX, V48, P702, DOI 10.1136/thx.48.7.702
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   O'Neill CL, 2012, J NEUROL NEUROSUR PS, V83, P371, DOI 10.1136/jnnp-2011-300480
   Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
   Qureshi MM, 2006, AMYOTROPH LATERAL SC, V7, P173, DOI 10.1080/14660820600640596
   Resqueti VR, 2011, TER MAN, V9, P503
   Severino FG, 2010, BRAZ J PHYS THER, V14, P426, DOI 10.1590/S1413-35552010000500012
   Singh D, 2011, J NEUROL SCI, V306, P76, DOI 10.1016/j.jns.2011.03.039
   Spataro R, 2010, ACTA NEUROL SCAND, V122, P217, DOI 10.1111/j.1600-0404.2009.01290.x
   Steier J, 2007, THORAX, V62, P975, DOI 10.1136/thx.2006.072884
   Tsara V, 2010, HIPPOKRATIA, V14, P33
   Uldry C, 1997, EUR RESPIR J, V10, P1292, DOI 10.1183/09031936.97.10061292
NR 28
TC 7
Z9 7
U1 0
U2 5
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD MAR
PY 2013
VL 71
IS 3
BP 146
EP 152
DI 10.1590/S0004-282X2013000300004
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 122JY
UT WOS:000317315600004
PM 23563713
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Fregonezi, G
   Araujo, T
   Dourado, ME
   Ferezini, J
   Silva, E
   Resqueti, V
AF Fregonezi, Guilherme
   Araujo, Thaise
   Dourado Junior, Mario Emilio
   Ferezini, Joceline
   Silva, Ester
   Resqueti, Vanessa
TI Heart Rate Variability in Myotonic Dystrophy Type 1 Patients
SO ARQUIVOS BRASILEIROS DE CARDIOLOGIA
LA English
DT Article
DE Heart rate; myotonic dystrophy; spectrum analysis; autonomic nervous
   system
ID MICROPROCESSOR QRS DETECTOR; AUTONOMIC FUNCTION; SPECTRAL-ANALYSIS;
   REPRODUCIBILITY; TIME; ACCURACY; DISEASE; REST; RISK
AB Background: Cardiac involvement is common in myotonic dystrophy (MD) patients. Heart rate variability (HRV) is a simple and reliable technique that can be useful for studying the influence of the autonomic nervous system on the heart.
   Objective: Study heart rate variability in patients with type 1 MD.
   Methods: We studied HRV during 5-minute recordings in MD patients and in a healthy control group. We analyzed frequency domains (LF and HF) in normalized units (nu) and sympathovagal balance, in the sitting and supine position.
   Results: Seventeen patients (10 men and 7 women) and seventeen matched healthy individuals (10 men and 7 women) were studied. Sympathetic and parasympathetic modulations of the heart increased in male MD patients from supine to sitting position in 19% of LFnu and the LF/HF ratio rose by 42.3%. In the sitting position, male MD patients exhibited significantly higher sympathovagal balances in 50.9% compared to healthy control individuals. HRV was influenced by both gender and disease. Gender influenced LFnu in the supine position while the LF/HF ratio and HFnu were affected in both positions. Post hoc analyses showed that gender significantly impacts MD patients and healthy individuals in different ways (p < 0.01). The low frequency domain in the sitting position (LFnu) was significantly influenced by the disease.
   Conclusion: The results of this study suggest that the sympathetic drive in middle-aged male MD patients who are not severely impaired and present moderate disease duration seems to be greater than in healthy matched individuals. (Arq Bras Cardiol 2012; 98(4): 353-361)
C1 [Fregonezi, Guilherme; Araujo, Thaise; Ferezini, Joceline; Resqueti, Vanessa] Univ Fed Rio Grande do Norte, Dept Fisioterapia, Ctr Ciencias Saude, Lab Fisioterapia Pneumocardiovasc, BR-59072970 Natal, RN, Brazil.
   [Dourado Junior, Mario Emilio] Univ Fed Rio Grande do Norte, Hosp Onofre Lopes, Clin Doencas Neuromusculares, BR-59072970 Natal, RN, Brazil.
   [Silva, Ester] Univ Metodista Piracicaba, Lab Doencas Cardiovasc, Piracicaba, SP, Brazil.
RP Fregonezi, G (corresponding author), Univ Fed Rio Grande do Norte, Dept Fisioterapia, Ctr Ciencias Saude, Lab Fisioterapia Pneumocardiovasc, Campus Lagoa Nova,Caixa Postal 1524, BR-59072970 Natal, RN, Brazil.
EM fregonezi@ufrnet.br
RI Silva, Ester/I-3866-2013; DA SILVA, ESTER/G-8780-2012; Fregonezi,
   Guilherme AF/B-2186-2019; Resqueti, Vanessa R/I-3604-2015; Fregonezi,
   Guilherme/AAQ-1493-2020
OI Fregonezi, Guilherme AF/0000-0003-4938-7018; Fregonezi,
   Guilherme/0000-0003-4938-7018
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERN
FX This study was funded by CNPq and FAPERN.
CR Acharya UR, 2005, J BODYW MOV THER, V9, P134, DOI 10.1016/j.jbmt.2004.04.001
   Bouhour F, 2007, PRESSE MED, V36, P965, DOI 10.1016/j.lpm.2007.01.002
   Camm AJ, 1996, CIRCULATION, V93, P1043, DOI 10.1016/0044-8486(94)90048-5
   Carnethon MR, 2002, AM J EPIDEMIOL, V155, P48, DOI 10.1093/aje/155.1.48
   Chemla D, 2005, INT J CARDIOL, V104, P307, DOI 10.1016/j.ijcard.2004.12.018
   Dantas EM, 2010, BRAZ J MED BIOL RES, V43, P982, DOI 10.1590/S0100-879X2010001000010
   Day JW, 1999, NEUROMUSCULAR DISORD, V9, P19, DOI 10.1016/S0960-8966(98)00094-7
   DENHEIJER JC, 1991, J NEUROL NEUROSUR PS, V54, P531, DOI 10.1136/jnnp.54.6.531
   Di Leo R, 2004, NEUROMUSCULAR DISORD, V14, P136, DOI 10.1016/j.nmd.2003.11.002
   EWING DJ, 1991, BRIT HEART J, V65, P239
   Flachenecker P, 2003, NEUROMUSCULAR DISORD, V13, P289, DOI 10.1016/S0960-8966(02)00277-8
   Groh WJ, 2008, NEW ENGL J MED, V358, P2688, DOI 10.1056/NEJMoa062800
   Groh WJ, 2011, MUSCLE NERVE, V43, P648, DOI 10.1002/mus.21934
   Hardin BA, 2003, ANN NONINVAS ELECTRO, V8, P227, DOI 10.1046/j.1542-474X.2003.08310.x
   Hoikkala H, 2010, MENOPAUSE, V17, P315, DOI 10.1097/gme.0b013e3181c2bb6d
   Hojgaard MV, 2005, BLOOD PRESS MONIT, V10, P19
   INOUE K, 1995, J AUTONOM NERV SYST, V55, P131, DOI 10.1016/0165-1838(95)00040-5
   Logigian EL, 2007, MUSCLE NERVE, V35, P479, DOI 10.1002/mus.20722
   Loimaala A, 1999, CLIN PHYSIOL, V19, P84
   Lord SW, 2001, CLIN SCI, V100, P43, DOI 10.1042/CS20000111
   Low P. A., 1997, CLIN AUTONOMIC DISOR
   Mathieu J, 2001, NEUROLOGY, V56, P336, DOI 10.1212/WNL.56.3.336
   McNally EM, 2011, HEART, V97, P1094, DOI 10.1136/hrt.2010.214197
   OLOFSSON BO, 1990, J AUTONOM NERV SYST, V29, P187, DOI 10.1016/0165-1838(90)90144-8
   Palmer PM, 2010, J SPEECH LANG HEAR R, V53, P1567, DOI 10.1044/1092-4388(2010/09-0068)
   Pelargonio G, 2002, HEART, V88, P665, DOI 10.1136/heart.88.6.665
   Pichon A, 2006, J ELECTROCARDIOL, V39, P31, DOI 10.1016/j.jelectrocard.2005.08.001
   Pinna GD, 2007, CLIN SCI, V113, P131, DOI 10.1042/CS20070055
   Rakocevic-Stojanovic V, 2007, Acta Myol, V26, P112
   Romigi A, 2011, EUR J NEUROL, V18, P1139, DOI 10.1111/j.1468-1331.2011.03352.x
   Ruha A, 1997, IEEE T BIO-MED ENG, V44, P159, DOI 10.1109/10.554762
   Sandercock GRH, 2005, INT J CARDIOL, V103, P238, DOI 10.1016/j.ijcard.2004.09.013
   Stein PK, 1999, ANNU REV MED, V50, P249, DOI 10.1146/annurev.med.50.1.249
   Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850
   *WORLD MED ASS, 2004, DECL HELS ETH PRINC
NR 35
TC 7
Z9 7
U1 0
U2 3
PU ARQUIVOS BRASILEIROS CARDIOLOGIA
PI RIO DE JANEIRO
PA AVENIDA MARECHAL CAMARA 160-330 CENTRO, RIO DE JANEIRO, RJ 20 020-907,
   BRAZIL
SN 0066-782X
J9 ARQ BRAS CARDIOL
JI Arq. Bras. Cardiol.
PD APR
PY 2012
VL 98
IS 4
BP 353
EP 360
DI 10.1590/S0066-782X2012005000021
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 965JZ
UT WOS:000305765200016
PM 22406991
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Dourado, ME
   Miranda, RHF
   Jeronimo, SM
AF Dourado, M. E.
   Felix Miranda, R. H.
   Jeronimo, S. M.
TI Response: serial nerve conduction studies in Guillain-Barre syndrome
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Letter
C1 [Dourado, M. E.; Felix Miranda, R. H.; Jeronimo, S. M.] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, BR-59072970 Natal, RN, Brazil.
RP Dourado, ME (corresponding author), Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, BR-59072970 Natal, RN, Brazil.
EM medourado@ufrnet.br
RI Jeronimo, Selma M.B./M-8672-2014; Jeronimo, Selma/AAY-4033-2020
OI Jeronimo, Selma M.B./0000-0002-4784-9904; Jeronimo,
   Selma/0000-0002-4784-9904
CR Dourado ME, 2012, ACTA NEUROL SCAND, V125, P47, DOI 10.1111/j.1600-0404.2011.01503.x
   HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597
   Kokubun N, 2010, BRAIN, V133, P2897, DOI 10.1093/brain/awq260
   Nagasawa K, 2006, MUSCLE NERVE, V33, P766, DOI 10.1002/mus.20520
   Sladky JT, 2007, NEUROLOGY, V69, P1647, DOI 10.1212/01.wnl.0000280583.84253.05
NR 5
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-6314
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD APR
PY 2012
VL 125
IS 4
BP e23
EP e23
DI 10.1111/j.1600-0404.2011.01565.x
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 904UJ
UT WOS:000301223100002
DA 2020-12-09
ER

PT J
AU Dourado, ME
   Felix, RH
   da Silva, WKA
   Queiroz, JW
   Jeronimo, SMB
AF Dourado, M. E.
   Felix, R. H.
   da Silva, W. K. A.
   Queiroz, J. W.
   Jeronimo, S. M. B.
TI Clinical characteristics of Guillain-Barre syndrome in a tropical
   country: a Brazilian experience
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article
DE Guillain-Barre syndrome; electromyography; critical care;
   neuroimmunology; neuropathy; peripheral neuropathy
ID CAMPYLOBACTER-JEJUNI; GANGLIOSIDE MIMICRY; ANTIBODIES; FEATURES;
   PREDICTORS; NEUROPATHY; PROGNOSIS; PATTERNS; CRITERIA
AB Objective - To analyze the clinical variants, outcomes, and prognosis of Guillain-Barre syndrome (GBS) in a Brazilian population. Materials and methods - Clinical and laboratory data of 149 cases of GBS diagnosed from 1994 to 2007 were analyzed. Results - Acute inflammatory demyelinating polyneuropathy (AIDP) was the most frequent variant (81.8%) of GBS, followed by acute motor axonal neuropathy (AMAN) (14.7%) and acute motor and sensory axonal neuropathy (AMSAN) (3.3%). The incidence of GBS was 0.3/100,000 for the state of Rio Grande do Norte and cases occurred at a younger age. GBS was preceded by infections, with the axonal variant associated with episodes of diarrheas (P = 0.025). Proximal weakness was more frequent in AIDP, and distal weakness predominant in the axonal variant. Compared to 42.4% of cases with AIDP (P < 0.0001), 84.6% of cases with the axonal variant had nadir in < 10 days. Individuals with the axonal variant took longer to recover deambulation (P < 0.0001). The mortality of GBS was 5.3%. Conclusion - A predominance of the AIDP variant was seen, and the incidence of the disease decreased with age. As expected, the distribution of weakness correlated with the clinical variants, and individuals with the axonal variant had a poorer prognosis.
C1 [Dourado, M. E.] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, BR-59072970 Natal, RN, Brazil.
   [Dourado, M. E.; Felix, R. H.; Queiroz, J. W.; Jeronimo, S. M. B.] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Hlth Post Grad Program, BR-59072970 Natal, RN, Brazil.
   [da Silva, W. K. A.; Queiroz, J. W.; Jeronimo, S. M. B.] Univ Fed Rio Grande do Norte, Dept Biochem, Biosci Ctr, BR-59072970 Natal, RN, Brazil.
   [Jeronimo, S. M. B.] CNPq, MCT, INCT DT, Campinas, SP, Brazil.
RP Dourado, ME (corresponding author), Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, CP 1624, BR-59072970 Natal, RN, Brazil.
EM medourado@ufrnet.br
RI Jeronimo, Selma/AAY-4033-2020; Jeronimo, Selma M.B./M-8672-2014
OI Jeronimo, Selma/0000-0002-4784-9904; Jeronimo, Selma
   M.B./0000-0002-4784-9904
FU Brazilian Research Council (Conselho Nacional de Pesquisa e
   Desenvolvimento, CNPq-Universal) [14/2009]; Instituto Nacional de
   Ciencia e Tecnologia de Doencas Tropicais (INCT-DT)
FX We thank the staff of the Hospital Walfredo Gurgel, Hospital
   Universitario Onofre Lopes and Hospital Infantil Varella Santiago in
   Natal for the referral of the patients with Guillain-Barre syndrome and
   Kate Dupnik, MD (New York Presbyterian Hospital/Weil Cornell Medical
   College) for her helpful suggestions. This work was supported by the
   Brazilian Research Council (Conselho Nacional de Pesquisa e
   Desenvolvimento, CNPq-Universal 14/2009) and by the Instituto Nacional
   de Ciencia e Tecnologia de Doencas Tropicais (INCT-DT).
CR Andrade IG, 2009, T ROY SOC TROP MED H, V103, P506, DOI 10.1016/j.trstmh.2008.12.017
   ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707
   DEARRUDA E, 1991, J INFECT DIS, V164, P252, DOI 10.1093/infdis/164.2.252
   Dias-Tosta E, 2002, ARQ NEURO-PSIQUIAT, V60, P367, DOI 10.1590/S0004-282X2002000300005
   Dourado ME, 2003, ACTA NEUROL SCAND, V108, P102, DOI 10.1034/j.1600-0404.2003.00103.x
   Durand MC, 2006, LANCET NEUROL, V5, P1021, DOI 10.1016/S1474-4422(06)70603-2
   Franca MC, 2005, ARQ NEURO-PSIQUIAT, V63, P772, DOI 10.1590/S0004-282X2005000500010
   Funakoshi K, 2009, J NEUROL NEUROSUR PS, V80, P60, DOI 10.1136/jnnp.2008.154351
   GRIFFIN JW, 1995, BRAIN, V118, P577, DOI 10.1093/brain/118.3.577
   Hao Q, 1998, J NEUROIMMUNOL, V81, P116, DOI 10.1016/S0165-5728(97)00166-5
   Hao Q, 1999, ANN NEUROL, V45, P758
   Hauck LJ, 2008, J NEUROL NEUROSUR PS, V79, P318, DOI 10.1136/jnnp.2007.118810
   Hiraga A, 2005, NEUROLOGY, V64, P856, DOI 10.1212/01.WNL.0000153071.71335.E9
   Ho TW, 1999, ANN NEUROL, V45, P168, DOI 10.1002/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6
   Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9
   Hughes RAC, 1997, LANCET, V349, P225
   Hui ACF, 2005, J CLIN NEUROSCI, V12, P134, DOI 10.1016/j.jocn.2003.10.018
   Kushnir M, 2008, ACTA NEUROL SCAND, V117, P347, DOI 10.1111/j.1600-0404.2007.00949.x
   Lawn ND, 1999, MUSCLE NERVE, V22, P1058
   McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748
   MCKHANN GM, 1993, ANN NEUROL, V33, P333, DOI 10.1002/ana.410330402
   MEULSTEE J, 1995, J NEUROL NEUROSUR PS, V59, P482, DOI 10.1136/jnnp.59.5.482
   Mori M, 2001, NEUROLOGY, V56, P1104, DOI 10.1212/WNL.56.8.1104
   Nachamkin I, 2007, NEUROLOGY, V69, P1665, DOI 10.1212/01.wnl.0000265396.87983.bd
   Nagasawa K, 2006, MUSCLE NERVE, V33, P766, DOI 10.1002/mus.20520
   Paradiso G, 1999, ANN NEUROL, V46, P701, DOI 10.1002/1531-8249(199911)46:5<701::AID-ANA4>3.0.CO;2-7
   REES JH, 1995, ANN NEUROL, V38, P809, DOI 10.1002/ana.410380516
   Rocha MSG, 2004, ARQ NEURO-PSIQUIAT, V62, P33, DOI 10.1590/S0004-282X2004000100006
   ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P511, DOI 10.1001/archneur.1984.04050170057018
   Soares CN, 2008, ARQ NEURO-PSIQUIAT, V66, P234, DOI 10.1590/S0004-282X2008000200018
   Uncini A, 2010, J NEUROL NEUROSUR PS, V81, P1157, DOI 10.1136/jnnp.2010.208538
   van Doorn PA, 2008, LANCET NEUROL, V7, P939, DOI 10.1016/S1474-4422(08)70215-1
   van Koningsveld R, 2001, NEUROLOGY, V56, P1467, DOI 10.1212/WNL.56.11.1467
   VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705
   VISSER LH, 1995, BRAIN, V118, P841, DOI 10.1093/brain/118.4.841
   Walgaard C, 2010, ANN NEUROL, V67, P781, DOI 10.1002/ana.21976
   Yuki N, 2005, CURR OPIN NEUROL, V18, P557, DOI 10.1097/01.wco.0000174604.42272.2d
   Yuki N, 2007, MUSCLE NERVE, V35, P691, DOI 10.1002/mus.20762
NR 38
TC 23
Z9 24
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD JAN
PY 2012
VL 125
IS 1
BP 47
EP 53
DI 10.1111/j.1600-0404.2011.01503.x
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 867TN
UT WOS:000298477600010
PM 21428966
DA 2020-12-09
ER

PT J
AU Araujo, TL
   Resqueti, VR
   Bruno, S
   Azevedo, IG
   Dourado, ME
   Fregonezi, G
AF Lucena Araujo, T.
   Regiane Resqueti, V.
   Bruno, S.
   Guerra Azevedo, I.
   Dourado Junior, M. E.
   Fregonezi, G.
TI Respiratory muscle strength and quality of life in myotonic dystrophy
   patients
SO REVISTA PORTUGUESA DE PNEUMOLOGIA
LA Portuguese
DT Article
DE Maximal respiratory pressures; Sniff test; Neuromuscular disease; SF-36;
   Respiratory muscles
ID NASAL INSPIRATORY PRESSURE; LUNG-FUNCTION TESTS; REFERENCE VALUES;
   INDIVIDUALS; RECRUITMENT; DISEASE; AWAKE
AB Introduction: Studies on quality of life in myotonic dystrophy (MD) are scarce and the relationship between respiratory muscle strength and health-related quality of life (HRQoL) has yet to be determined. The present study aims to investigate respiratory muscle strength and HRQoL and their relationship in MD patients.
   Methods: Twenty-three patients (13 men, aged 40 +/- 16 years) with MD were evaluated for pulmonary function, maximal inspiratory and expiratory pressure (MIP and MEP, respectively), sniff nasal inspiratory pressure (SNIP) and HRQoL using the Short Form (SF-36) quality of life questionnaire.
   Results: Respiratory muscle strength values were 71 +/- 20 cmH(2)O (64% predicted), 76 +/- 32 cmH(2)O (70% predicted), and 79 +/- 28 cmH(2)O (80% predicted) for MEP, MIP, and SNIP respectively. Significant differences were found in the SF-36 domains of physical functioning 58.7 +/- 31.4 vs. 84.5 +/- 23 (p < 0.01, 95% CI = 1.6-39.9) and physical problems 43.4 +/- 35.2 vs. 81.2 +/- 34 (p < 0.001, 95% CI = 19.4-6.1) when compared with the reference values. According to single linear regression analysis, MIP explains 29% of the variance in physical functioning, 18% of physical problems and 20% of vitality.
   Conclusions: Individuals with MD have reduced expiratory muscle strength. HRQoL may be more impaired in some physical domains, which might be influenced by variations in inspiratory muscle strength. (c) 2010 Published by Elsevier Espana, S.L. on behalf of Sociedade Portuguesa de Pneumologia. All rights reserved.
C1 [Bruno, S.; Fregonezi, G.] Univ Fed Rio Grande do Norte, Dept Phys Therapy, PneumoCardioVasc Phys Therapy Lab, Master Degree Phys Therapy Program, BR-59072970 Natal, RN, Brazil.
   [Dourado Junior, M. E.] Univ Fed Rio Grande do Norte, Onofre Lopes Univ Hosp, Electroneuromyog Serv, BR-59072970 Natal, RN, Brazil.
RP Fregonezi, G (corresponding author), Univ Fed Rio Grande do Norte, Dept Phys Therapy, PneumoCardioVasc Phys Therapy Lab, Master Degree Phys Therapy Program, BR-59072970 Natal, RN, Brazil.
EM fregonezi@ufrnet.br
RI Resqueti, Vanessa R/I-3604-2015; Fregonezi, Guilherme/AAQ-1493-2020;
   Azevedo, Ingrid/AAL-9413-2020; Fregonezi, Guilherme AF/B-2186-2019
OI Fregonezi, Guilherme/0000-0003-4938-7018; Azevedo,
   Ingrid/0000-0001-7305-7583; Fregonezi, Guilherme AF/0000-0003-4938-7018
CR Ahlstrom G, 1996, SCAND J REHABIL MED, V28, P147
   AHLSTROM G, 1994, CHEST, V106, P173, DOI 10.1378/chest.106.1.173
   Antonini G, 2006, J REHABIL MED, V38, P181, DOI 10.1080/16501970500477967
   Begin P, 1997, AM J RESP CRIT CARE, V156, P133, DOI 10.1164/ajrccm.156.1.9509041
   BLACK LF, 1969, AM REV RESPIR DIS, V99, P696
   Bouhour F, 2007, PRESSE MED, V36, P965, DOI 10.1016/j.lpm.2007.01.002
   Ciconelli RM, 1997, THESIS U FEDERAL SAO
   de Die-Smulders CEM, 1998, BRAIN, V121, P1557, DOI 10.1093/brain/121.8.1557
   Fregonezi GAD, 2006, ARCH BRONCONEUMOL, V42, P218
   FINNIMORE AJ, 1994, THORAX, V49, P66, DOI 10.1136/thx.49.1.66
   Ford Chris, 2006, N Z Med J, V119, pU2145
   Grootenhuis MA, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-31
   Kumar S, 2007, CHEM WORLD-UK, V4, P15, DOI 10.1177/1479972306074480
   Lofaso F, 2006, EUR RESPIR J, V27, P980, DOI 10.1183/09031936.06.00121305
   Masdeu MJ, 2003, ARCH BRONCONEUMOL, V39, P176, DOI 10.1157/13045953
   Mathieu J, 2001, NEUROLOGY, V56, P336, DOI 10.1212/WNL.56.3.336
   Morgan RK, 2005, AM J RESP CRIT CARE, V171, P269, DOI 10.1164/rccm.200403-314OC
   NAVA S, 1993, THORAX, V48, P702, DOI 10.1136/thx.48.7.702
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007
   Neder JA, 1999, BRAZ J MED BIOL RES, V32, P703, DOI 10.1590/S0100-879X1999000600006
   PERE CC, 2007, ARCH BRONCONEUMOL S3, V43, P2
   Perrin C, 2004, MUSCLE NERVE, V29, P5, DOI 10.1002/mus.10487
   *SOC BRAS PNEUM TI, 2002, J PNEUMOL S3, V28, pS1
   Steier J, 2007, THORAX, V62, P975, DOI 10.1136/thx.2006.072884
   Terzi N, 2008, EUR RESPIR J, V31, P93, DOI 10.1183/09031936.00094707
   Troosters T., 2005, EUROPEAN RESP MONOGR, V31, P57
   Ugalde V, 2001, J APPL PHYSIOL, V91, P395
   ULDRY C, 1995, THORAX, V50, P371, DOI 10.1136/thx.50.4.371
   VEALE D, 1995, EUR RESPIR J, V8, P815
   Zifko UA, 1996, BRAIN, V119, P1911, DOI 10.1093/brain/119.6.1911
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 31
TC 7
Z9 8
U1 0
U2 2
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0873-2159
J9 REV PORT PNEUMOL
JI Rev. Port. Pneumol.
PD NOV-DEC
PY 2010
VL 16
IS 6
BP 892
EP 898
PG 7
WC Respiratory System
SC Respiratory System
GA 686VJ
UT WOS:000284724300006
PM 21067695
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Martins, ANN
   de Figueiredo, MM
   Rocha, OD
   Fernandes, MAF
   Jeronimo, SMB
   Dourado, ME
AF Martins, Antonio N. N., Jr.
   de Figueiredo, Marcelo M.
   Rocha, Orlandil D.
   Fernandes, Maria A. F.
   Jeronimo, Selma M. B.
   Dourado, Mario E., Jr.
TI Frequency of stroke types at an emergency hospital in Natal, Brazil
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE stroke; Brazil; hypertension
ID CASE-FATALITY; BLOOD-PRESSURE; EPIDEMIOLOGY; PREVALENCE; POPULATION;
   MORTALITY
AB We performed a cross-sectional study of stroke type frequency at a local emergency hospital, in Natal, Brazil. The sample consisted of all patients who were admitted to an emergency hospital with a presumptive diagnosis of stroke. Of the 416 patients, 328 were studied, 88 were excluded for not meeting inclusion criteria, 74.7% (n= 245) had ischemic stroke 17.7% (n=58) had intracerebral hemorrhage, 7.6% (n=25) had subarachnoid hemorrhage; 173 were men (52.7%). Mean age was 64.1 years. The intrahospital mortality rate was 10.2%, 17.2% and 36% for ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage, respectively. The most prevalent modifiable risk factor was hypertension for ischemic stroke (67.6%) and hemorrhage stroke (57.8%). Logistic regression analysis identified diabetes (OR=3.70; CI=1.76-7.77) as independent risk factor for ischemic stroke. The ischemic stroke was most common type of stroke. Hypertension and diabetes were important risk factors for stroke.
C1 [Martins, Antonio N. N., Jr.; de Figueiredo, Marcelo M.; Rocha, Orlandil D.; Fernandes, Maria A. F.; Jeronimo, Selma M. B.; Dourado, Mario E., Jr.] Monsenhor Walfredo Gurgel Hosp, Natal, RN, Brazil.
   [Martins, Antonio N. N., Jr.; de Figueiredo, Marcelo M.; Rocha, Orlandil D.; Jeronimo, Selma M. B.; Dourado, Mario E., Jr.] Ctr Biosci, Dept Biochem, Natal, RN, Brazil.
   [Fernandes, Maria A. F.] Hlth Sci Ctr, Hlth Grad Program, Dept Dent, Natal, RN, Brazil.
   [Dourado, Mario E., Jr.] Univ Fed Rio Grande do Norte, BR-59072970 Natal, RN, Brazil.
RP Dourado, ME (corresponding author), Rua Marcilio Furtado, BR-59063360 Natal, RN, Brazil.
EM medourado@digi.com.br
RI Jeronimo, Selma/AAY-4033-2020; Jeronimo, Selma M.B./M-8672-2014
OI Jeronimo, Selma/0000-0002-4784-9904; Jeronimo, Selma
   M.B./0000-0002-4784-9904
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Ala L, 2004, J HUM HYPERTENS, V18, P775, DOI 10.1038/sj.jhh.1001750
   Andre C, 2006, STROKE, V37, P2784, DOI 10.1161/01.STR.0000244768.46566.73
   Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D
   BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989
   BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U
   Cabral NL, 1997, ARQ NEURO-PSIQUIAT, V55, P357, DOI 10.1590/S0004-282X1997000300002
   COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892
   Cox AM, 2006, LANCET NEUROL, V5, P181, DOI 10.1016/S1474-4422(06)70351-9
   Donnan GA, 2003, J HYPERTENS, V21, pS25, DOI 10.1097/00004872-200306005-00006
   Donnan GA, 2003, CURR OPIN NEUROL, V16, P81, DOI 10.1097/00019052-200302000-00011
   Feigin VL, 2005, LANCET, V365, P2160, DOI 10.1016/S0140-6736(05)66755-4
   Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7
   Lavados PM, 2005, LANCET, V365, P2206, DOI 10.1016/S0140-6736(05)66779-7
   Lotufo Paulo Andrade, 2005, Sao Paulo Med. J., V123, P3, DOI 10.1590/S1516-31802005000100001
   MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5
   *MIN SAUD, 2001, AN EST SAUD BRAS
   Neal B, 2000, LANCET, V356, P1955
   Radanovic M, 2000, ARQ NEURO-PSIQUIAT, V58, P99, DOI 10.1590/S0004-282X2000000100015
   Sagui E, 2005, STROKE, V36, P1844, DOI 10.1161/01.STR.0000177864.08516.47
   Saposnik G, 2003, STROKE, V34, P2103, DOI 10.1161/01.STR.0000088063.74250.DB
   Saposnik G, 2001, ACTA NEUROL SCAND, V104, P130, DOI 10.1034/j.1600-0404.2001.00039.x
   SICHIERI R, 1994, AM J PUBLIC HEALTH, V84, P793, DOI 10.2105/AJPH.84.5.793
   Smadja D, 2001, STROKE, V32, P2741, DOI 10.1161/hs1201.099385
   Truelsen T, 2006, EUR J NEUROL, V13, P581, DOI 10.1111/j.1468-1331.2006.01138.x
NR 25
TC 9
Z9 10
U1 0
U2 0
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD DEC
PY 2007
VL 65
IS 4B
BP 1139
EP 1143
DI 10.1590/S0004-282X2007000700009
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 245UI
UT WOS:000251963900009
PM 18345418
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Dourado, ME
   Duarte, RC
   Ferreira, LC
   Queiroz, JW
   Illa, I
   Perez-Perez, G
   Guerrant, RL
   Jeronimo, SMB
AF Dourado, ME
   Duarte, RC
   Ferreira, LC
   Queiroz, JW
   Illa, I
   Perez-Perez, G
   Guerrant, RL
   Jeronimo, SMB
TI Anti-ganglioside antibodies and clinical outcome of patients with
   Guillain-Barre Syndrome in northeast Brazil
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article
DE Guillain-Barre Syndrome; gangliosides; Campylobacter jejuni;
   anti-ganglioside antibodies
ID CAMPYLOBACTER-JEJUNI INFECTION; MOTOR AXONAL NEUROPATHY; ANTI-GM1
   ANTIBODIES; GM1 GANGLIOSIDE; MOLECULAR MIMICRY; PERIPHERAL-NERVE; IGG
   ANTIBODIES; POLYNEUROPATHY; CONDUCTION; CHINA
AB Objectives - The goal of this study was to investigate the frequency of GM1 antibodies and to assess whether exposure to Campylobacter jejuni was associated with a distinct clinical variant of Guillain-Barre Syndrome (GBS) or disease outcome in Rio Grande do Norte, Brazil. Material and methods - Forty-one patients with a presumed diagnosis of GBS were enrolled and prospectively studied between June 1994 and November 1999. Results - Anti-GM1 was present in 51.2% (n = 21) of patients. The presence of anti-GM1 was significantly associated with acute axonal motor neuropathy when compared to acute inflammatory demyelinating polyneuropathy (P = 0.01). Patients with anti-GM1 antibodies presented distal muscle involvement and fewer sensory deficits. Age, time to nadir and ventilatory assistance were not associated with anti-GM1 antibodies. Eight out of 21 patients (32%) presented with anti-C. jejuni antibodies. Clinical features were similar for patients with GBS with positive and negative C. jejuni antibodies. Anti-GM1 antibodies were associated with C. jejuni infection (P = 0.0005). Presence of anti-GM1 and C. jejuni antibodies did not indicate a worse prognosis. Conclusion - Patients with GBS and anti-GM1 antibodies had more distal muscle weakness, fewer sensory deficits, more axonal degeneration and C. jejuni infection, but these findings were not associated with a worse prognosis.
C1 Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Bioquim, BR-69072970 Natal, RN, Brazil.
   Univ Fed Rio Grande do Norte, Unidade Neurol, BR-69072970 Natal, RN, Brazil.
   Univ Barcelona, Dept Neurol, Barcelona, Spain.
   NYU, Sch Med, Dept Med & Microbiol, New York, NY USA.
   Univ Virginia, Dept Med, Charlottesville, VA USA.
RP Jeronimo, SMB (corresponding author), Univ Fed Rio Grande do Norte, Ctr Biociencias, Dept Bioquim, CP 1624, BR-69072970 Natal, RN, Brazil.
EM smbj@cb.ufrn.br
RI Jeronimo, Selma/AAY-4033-2020; ILLA, Isabel/AAD-1816-2019; Perez,
   Guillermo Perez/AAJ-3761-2020; Jeronimo, Selma M.B./M-8672-2014
OI Jeronimo, Selma/0000-0002-4784-9904; Jeronimo, Selma
   M.B./0000-0002-4784-9904
CR Ang CW, 1999, NEUROLOGY, V53, P2122, DOI 10.1212/WNL.53.9.2122
   ARASAKI K, 1993, MUSCLE NERVE, V16, P587, DOI 10.1002/mus.880160603
   ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707
   ENDERS U, 1993, ANN NEUROL, V34, P136, DOI 10.1002/ana.410340208
   Gallardo E, 2001, NEUROLOGIA, V16, P293
   GREGSON NA, 1993, Q J MED, V86, P111
   GRIFFIN JW, 1995, BRAIN, V118, P577, DOI 10.1093/brain/118.3.577
   GUERRANT RL, 1983, J INFECT DIS, V148, P986, DOI 10.1093/infdis/148.6.986
   Hadden RDM, 2001, J APPL MICROBIOL, V90, p145S, DOI 10.1046/j.1365-2672.2001.01363.x
   HaferMacko C, 1996, ANN NEUROL, V40, P635, DOI 10.1002/ana.410400414
   Hao Q, 1999, ANN NEUROL, V45, P758
   HARTUNG HP, 1995, MUSCLE NERVE, V18, P137, DOI 10.1002/mus.880180202
   HARVEY GK, 1995, MUSCLE NERVE, V18, P388, DOI 10.1002/mus.880180404
   Hirota N, 1997, BRAIN, V120, P2159, DOI 10.1093/brain/120.12.2159
   Ho TW, 1997, NEUROLOGY, V48, P717, DOI 10.1212/WNL.48.3.717
   HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597
   Ho TW, 1999, ANN NEUROL, V45, P168, DOI 10.1002/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6
   HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2
   HUGHES RAC, 1997, J INFECT DIS S2, V179, P92
   ILLA I, 1995, ANN NEUROL, V38, P218, DOI 10.1002/ana.410380214
   Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110
   Jacobs BC, 1996, ANN NEUROL, V40, P181, DOI 10.1002/ana.410400209
   Kaida K, 2000, BRAIN, V123, P116, DOI 10.1093/brain/123.1.116
   Koga M, 2001, J NEUROL NEUROSUR PS, V71, P123, DOI 10.1136/jnnp.71.1.123
   Kusunoki S, 1997, MUSCLE NERVE, V20, P840
   Kuwabara S, 1998, NEUROLOGY, V51, P1656, DOI 10.1212/WNL.51.6.1656
   Ma JJ, 1998, NEUROLOGY, V51, P379, DOI 10.1212/WNL.51.2.379
   MCKHANN GM, 1991, LANCET, V338, P593, DOI 10.1016/0140-6736(91)90606-P
   Miyazaki T, 2001, NEUROLOGY, V56, P1227, DOI 10.1212/WNL.56.9.1227
   Monos DS, 1997, J INFECT DIS, V176, pS180, DOI 10.1086/513786
   Nishimura M, 1997, J NEUROL SCI, V153, P91, DOI 10.1016/S0022-510X(97)00170-6
   NOBILEORAZIO E, 1992, J NEUROL SCI, V109, P200, DOI 10.1016/0022-510X(92)90169-L
   O'Hanlon GM, 1998, ACTA NEUROPATHOL, V95, P605, DOI 10.1007/s004010050847
   OOMES PG, 1995, ANN NEUROL, V38, P170, DOI 10.1002/ana.410380208
   PEREZPEREZ GI, 1989, J INFECT DIS, V160, P460, DOI 10.1093/infdis/160.3.460
   PESTRONK A, 1988, ANN NEUROL, V24, P73, DOI 10.1002/ana.410240113
   REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102
   REES JH, 1995, ANN NEUROL, V38, P809, DOI 10.1002/ana.410380516
   ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706
   Sheikh KA, 1998, NEUROLOGY, V51, P371, DOI 10.1212/WNL.51.2.371
   TAKIGAWA T, 1995, ANN NEUROL, V37, P436, DOI 10.1002/ana.410370405
   VANDENBERG LH, J NEUROL NEUROSURG P, V55, P8
   VISSER LH, 1995, BRAIN, V118, P841, DOI 10.1093/brain/118.4.841
   VRIESENDORP FJ, 1993, ANN NEUROL, V34, P130, DOI 10.1002/ana.410340206
   Willison HJ, 1997, J INFECT DIS, V176, pS144, DOI 10.1086/513799
   Yoshino H, 2000, J NEUROIMMUNOL, V105, P195, DOI 10.1016/S0165-5728(99)00280-5
   Yuki N, 1998, J NEUROL SCI, V154, P14, DOI 10.1016/S0022-510X(97)00174-3
   YUKI N, 1993, NEUROLOGY, V43, P414, DOI 10.1212/WNL.43.2.414
   Yuki N, 2001, ANN NEUROL, V49, P712, DOI 10.1002/ana.1012
   YUKI N, 1991, NEUROLOGY, V41, P1561, DOI 10.1212/WNL.41.10.1561
   YUKI N, 1993, J EXP MED, V178, P1771, DOI 10.1084/jem.178.5.1771
   YUKI N, 1990, NEUROLOGY, V40, P1900, DOI 10.1212/WNL.40.12.1900
NR 52
TC 11
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD AUG
PY 2003
VL 108
IS 2
BP 102
EP 108
DI 10.1034/j.1600-0404.2003.00103.x
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 702AB
UT WOS:000184201000005
PM 12859286
DA 2020-12-09
ER

PT J
AU Dourado, ME
   De Freitas, ML
   Dos Santos, FM
AF Dourado, ME
   De Freitas, ML
   Dos Santos, FM
TI Fluctuations in Guillain-Barre syndrome related to treatment with
   intravenous human immunoglobulin (triphasic course): case report
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA Portuguese
DT Article
DE Guillain-Barre syndrome; intravenous immunoglobulin; treatment related
   fluctuations
ID HUMAN IMMUNE GLOBULIN; PLASMA-EXCHANGE; TRIAL
AB The authors report the case of a patient with severe Guillain-Barre syndrome (tetraplegic and on mechanical ventilation), that was treated with intravenous immunoglobulin (IVIg), 2 g/Kg. At first, there was clinical improvement, followed by clinical deterioration two weeks later. On the second course of IVIg there was, again, clinical improvement and then deterioration, 65 days after treatment. Finally, on the third course of treatment definitive recovery was achieved and no more relapses happened so far (three years after the treatment). The authors review the literature about fluctuations related to treatment with IVIg. Conclusions are that these patients should be closely observed during the first weeks after IVIg treatment, and that further studies are still necessary to elaborate alternative protocols on the prevention of these cases.
C1 UNINEURO, Setor Invest Doencas Neuromusculares, BR-59014160 Natal, RN, Brazil.
CR [Anonymous], 1994, Ann Neurol, V35, P749
   ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707
   CASTRO LHM, 1993, NEUROLOGY, V43, P1034, DOI 10.1212/WNL.43.5.1034
   DOURADO ME, 1993, NEUROLOGIA BARCELONA, V8, P343
   DOURADO ME, 1996, ARQ NEUROPSIQUIATR S, V54, P234
   DYCK PJ, 1993, NEUROLOGY, V43, P1277, DOI 10.1212/WNL.43.7.1277
   HARTUNG HP, 1995, MUSCLE NERVE, V18, P137, DOI 10.1002/mus.880180202
   Hughes RAC, 1997, LANCET, V349, P225
   HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2
   IRANI DN, 1993, NEUROLOGY, V43, P872, DOI 10.1212/WNL.43.5.872
   JACKSON MC, 1993, J NEUROL, V240, P51, DOI 10.1007/BF00838447
   KLEYWEG RP, 1991, J NEUROL NEUROSUR PS, V54, P957, DOI 10.1136/jnnp.54.11.957
   MCKHANN, 1985, NEUROLOGY, V35, P1096
   MCKHANN GM, 1990, ANN NEUROL, V27, pS13, DOI 10.1002/ana.410270705
   OSTERMAN PO, 1986, LANCET, V2, P1161
   RAPHAEL JC, 1987, ANN NEUROL, V22, P753
   ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706
   ROPPER AH, 1985, ARCH NEUROL-CHICAGO, V45, P314
   ROPPER AH, 1991, CONT NEUROLOGY SERIE, P18
   RUDNICKI S, 1992, MUSCLE NERVE, V15, P57, DOI 10.1002/mus.880150111
   VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705
   VANDERMERCHE FGA, 1995, NEUROLOGY S, V37, pS14
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 1998
VL 56
IS 3A
BP 476
EP 479
DI 10.1590/S0004-282X1998000300020
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 108KR
UT WOS:000075266000020
PM 9754432
OA Bronze, Other Gold
DA 2020-12-09
ER

PT J
AU MARTIFABREGAS, J
   DOURADO, M
   SANCHIS, J
   MIRALDA, R
   PRADAS, J
   ILLA, I
AF MARTIFABREGAS, J
   DOURADO, M
   SANCHIS, J
   MIRALDA, R
   PRADAS, J
   ILLA, I
TI RESPIRATORY-FUNCTION DETERIORATION IS NOT TIME-LINKED WITH UPPER-LIMB
   ONSET IN AMYOTROPHIC-LATERAL-SCLEROSIS
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Note
DE AMYOTROPHIC LATERAL SCLEROSIS; MOTOR NEURON DISEASE; RESPIRATORY
   FUNCTION TESTS; FORCED VITAL CAPACITY
AB Introduction - In amyotrophic lateral sclerosis (ALS), symptoms apparently spread following regional rules, and depending on the site of onset. We examined if respiratory function deterioration appears earlier or is more severe in patients with upper-limb onset. Material & methods - We compared the results of various pulmonary function tests (PFT) obtained at diagnosis depending on the site of onset in 49 ALS patients. In a longitudinal study, we compared the deterioration of forced vital capacity (FVC) in relation to the site of onset, and analyzed the time elapsed to reach values below 80% of predicted according to site of onset, and we compared the survival depending on the site of onset. Results - No significant differences in PFT were found in the upper-limb onset group in any of the analysis performed. No differences in survival were detected in any disease onset group. Conclusion - Pulmonary function deterioration does not appear to be time-linked to arm onset in ALS.
C1 UNIV AUTONOMA BARCELONA,HOSP ST CREU & ST PAU,DEPT PNEUMOL,E-08025 BARCELONA,SPAIN.
RP MARTIFABREGAS, J (corresponding author), UNIV AUTONOMA BARCELONA,HOSP ST CREU & ST PAU,DEPT NEUROL,SERV NEUROL,E-08025 BARCELONA,SPAIN.
RI ILLA, Isabel/AAD-1816-2019; Marti-Fabregas, Joan/I-5933-2019
OI Marti-Fabregas, Joan/0000-0001-9229-8649
CR ANDRES PL, 1988, NEUROLOGY, V38, P405, DOI 10.1212/WNL.38.3.405
   BEHNIA M, 1991, MUSCLE NERVE, V14, P1236, DOI 10.1002/mus.880141217
   BLACK LF, 1969, AM REV RESPIR DIS, V99, P696
   BOMAN K, 1967, ACTA NEUROL SCAND, V43, P489, DOI 10.1111/j.1600-0404.1967.tb05755.x
   BROOKS BR, 1991, ADV NEUROL, V56, P521
   CAROSCIO JT, 1987, NEUROLOGIC CLIN AMYO, P1
   FALLAT RJ, 1979, ARCH NEUROL-CHICAGO, V36, P74, DOI 10.1001/archneur.1979.00500380044004
   QUANJER P, 1983, B EUR PHYS RESP S, V5, P19
   ROCA J, 1986, B EUR PHYSIOPATH RES, V22, P217
   SCHIFFMAN PL, 1993, CHEST, V103, P508, DOI 10.1378/chest.103.2.508
   SUFIT R L, 1991, Neurology, V41, P314
   SWASH M, 1986, BRAIN, V109, P939, DOI 10.1093/brain/109.5.939
NR 12
TC 12
Z9 12
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0001-6314
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD SEP
PY 1995
VL 92
IS 3
BP 261
EP 264
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA RR594
UT WOS:A1995RR59400013
PM 7484083
DA 2020-12-09
ER

EF